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L ist Of A bbreviations U sed in  th e  Body o f T his T hesis
a Alpha.
0C2M Alpha-2-macroglobulin.
a-CN 4-Chloro-l-Napthol.
A Adenine.
Axxx nm Absorption a t xxx nm.ACS American Chemical Society.
AD Alzheimer’s disease.
AFP Alpha-Fetoprotein.
Arg Arginine.
APP-KD Amyloid p-protein precursor-Kunitz domain.
APS Ammonium Persulphate.
ATZ Anilinothiazoline
P Beta.
BCA Bicinchoninic Acid.
Bp Base pairs.
BPB Bromophenol Blue.
BSA Bovine serum albumin.
C Cytosine.
Ca2+ Calcium
CAPS 3- [cyclohexylamino] - 1-propanesulfonic acid.
CBB Coomassie Brilliant Blue®.
cDNA complementary DNA.
CL Cornelia-de-Lange.
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Con-A Concanavalin - A.
Cong. Congenital.
CPM Counts per minute.
CV Coefficient of variation.
CVS Chorionic villus sample.
d. Density.
DEAE-Trisacryl Diethyl aminoethyl(Trisacryl).
DMAB p-dimethyl aminobenzaldehyde.
DMF Dimethyl formamide.
DMSO Dimethyl sulphoxide.
DNA Deoxyribonucleic acid.
dNTP’s Deoxyribonucleoside Triphosphates
DS Down syndrome.
DTT Dithiothreitol.
EDTA Ethylenediamine tetra-acetic acid.
EEO Electro-endosmosis.
EGF Epidermal growth factor
EGF-BP Epidermal growth factor binding protein
ELISA Enzyme Linked Im munosorbent Assay.
EtBr Ethidium Bromide.
EtOH Ethanol.
F(ab')2 Divalent antigen binding region.
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FPLC Fast performance liquid chromatography™.
Fig. Figure.
G Guanine.
g- Gramme.GalNAc N-Acetylgalactosamine
gl. Glacial.GlcNAc N-Acetylglucosamine.
GPR General Purpose Reagent Grade.
gr. Grade.
hCG hum an Chorionic Gonadotrophin.
HC1 Hydrochloric acid.
HGE Hum an Granulocyte Elastase.
HOAc Acetic acid.
hPL H um an placental lactogen.
HPLC High performance liquid chromatography.
HRP Horseradish Peroxidase.
HSA Hum an serum albumin.
IPTG P -D -isopropyl-thiogalactopyranoside.
IU International units.
K 103.
kDa 103 daltons.
X Lambda.
LB Luria Broth.
LCA Lentil lectin (Lens culinaris) agglutinin
LP4 Size of plastic tube (Denley).
M Molar.
mA 10'3 Amps.
mAb Monoclonal antibody.
Mat. M aternal.
mCi 10'3 Curie.
MEGA-10 Decanoyl-N-Methyl Glucamide
MeOH Methanol.
mg I q-3 gramme.
ml 10-3 litre.
mm 10'3 Metre.
mM 10'3 Molar.
Mol. Biol. Gr. Molecular Biology Grade chemical.
MP M embrane associated placental protein.
mRNA messenger RNA.
MW Molecular weight.
NaCl Sodium Chloride.
NAG N -Ace tylglucos am ine.
NaOAc Sodium acetate.
nd. Not determined.
NDS Napthalene-l-5-disulphonic acid-disodium salt.
NeuAc Sialic acid (N-Acetyl-neuraminic acid).
nmole 10-9 Mole.
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NSB Non-Specific background.
NT Nuchal translucency.
°C Centigrade.
2-ME 2-mercapto-ethanol.
*X Stock *times concentrate(where *= No.)
[ ] Concentration.
PAPP-A Pregnancy-associated Plasm a Protein-A.
PEG Polyethylene Glycol(Average MW 6000).
PET Pre-eclamptic toxaemia.
pfu Plaque forming unit.
Pg 10 -12  gramme.
PHA Phytohaemagglutinin.
Pi Iso-electric point.
pmole 10-12 Mole.
PMSF Phenyl methyl sulphonyl fluoride.
PP Placental protein.
PBS Phosphate Buffered Saline.
PCR Polymerase Chain Reaction.
PITC Phenyl isothiocyanate
proMBP Proform of eosinophil major basic protein.
PTC Phenylthiocarbamoyl
PTH Phenylthiohydantoin
PVDF Polyvinylidene difluoride
PVP-360 Polyvinylpyrolidone-360.
PZP Pregnancy zone protein.
RCF Relative Centrifugal force.
Rf Relative mobility
RIA Radioimmunoassay.
RID Radial Immunodiffusion.
RIE Rocket Immunoelectrophoresis.
RMM Relative molecular Mass.
RP-HPLC Reverse Phase-HPLC
rpm Revolutions per minute.
RT Ambient Room Tem perature (Approx. 21°C).
SDS Sodium dodecyl sulphate.
ss. Single stranded
Sp. Ac. Specific activity.
SP1 Schwangerschaft spezifische p glycoprotein-1.
T Thymidine.
TAE Tris-Acetate-EDTA buffer.
TAME Na-p-Tosyl-L-Arginine Methyl Ester.
TBE Tris-Borate-EDTA buffer.
TBS Tris Buffered saline.
TCA Trichloroacetic acid.
TEMED N,N,N',N '-tetramethyl ethylene diamine.
TFA Trifluoroacetic Acid.
TMB 3,3',5,5'- Tetramethylbenzidine.
TMC Threatened Miscarriage.
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TPCK N-Tosyl-L-Phenylalanine Chloro-Methyl Ketone.
TLCK Na-p-Tosyl--L-Lysine Chloro-methyl Ketone.
TRIS (TRIZMA) Tris(hydroxymethyl)aminomethane.
Triton® X-100 Octyl polyethylene ether.
Tween®-20 Polyoxyethylenesorbitan M onolaurate.
gg 10'6 g.
gl 1 0 -6 1 .
gM 10-6 M.
uE3 Unconjugated Oestriol.
v/v Volume : volume ratio.
V0 Void volume. .
Vt Total volume.
Vc Column volume.
V8 Alternative name for Endoproteinase Glu-C.
w/v W eigh t: volume ratio.
X-gal 5-Bromo-4-Chloro-3-Indolyl-p-galactopyranoside.
XIE Crossed Immunoelectrophoresis
Coomassie Brilliant Blue® is a registered tradem ark of ICI. 
Tween® is a registered tradem ark of ICI.
Triton® is a registered tradem ark of Rohm & Haas, USA.
O ther Abbreviations are as found and understood by general texts as 
illustrated by the scientific literature and texts such as th a t devoted to the 
usage of Abbreviations (Baron, 1994).
- xx -
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Post-graduate courses, attendance a t conferences, active participation 
in  research sem inars and teaching th a t was undertaken as p a rt of the 
programme of research th a t was required as a partial fulfilment of the 
requirem ents for the degree of PhD.
Attendance a t biochemical society meetings and a British Society for 
Immunology meeting.
Regular participation in research sem inars at:
• The school of science.
• Jessop hospital for Women.
• The Institu te  of Virology, The Royal Hallam shire hospital.
The presentation of a research sem inar on the molecular 
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A bstract
PAPP-A is a large glycoprotein with 0C2 - electrophoretic mobility th a t is 
produced by the placenta during pregnancy. In  th is thesis a biochemical 
and molecular characterisation of PAPP-A was performed.
The polyclonal antiserum  (DAKO) directed against PAPP-A has been 
shown to also in teract with proteins other than  PAPP-A. These non-specific 
interactions were abolished by performing W estern blotting 
immunodetection a t a high salt concentration (0.6M NaCl). At this salt 
concentration a single band of 195 kDa was imm unodetected and this 
corresponded to the monomeric PAPP-A molecule. I t  was also discovered 
th a t a subset of paratopes in  this antiserum  reacted, under the described 
high salt concentration conditions, with the glycan component of PAPP-A.
A placental cDNA library was screened using th is antibody for the 
PAPP-A cDNA but this did not yield a clone for PAPP-A. A possible 
explanation is th a t the interaction with this antibody requires carbohydrate 
components to be present on the PAPP-A molecule. I t is known th a t proteins 
expressed in bacterial systems are not post-translationally modified. 
Therefore another approach to the isolation of the PAPP-A cDNA clone was 
adopted, bu t this required some prim ary amino acid sequence of this protein 
th a t was unavailable a t the time. To generate this information, PAPP-A was 
purified using its previously unpublished affinity for L-arginine in 
combination w ith the already described procedures of ammonium sulphate 
precipitation, ion exchange and gel filtration. Final purification of PAPP-A 
was achieved by SDS-PAGE electrophoresis. The isolated monomeric PAPP- 
A gave a unique single N-terminal amino acid sequence: N-EARGATEEPS.
The N term inal sequence combined with the sequence obtained from 
limited proteolytic digestion of PAPP-A were used to design oligonucleotide 
primers specific for PAPP-A. These primers were used in a PCR reaction 
th a t produced 500 and >1200 bp fragm ents using the cDNA library as DNA 
template; thus dem onstrating th a t PAPP-A is synthesised in  the placenta.
PAPP-A was shown to have 0  and N-linked carbohydrate chains. 
Enzymatic deglycosylation dem onstrated th a t the N-linked chains were 8% 
(w/w) of the molecule. The O-linked groups were extensively modified w ith 
the presence of oligomers of N-acetyl-glucosamine. I t  was also shown th a t it 
was these groups the PAPP-A antibodies bind to a t high salt concentration.
A physical interaction of PAPP-A with endoproteinase Arg-C (EGF-BP) 
was observed. I t  was seen th a t they form a 1:1 (PAPP-A: endoproteinase) 
sub-unit complex th a t was stable in SDS. A further investigation revealed 
th a t PAPP-A interacted with the endoproteinase Arg-C and this resulted in 
a 30% inhibition of the esterolytic activity of this enzyme.
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CHAPTER
ONE
Chapter One
P regnancy and P regnancy P roteins
1.1 In trod u ction
The changes th a t are imposed on the m aternal hum an system by 
pregnancy have led to an  in terest in the molecules th a t are synthesised 
during pregnancy. The placenta is a highly invasive organ th a t is 
analogous to a locally invasive tumour. I t  is hoped th a t an  understanding of 
the control mechanisms and molecules produced a t the trophoblastic 
interface will lead to a better understanding of how the conceptus in the 
majority of cases survives to term.
1.2 The E stab lishm ent o f th e H um an Foeto-M aternal 
Interface
After fertilisation of the hum an female oocyte by the male spermatozoan 
a series of mitotic cleavage divisions occur and two distinctive groups of 
blastomeres emerge, surrounded by the zona pellucida. One of these groups 
form the inner cell mass which include the embryogenic cells, while the 
other consists of a m ass of flattened polyhedral cells th a t compose the 
blastocystic trophoblast. At this stage the repeated divisions produce a 
characteristic mulberry-shaped mass of cells (a morula). By the fifth day 
following ovulation and fertilisation the zona pellucida is shed. The uterine 
wall now consists of two m ain layers, the myometrium (a thick layer of 
muscles) and the endometrium (an inner mucous membrane, Figure 1.1a). 
Im plantation of the morula now occurs with the trophoblastic cells adhering 
to the endometrium. On adhering they exert histiolytic activity on the 
endometrial epithelium with invasion and destruction of a p a rt of the 
m aternal vascular epithelia. The endometrium then  undergoes a series of
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changes th a t results in the decidualisation of the secretory endometrium. 
These cells acquire a characteristic polygonal shape and th is decidual layer 
thickens and becomes more heavily vascularised (Figure 1.1b)._____________
Corpus luteum
Z o n a  p e l l u c i d a  \ p r a a ^ a n  f o l l i c l e ^ . ^
r~ L ■ /  Myometrium \;\ Fimbria' '
Endometrium (progestational stage)
(a)
(b)
Figure 1.1
Schematic illustration of events leading to im plantation (a) and the 
development of the Chorion and Decidua (b).
(Adapted from Langm an, 1975)
During th is invasive process the trophoblastic cells divide w ith great 
rapidity and the progeny fuse with each other to form a th in  polarized 
membrane (the syncytio-trophoblast). This places the chorionic 
(trophoblastic and foetal vascular tissue) a ttachm ent to the u terus in direct 
contact w ith the m aternal blood stream  and so th is is a haem ochorial type of 
placentation (Bjorkman,1985).
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Decidua Decidua basalis
Chorion
During the described invasive process large lacunar spaces are formed 
and after enlargem ent become blood filled intervillous spaces th a t initially 
contain a labyrinthine chorionic structure th a t develops into a secondary 
villous structure (Williams and Warick, 1980). The chorion is vascularized 
by the allantoic blood vessels and so is term ed chorioallantoic. The 
chorionic attachm ent enlarges in a discoidal p a tte rn  to cover approximately 
25% of the endometrium  a t about the th ird  m onth of pregnancy. At this 
stage this attachm ent is known as the placenta; which is deciduate as 
m aternal tissue and placental mem branes are shed as p a rt of the afterbirth  
at term  (Figures 1.2a and 1.2b).
Uterine cervical canal
Internal os uteri
, Amnion
j (cytotrophoblast) 
Oecidua capsularls
Amniochorion
Virtual uterine lumen - 
Decidua parietalis " 
Myometrium ' 
Amniotic cavity-
Placental disc
Figure 1.2a
Schematic illustration of the foetal placental in trau terine  complex
(Adapted from Panigel e t al. 1985)
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Cbcriai piaca
Syncyciscrccr.coiaszCycacracnaoias- call islanc-C^
) C y c = c r a c n c = i a s c ( b a s a l  p l a c a j  
? □ a c i c u a C b a s a l  p l a c a ]rnceracicial cyrai 
Lina ar* placancal 
(paac-parcam)
Oaec cecicsja
UPar:
F ig u re  1.2b
Schematic enlargem ent of inset seen in Figure 1.2a
If you consider Mossman's (1987) definition of the placenta as an 
“ apposition of foetal and paren tal tissues for the purpose of physiological 
exchange. ” then it is well suited to this task  from a struc tu ra l point of 
view as its surface area is equivalent to the calculated absorptive area of 
the entire adult gastro-intestinal tract.
The placenta also acts as an anchoring device for the foetus, providing it 
with buoyancy and allowing for freedom of movement and growth in an 
aquatic environment. Allowing for these described features the placental 
unit m ust provide for effective synthesis, storage, transport and breakdown 
of compounds th a t are vital for foetal growth. These physiological processes 
have been reviewed by Bjorkman (1985) and it is not proposed to further 
cover them  here.
The foetus also contains m aterial acquired from the pa te rnal genotype, 
which to the mothers immune system m ust make the placenta look 
somewhat allogeneic, so it comes as a surprise th a t the semi-allogeneic
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gestation survives and proceeds to term. This apparent contradiction is 
further deepened w ith the demonstration by Voisin e ta l, (1985) that:
• The immunological capacity of the m other to defend against microbial 
infections is not significantly impaired.
• The m aternal immune system recognises the foreign paternal antigens.
• The haemochorial placentation bathes the paternal antigens present on 
the trophoblast in  blood and hence one of the major channels for 
transport of cells involved in immune surveillance and response. 
Therefore it is a surprise th a t the immune system does not react as
expected to the presence of this semi-allogeneic allograft. I t  is also likely 
th a t any communication between the foetal and m aternal systems will be 
endocrine in  na tu re  (Bell, 1988). So a more detailed understanding of the 
trophoblast and related tissues is needed, as they are likely to play a key 
role in this physiological and immunological exchange th a t occurs between 
the foetal and m aternal systems.
1.3 M olecules P roduced  In R esponse to  th e F oeta l 
M aternal Intra-U terine Com plex
The placenta, foetus and endometrial tissues produce a wide variety of 
biologically active proteins, which have historically been split into two 
groups (Bohn and Winkler, 1988).
• Group-A: Molecules th a t were identified on the basis of their activity.
• Group-B: Molecules th a t were identified using an immunochemical
approach.
The first group-A molecule was discovered by Aschheim and Zondek in 
1927 who found a hormone with gonadotrophic activity and nam ed it hum an 
gonado-tropin (later renam ed hum an chorionic gonadotropin, hCG). Some of 
the molecules identified in  this group are identical or analogues to 
functional proteins th a t have been found in other tissues, w hilst others are
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biologically active substances th a t are necessary for the m aintenance of 
pregnancy.
Studies of the group B proteins were in itiated by M acLaren et a l, (1959) 
and their cited work on the protein composition of blood in hum an 
pregnancy dem onstrated the presence of additional antigenic determ inants, 
when compared to sera from non-pregnant or male donors. This 
dem onstration led to the suggestion th a t a new group of pregnancy-specific 
proteins exist during pregnancy. Using the immunochemical approach 
Tatarinov and Masyukevich (cited from 1970) and Bohn (cited from 1971)
isolated pregnancy-specific proteins in  the early ‘70s. Lin et al, (1974a,
1974b) produced antisera to hum an pregnancy plasm a th a t had  been 
adsorbed with plasm a from males. Using this antisera they showed the 
presence of four distinct immunoprecipitin lines. They were nam ed 
alphabetically from the immunoprecipitin pa ttern  seen as pregnancy- 
associated plasm a protein's A, B, C and D. Since then  num erous placental 
proteins have been isolated, with Bohn et a l, (1988) isolating more th an  50 
different antigens over the past 20 years. The initial work utilised whole 
term  placental tissue th a t was composed of foetal and m aternal tissue. This 
led to the identification of a num ber of m aternal proteins initially defined as 
P ’lacental P ’roteins (PP), e.g. PP2 has subsequently shown to be ferritin  
(Bohn and Winkler, 1988 cited from Bohn’s initial work, 1973). Subsequent 
work by other investigators has used a more closely defined tissue source 
and has led to the characterisation of :-
• Foetal antigens (Fay e ta l, 1989, Price et a l. 1995).
• Soluble tissue proteins (PP's). and
• Membrane associated placental proteins (MP’s).
The immunochemical approach has led to many proteins being identified,
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some of the components have been seen in more th an  one tissue 
com partm ent and have been shown to be immunochemically identical, e.g. 
MP2-C shown to be identical to PP21 (Bohn and Winkler, 1988).
An overall class of proteins defined as pregnancy-associated has emerged, 
several of these proteins have been found outside of pregnancy e.g. in the 
seminal plasm a and follicular fluid. To keep these proteins as a class it was 
suggested th a t a more appropriate term  be Reproductive Proteins (Chard, 
1985). One of the proteins whose levels are modulated by pregnancy is 
term ed pregnancy-associated plasm a protein-A (PAPP-A) and is considered 
further.
1.4 P regnancy-A ssociated  P lasm a Protein-A  (PAPP-A)
1.4.1 T h e I s o la t io n  a n d  P u r if ic a t io n  o f  P A P P -A
Lin et al (1974a) were the first group to purify PAPP-A and raise a 
polyclonal antiserum  against it. Folkersen et al (1979) subsequently isolated 
a protein they called pregnancy specific protein-4, which was shown using 
immunological methods to be identical to PAPP-A. Subsequently Sutcliffe et 
al (1979), Bischof (1979a), M cIntyre et al (1981), Davey et al (1982) and 
Oxvig et a l. (1994) isolated PAPP-A by a variety of chromatographic 
techniques (Table 1.1). The described purification procedures were applied 
to purify PAPP-A from m aternal blood samples, although PAPP-A has also 
been purified from placental homogenates (Lin and Halbert, 1976 and 
Davey et ah 1983). In  all purification schemes it was found to be difficult to 
obtain a homogeneous preparation, without resorting to negative (or 
positive) immuno-affinity chromatography or utilising PAPP-A's interaction 
with heparin (Sinosich et a l. 1981). Techniques th a t utilise positive affinity 
chromatography, i.e. selective binding of PAPP-A to an  antibody directed 
against it require subsequent elution with chaotropic agents (Sutcliffe et a l. 
1979).
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All schemes for the purification of PAPP-A except th a t of Oxvig et a l, 
(1994) were published prior to the practical work of this thesis. A guide to 
the yield and purity  of PAPP-A prepared by the various schemes outlined in 
Table 1.1 is shown in Table 1.2. An assessm ent of the purity  can also be 
made by looking a t specificity of antisera produced by the various 
investigators, in which they used this m aterial as immunogen for the 
production of antisera directed against PAPP-A (Table 1.5).
1.4.2 P h y sico -C h em ica l C h a ra c te r is tic s  o f  PA PP-A
PAPP-A is a glycoprotein containing 19.2-19.4% (Sutcliffe et ah 1980. 
Sinosich et a l. 1990) carbohydrates w ith the major sugar residue being 
glucose (48%). The carbohydrate content has been analysed using lectins 
which have revealed the presence of sialic acid, a-D-glucose, a-D-mannose,
N-Acetyl-glucosamine and N-Acetyl-galactosamine (Sinosich, 1988a). A 
sum m ary of the various findings is given in Table 1.3
1.4.2.1 M o lecu la r O rg a n isa tio n
Prior to the work by Oxvig et a l. (1993) it was proposed th a t PAPP-A is a 
hom o-tetram er w ith a Mr of 710 - 820 kDa, (Lin e t a l. 1974b. Bischof, 
1979a. Sinosich et a l. 1987) which consists of two dimers held together by 
van der W aal's forces, each dimer being composed of identical subunits of Mr 
200 - 236 kDa covalently linked by disulphide bridges (Bischof, 1979b. 
Sinosich et a l, 1990). This proposed structure was also shown not to contain 
any thiol-esters. The carbohydrate moiety has also been suggested to play a 
role in the m aintenance of PAPP-A’s structure (Sinosich, 1990). Recently 
Oxvig et a l, (1994) have suggested th a t PAPP-A is a hetero te tram er 
composed of two sub-units of PAPP-A with two sub-units of proMBP w ith a 
calculated Mr of 474 kDa. The exact tertiary  form of PAPP-A present in  the 
m aternal serum  is unknown, it has not been established w hether all of the
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PAPP-A is in  a complex with proMBP or if it  also exists as a hom otetram er 
as described by previous investigators.
T ab le  1.3 Glycan components of PAPP-A as found by other investigators
PA PP-A  p u r if ie d  C a rb o h y d ra te  re s id u e s  fo u n d  o n  p u r if ie d
a n d  m e a su re d  by: m a te ria l:
No Galactosamine bu t contains 
Bischof (1979b) 3.1% Glucosamine.
Presence of sialic acid as determ ined by 
Sutcliffe et a l. (1980) treatm ent w ith neuram indase, N-linked groups
present as determined by incubation w ith the 
glycosidic enzyme, Endo-H.
% Total carbohydrate: 19.2% (w/w)
3.8% Glucuronic acid 
9.4% Glucose
Sinosich et a l.(T990) 3.1% Fucose
2.3% Mannose
0.8% Galactose.
% Total carbohydrate: 19.4% (w/w)
Oxvig et a l, (1994) PAPP-A monomer PAPP-A/proMBP
nd.............. Glucuronic a c id  0.92%
0.42%  F ucose....................0.41%
3.39%  M annose................ 3.05%
0.03%  G lucose...................0.03%
1.87%  G alactose............... 3.11%
4.52%  N-Acetylglucosamine .. 6.34%
0 %  N-Acetylgalactosamine.. 0.23%
3.09% .N-Acetylneuraminic acid..3.27%
13.4% Total Carbohydrate (w/w) 17.4%
[Legend: The Carbohydrate composition of PAPP-A, pro-MBP and PAPP-A/pro-MBP 
complex were as determined by Oxvig et al. (1994) compared with that obtained for PAPP-A 
(PAPP-A/proMBP complex) by Sinosich et al. (1990). The 13.4% of glycan present on PAPP- 
A monomer being equivalent to 26.5kDa carbohydrate and the PAPP-A polypeptide 
chain,172 kDa as calculated from the cDNA sequence, Kristensen et al. 1994)]
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1.4.2.2 E le c tro p h o re t ic  M ob ility
PAPP-A has a2 electrophoretic mobility (Lin et ah 1974a. Bischof,
1979b) but its isoelectric point (pi) seems to depend on the body 
compartm ent from which it  was isolated (Table 1.4).
T ab le  1.4 The pi of PAPP-A isolated by various investigators
S o u rc e  o f  PA PP-A  m e a su re d  p i
S e r u m ............................................ 4.41 4.52
EDTA p la s m a .............................................  4.352
C i tra te d  p la s m a ........................ 4.3 - 4.53
P la c e n ta l  e x t r a c t ...................................... 4.752
Note: Investigators were, halbert and Lin (1979), 2Sinosich (1988a), 3Davey 
and Teisner (1982) and 4Sinosich et al,(1983)l
1.4.2.3 O th e r  C h a ra c te r is tic s
I t  has also been shown th a t PAPP-A is a metalloprotein containing zinc 
(Sinosich etal,1983) and th a t it interacts with heparin (Sinosich et al,1981). 
Detection of PAPP-A by immunological means is not affected by repeated 
freeze/thaw cycles or exposure to a pH between 4 - 10 a t 4°C for 2hrs, bu t it 
is destroyed a t pH 2 and 12 (Lin e tal,1974b). P a rt of the PAPP-A molecule 
is cleaved during incubations with chondroitinase suggesting th a t it is a 
proteoglycan (Sinosich, 1990).
1.4.3 P A P P -A  L o c a lisa t io n  a n d  C o n tro l o f  I ts  S y n th e s is
Work published after the completion of the practical aspects of th is 
thesis by S ilahtaroglu et al. (1993) has shown by using a cDNA probe (pPA- 
1, Kristensen et a l. 1994) and fluorescence in-situ hybridisation (FISH) th a t 
the PAPP-A gene is located on Chromosome 9 a t position, p33.1.
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1.4.3.1 T he  T ro p h o b la s t
L in and H albert (1976) dem onstrated by immuno-fluoresence th a t PAPP- 
-A is present in the placenta. W ahlstrom et a l. (1981) confirmed this, bu t 
found th a t it  was almost entirely restricted to the apical border of the 
syncytiotrophoblast. McIntyre et a l. (1981) also showed it  to be localised in 
the syncytiotrophoblast but found th a t not all tissue sections stained 
strongly for PAPP-A. However ju st because it is present in the 
syncytiotrophoblast does not necessarily m ean th a t th is is its site of 
synthesis, e.g. Isaka and Bischof (1986) dem onstrated th a t PAPP-A binds to 
placental subfractions of the trophoblast with a sim ilar binding affinity to 
th a t of insulin for its GnRH receptor.
Barnea et a l. (1986b) examined long term  cultures of prim ary cells from 
the trophoblast to see if they were capable of producing PAPP-A. They 
dem onstrated th a t PAPP-A was produced and this process was inhibited by 
incubating these cells with inhibitors of protein synthesis. Bersinger et a l. 
(1988) also showed th a t PAPP-A was produced by a perfused placenta and 
th a t its synthesis was energy dependant.
Recently the identification of PAPP-A cDNA (Kristensen et a l. 1994) has 
allowed the production of PAPP-A RNA probes th a t have confirmed th a t the 
site of production of PAPP-A mRNA are the placental X-cells and syncytio­
trophoblast (Bonno et al. 1994b).
Bischof et_al,(1986a) also dem onstrated th a t trophoblastic production of 
PAPP-A could be inhibited by RU486 (a progestogen) and th a t the inhibition 
could be overcome by addition of progesterone, with the suggestion th a t  
PAPP-A is a progesterone dependant protein. Sorensen et a l. (1995) found 
th a t differing rates of production by the placenta were seen between the 
proteins: PAPP-A, SP1, hPL and hCG w ith the suggestion th a t a more 
complicated control mechanism exists for synthesis of PAPP-A and hCG. 
Work on anim al models by Pepe et_al,(1994) dem onstrated using a Baboon 
anim al model th a t by performing a foetectomy (i.e. removal of the foetus, not 
the placenta) in  mid-gestation resulted in norm al delivery of the placenta a t 
term . They also observed continued secretion of PAPP-A bu t found th a t 
m aternal PAPP-A serum levels did not continue to rise when compared to a
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norm al control group of baboon pregnancies. This suggests th a t PAPP-A is 
regulated by factors th a t regulate placental growth, contradictory findings 
to th a t seen by Bischof et a l, (1986a) were observed in th a t progesterone 
was not seen to affect the m aternal serum levels of PAPP-A. The difference 
in control mechanisms will have to aw ait further molecular studies th a t can 
now be undertaken as the cDNA for PAPP-A has been produced.
1.4.4 E x tr a -T ro p h o b la s tic  s ite s  o f  p r o d u c t io n  fo r  P A P P -A
1.4.4.1 T he  E n d o m e tr iu m
Duberg et a l. (1982) have found th a t the endometrium contains 3-4 times 
more PAPP-A th an  the trophoblast, with the levels of PAPP-A tending to 
follow histological staging, they were lowest during the inactive phase and 
highest in the secretory phase. PAPP-A levels in  the endometrium also 
correlated with the level of steroids during the phases. Duenas e t a l. (1988) 
have localised PAPP-A in endometrial (glandular and stromal) tissues 
during its proliferative and secretory phases. Bischof and Tseng (1986) have 
also shown th a t like the prim ary trophoblast cells, a prim ary cell culture of 
hum an endometrial cells is capable of producing PAPP-A and th a t it is also 
progesterone dependent. This endometrial link for an extra-trophoblastic 
site of production is also strengthened by the finding of Ikarash i and 
Takeuchi (cited from 1987) th a t by analysis of PAPP-A and Tissue 
polypeptide antigen levels it is possible to screen for endom etrial cancer. 
However in light of the findings by Tornehave et al (1987) it is likely th a t 
the PAPP-A seen in the endometrium is an artefact of the 
imm unovisualisation technique th a t was used. This has subsequently been 
confirmed a t a molecular level by Bonno et al. (1994b).
1.4.4.2 O th e r  S ite s
Schindler et a l. (1986) have visualised PAPP-A in the male genital trac t
amongst cells in  the Leydig population, the epithelium of the Rete testis, the
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head of the epididymis and the seminal vesicles. Duenas et a l, (1988) have 
also found PAPP-A in  the strom a of the ovary, cervix and ductal epithelium 
of the breast. I t  should however be pointed out th a t PAPP-A localised by the 
immunoperoxidase technique is very dependant upon the specificity of the 
prim ary antibody and the technique used for imm unovisualisation 
(Tornehave et a l. 1986).
Tornehave et ah (1987) have already dem onstrated th a t the PAPP-A 
antisera available are not monospecific. Kuhajda et ah (1989) for example 
identified a cDNA clone for a haptoglobulin related protein using the 
commercially available antisera. I t  has also been shown th a t PAPP-A 
specific staining of tissues from Stage I breast cancer could be abolished by 
pre-incubating the prim ary antibody with haptoglobulin. I t  is therefore clear 
th a t care is needed in interpreting those studies th a t have localised PAPP- 
A using an  imm unovisualisation technique.
Recently Chemnitz et a l, (1986) have also shown th a t the antisera 
developed by Bischof and used in m any localisation studies is not 
monospecific for PAPP-A but contains specificities for a t least 6 other 
antigens. In  their study they compared four different polyclonal an tisera for 
PAPP-A and showed th a t if Bischof s antisera was adsorbed w ith hum an 
serum  and foetal/connective tissue then they could abolish the detection of 
PAPP-A on the decidualised endometrium. They found th a t PAPP-A was 
only found in the cytoplasm of the syncytiotrophoblast, suggesting th a t 
PAPP-A is localised in the trophoblast and th a t other immuno-localisations 
in other tissues may be due to using a polyspecific antisera. W estergaard et 
al, (1988) have also confirmed these findings, bu t have also noted th a t by 
setting up a competitive system between PAPP-A added and the tissue for 
the antisera it is possible to dem onstrate th a t PAPP-A is associated w ith the 
apical rim  of the syncytiotrophoblast, confirmation a t a molecular level 
using anti-sense probes confirmed th a t PAPP-A mRNA was produced by 
syncytio-trophoblast cells (Bonno et al, 1994b). PAPP-A mRNA was however
1 -  16
dem onstrated in  the testes and follicular cells (Kristensen e t a l, 1994). The 
use of anim al models (Pepe et a l. 1994) also allows an in - vivo model to be 
used to look a t the affect of hormones on regulating the placental 
production of PAPP-A.
1.4.5 Assay Systems For The Measurement of PAPP-A
The immunoassays which have been used by various investigators are 
listed in Table 1.5. Investigators term  pregnancy pools are compared to an 
International World H ealth Organisation term  serum  reference pool 
(W.H.O. 78/610) which consists of a pool of late pregnancy serum  allowed 
the comparison of PAPP-A levels th a t have been found by different 
investigators and revealed very disparate levels for PAPP-A with over a 
400% difference seen in the concentrations determined ((3) and (4a), Table 
1.5).
Various antisera have been raised against PAPP-A (Table 1.6) bu t as 
observed by Chemnitz et al (1986) not all of the an tisera produced had  
epitopes directed solely against PAPP-A. This variability in the quality of 
one of the prim ary reagents will ultim ately have an affect on assays for 
PAPP-A th a t utilise an immunochemical m easurem ent system e.g. the 
immunoassays and the subsequent levels found for PAPP-A using assays 
will also be affected by the quality of the prim ary reagents th a t have been 
used.
The Investigators represented in  Table 1.6 reported th a t their an tisera 
were specific for PAPP-A. The differences described in specificity were 
probably due to the methods chosen to evaluate the an tisera produced. For 
example, Bischof et al (1979c) reported his antisera to be specific for PAPP-- 
-A by immunodiffusion, whereas this antisera was subsequently shown to 
have specifities directed against other serum proteins when tested  using 
Line immunoelectrophoresis, a more sensitive method of analysis.
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A variety of non-specific effects on the described assay systems for 
PAPP-A (Table 1.5) have been observed, see Table 1.7. The ELISA described 
suffered from non-specific m atrix effects w ith markedly increased (by 50%) 
concentrations of PAPP-A found in haemolysed plasm a when compared to 
m atched non-haemolysed controls, suggesting th a t a red cell component can 
affect the levels of PAPP-A found when using this ELISA system.
T ab le  1.5 PAPP-A immunoassays used by other investigators.
M ethod aS e n s i t iv itv bT e rm  c f  Ref.
C rossed  Im m u n o e le c tro p h o re s is* Mid-2nd trim ester 156
R o ck e t Im m u n o e le c tro p h o re s is^ 2nd trim ester 123
R a d io ro c k e t lin e  e le c tro p h o re s is^ 30 pg/1. 65
R a d io im m u n o a ssay
a) - (Bischof et al, 1981b) 33 pg/1. 258
h) - (Sinosich et al, 1982b) 3 pg/1.
c) - (Anthonv et al,1983) 20 pg/1.d) - (Pinto-Furtado et al,1984) 5 pg/1. 110
R a d io im m u n o m etric4 5 pg/1. 110
E nzym e im m unoassayS 2-3rd trim ester 90
[Legend: a The sensitivity quoted were the own investigators measure of the minimum 
levels that the listed assay was capable of measuring, if no figure was quoted then it was 
given as an estimate of the minimum level able to be measured during pregnancy. b Term 
cf Ref: This referred to the investigators own late third trimester serum pool compared to 
the W.H.O. standard.]
(^Lin et al. 1976b. ^Bischof et al. 1979c. ^Folkersen et al. 1981.4Mowles et al. 1986. 
^Pledger and Bellfield, 1983.)
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T ab le  1.6 Antisera to PAPP-A produced by various investigators
Investigator
(designation)
aTvoe Antisera 
raised in:
Im munadsorbed
with:
bSoecificitv
Lin et a l 1 
(Miami)
P Rabbits HNPPP
Bischof et al 2 
(Aberdeen)
P Rabbits HNPPPO c a t least 6. 
others
Sutcliffe et al 3 
(Glasgow)
P Sheep HMS
Folkersen et 
al4 (Odense)
P Goats HNPPP+FCS dSpecific
DAKO5
(Commercial)
P Rabbits HNPPP e>f Other 
specificities
Sinosich et al6 
(Sydney)
P Rabbits MHS d Specific
Mowles et al7 
(London)
M Mice - -
[LEGEND: aType: (P) Polyclonal. (M) Monoclonal. bSpecificity: Cross - reactivity, also see 
text. c :PZP, (X2-M, P-lipoprotein, AT-III, SP1 plus 1 undefined specificity. d:Sinosich 
(1988a). e : Kuhajda et al (1989) antibody shares epitopes with haptoglobulin related 
protein. f : also binds SPl (Sinosich, 1988c). HNPPP: Human Non-Pregnant Plasma 
Proteins. HNPPPO: Human Non-Pregnant Plasma Proteins from women on Oestrogen 
therapy. MHS: Male Human Serum. FCS: Foetal Connective Tissue.]
OLin et al. (1974a), 2Bischof et al. (1979c), 3Sutcliffe et al. (1980), Folkersen et al. (1979), 
5DAKOPATTS (Appendix 1), 6 Sinosich et al. (1987) and 7Mowles et al. (1986)).
Two RIA procedures (Table 1.5) gave markedly different results 
depending on the type of anti-coagulant th a t was used to collect the blood 
samples. The difference in PAPP-A levels th a t were found when different 
anti-coagulants were used was most m arked in th is type of assay when 
serum was compared against EDTA plasm a (The RIA described by Sinosich
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et al, (1982b) noted a 100% increase in levels). The RIA described by Pinto- 
Furtado et a l. (1984) did find a statistically significant difference in the 
levels found in serum  compared to EDTA plasm a bu t th is RIA procedure 
had a far less pronounced difference (20% increase) in the levels th a t were 
seen. The exact nature  and cause of these observed differences is unknown.
T ab le  1.7 The affect of anti-coagulants on the m easured levels of PAPP-A
Type of Assay Type of Anticoagulant Used Effect of 
Haemolysis
dACD Citrate Oxalate Heparin EDTA -
RIE1 - nc - aInc. - -
RIE2 Dec. - - Inc. Inc. -
RIA3 Dec. nc nc nc Inc. -
RIA4 - - - aInc. bInc. -
ELISA5 - - - - - Clnc.
[Legend: Levels compared against its serum value in that assay. (-): Not determined, 
(nc): No significant change in levels observed. (Inc.): Increase in levels observed in relation 
to that seen in serum. (Dec.): Decrease in levels observed in relation to that seen in serum. 
a(Action reversed by protamine sulphate). b(Increase neutralised if chelation affect 
abolished). c(Higher values observed in haemolysed samples from males). d (Acid Citrate 
Dextrose). ] OWestergaard et al (1983a), 2Toop and Klopper (1983),3Pinto-Furtado et al 
(1984), 4Sinosich et al (1985) and 5Pledger and Bellfield (1983)).
I t  has been dem onstrated th a t it is the natu re  of the PAPP-A molecule 
used for the RIA standard  and tracer in  these assays th a t was responsible 
for these observed differences and not due to the antisera th a t was used 
(Bischof and Meisser, 1988); these investigators re-evaluated their RIA in 
term s of tracer, PAPP-A standard and antibody used and concluded th a t the 
PAPP-A isolated from late pregnancy EDTA plasm a had  a component th a t 
was recognised by an antiserum  against hum an serum  proteins. They also 
noted th a t irrespective of the source of antiserum  used (Table 1.6) th a t 
coagulation also changed the level of PAPP-A detected, therefore some form 
of immunological heterogeneity has been observed for PAPP-A. I t  has been 
recently shown (Oxvig et al, 1993) th a t PAPP-A is linked by disulphide 
bonds to pro-MBP. I t  is unknown however w hether all the PAPP-A found in
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the m aternal serum  of pregnant women is complexed with pro-MBP or w hat 
effect this complex has on the different assay systems. Sinosich et a l, (1991) 
have also dem onstrated th a t PAPP-A levels when m easured by crossed 
immuno-electrophoresis are reduced when Hum an Granulocyte Elastase 
(HGE) was included in an interm ediate gel, thus suggesting an  effect on the 
m easured level of PAPP-A when PAPP-A was interacting w ith HGE. I t  is 
not known w hether a sim ilar effect is seen for the suggested PAPP- 
A/proMBP complex.
PAPP-A is a metallo-protein (Sinosich et al, 1983) and was
dem onstrated to bind Zinc. This has been confirmed a t a structural level as 
the PAPP-A cDNA (Kristensen et a l. 1994) contains a Zinc binding region. 
Therefore it is possible th a t the effect observed by Sinosich et a l. (1985) th a t 
changes in the PAPP-A levels could be removed, if the chelating affect of the 
EDTA was neutralised immediately by the addition of an excess of m etal 
ions. I t  is interesting to speculate th a t as this reversible change in PAPP-A 
levels may be due to structural changes in the conformation of PAPP-A th a t 
are effected by the chelation of Zinc with EDTA which is reversed when this 
affect was abolished. Similar changes in the PAPP-A levels seen when 
heparin was present were reversed if the heparin  antagonist, protam ine 
sulphate was used. This indicates th a t the tertia ry  structure of PAPP-A 
affects the PAPP-A levels m easured in the blood using the described 
immunoassays
1.4.6 PAPP-A Levels Found In The Maternal Blood During 
Pregnancy
The affects of the PAPP-A immunoassays described in  th is Chapter may 
explain the different biochemical profiles th a t were obtained for PAPP-A 
when different investigators have followed the levels of PAPP-A found in the 
m aternal blood during pregnancy (Figures 1.3 and 1.4).
Bischof and M eisser (1988) have also observed th a t depending upon 
w hether the PAPP-A used to prepare the tracer in  an RIA was from EDTA
1 -  21
plasm a or serum , th a t m arkedly different results were obtained th a t were 
independant of the PAPP-A an tisera  used. The results affected, effectively 
changed w hether or not PAPP-A was found in non-pregnant individuals and 
may explain why some investigators find PAPP-A in the blood of males/non­
pregnant females (Bischof and Megevand, 1986. Bueler and Bersinger, 
1989), whilst others could not (Anthony et a l. 1983. Pinto-Furtado et a l, 
1984)._____________ _____________________________________________ _____
M a te rn a l PA PP-A  L evels (IU/L)
10 -
1- 0 -
0 - 1-
161210 148
W eeks o f G e s ta tio n
F ig u re  1.3
The levels of PAPP-A found in m aternal blood during the first trim ester of 
pregnancy.
[Legend: 1: Levels as found using a RIA described and adapted from Bischof et al,(1981a) 
with measurement of EDTA plasma samples. 2 : Levels as found using a RIA described and 
adapted from Pinto Furtado et_al,(1984) with measurement of serum samples. Note: 
Assumed that the International Reference Standard 78/610, contained 100 IU/L.]
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The differences in the m easured level of PAPP-A are dependant upon 
assay type, sta te  of the blood (e.g. serum  or plasma) and are m aintained 
throughout pregnancy (Figure 1.4). I t  is however generally believed th a t 
PAPP-A can be detected in the blood from the fourth week of gestation and 
th a t it continues to rise until parturition. The problems outlined make the 
in terpretation of many of the clinical studies performed not only dependent 
upon clinical differences between patients bu t also to artefactual differences 
in the m easurem ent of PAPP-A and may explain why such conflicting 
clinical data has accumulated (Section 1.4.7).
M a te rn a l PA PP-A  L evel (IU/L)
2 0 t h  C e n t i l s
M e d ia n
2 0 t h  C a n t i i s
/  1 0 th  C e n t i i e
M e d ia n
1 0 th  C e n t i i e
5 4
W eeks o f G e s ta t io n
F ig u re  1.4
Schematic illustration of the m aternal levels of PAPP-A found in  the blood 
during pregnancy.
[Legend:1: Adapted from Barnea et al. (1986a). 2: Adapted from Westergaard and Teisner, 
(1983b). Note: Assumed that the International Reference Standard 78/610 contained 100 IU/L.]
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1.4.7 T h e  D ia g n o s t ic  U s e fu ln e s s  O f P A P P -A  M e a su r e m e n ts
M any stud ies have been performed to see if circulating PAPP-A levels 
can be used as a biochemical param eter in obstetric diagnosis. The basic 
criterion for a biochemical param eter of foetal/placental function is w hether 
th a t param eter can be used to distinguish norm al from pathological 
pregnancies. PAPP-A is found in relatively high concentrations in  the 
m aternal serum, therefore it can be m easured by simple immunochemical 
methods. I t  also shows very little diurnal variation and so fulfils some of the 
secondary criteria for an obstetric biochemical param eter (Chard, 1976). 
Quantification of m aternal PAPP-A levels have been performed to see if it 
would be of use in the prediction and m anagem ent of certain abnorm alities 
of pregnancy:
• Threatened miscarriage.
• Ectopic pregnancy.
• Pre-eclamptic toxaemia.
• Congenital disorders.
1.4.7.1 T h re a te n e d  M isca rriag e /A b o rtio n
“ Abortion, spontaneous abortion and m iscarriage  refer to the
unexpected loss of a pregnancy prior to the period of fetal viability. ” (as 
quoted from W inter et a l.1988). Threatened M iscarriage (TMC) being the 
appearance of prelim inary signs of being about to abort the foetus/embryo 
but stopping before this outcome is reached. I t  is estim ated th a t TMC occurs 
in  up to 25% of all pregnancies (Stabile et a l, 1988) and th is is a figure th a t 
has rem ained unchanged for decades. TMC can be diagnosed by direct 
vaginal exam ination if the cervix is dilated, however a diagnosis of TMC is 
not possible by physical examination where the cervix is closed. Initially  it 
was hoped th a t bleeding could be used as an  indicator of TMC, b u t as m any
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as 20% of patients have vaginal bleeding. I t  has been shown th a t a higher 
percentage of this group of patients who present with vaginal bleeding do 
subsequently abort when compared to those patients who do not present 
w ith vaginal bleeding. This diagnostic problem has partially  been solved 
with the advent of Ultrasound, now it is possible to reliably determine the 
presence of a live foetus after six weeks gestation and therefore a lter the 
clinical m anagem ent of women with TMC.
Stabile et a l. (1988) have showed th a t ultrasound is of use in the 
m anagem ent of TMC post 7 weeks gestation, w ith the prognosis th a t if 
foetal life is confirmed during the first trim ester of pregnancy then  95 - 98% 
of these women will progress to the normal outcome of pregnancy.
Of the possible biochemical indicators th a t can be used it has been found 
th a t if PAPP-A levels are depressed when compared to norm al pregnancy, it 
can then  be used as a predictor of miscarriage (Bischof et a l, 1986a. Stabile 
et a l. 1988. and Bischof e t a l. 1989). W estergaard et al,(1985) has 
subsequently qualified this in th a t PAPP-A can be used as a biochemical 
indicator if foetal life is evident by ultrasound. If the h eart action was 
normal and the level of PAPP-A were normal, then  the chance of a normal 
outcome of pregnancy was in excess of 98%. I t  was also found (W estergaard 
et a l. 1983b) th a t of the biochemical param eters (hCG, SP1, hPL and PAPP- 
A), only PAPP-A levels were depressed if foetal heart action was present and 
a subsequent abortion occurred. Moussa et a l. (1988) have also shown th a t 
PAPP-A levels were consistently lower in those patients who spontaneously 
abort when compared against another group in which abortion was elected 
for by the patient. However the usefulness of PAPP-A to predict subsequent 
abortions has not been found to be superior to other biochemical param eters 
by all investigators. Bersinger et a l. (1987) did find th a t PAPP-A levels were 
depressed in  TMC but th a t it did not improve upon the predictability 
conferred by a hCG measurement.
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1.4.7.2 E c to p ic  P re g n a n c y
Im plantation of the blastocyst normally occurs in the endometrium of the 
uterine body, bu t it may also occur in an extrauterine or ectopic site. 
Im plantation occurring near the in ternal os u teri (Figure 1.2a) gives rise to 
a condition known as placenta praevia which can cause severe ante-partum  
haem orrhage. This condition has been found to occur in 0.5 % of 
pregnancies. Modern diagnostic methods and rapid surgical intervention 
have led to a fall in  m aternal m ortality caused by ectopic pregnancy. 
However better treatm ent of the other causes of m aternal m ortality has led 
to Ectopic pregnancy being an even greater contributor to m aternal 
m ortality in  the w estern world (W estergaard et a l. 1988). The risk  of ectopic 
pregnancy has also been compounded by a study th a t has shown a link 
between those patients undergoing tubal surgery and IVF-ET having a 
higher incidence of ectopic pregnancies (Bischof et al, 1989). These two 
factors have led to a renewed in terest in methods th a t can be used to 
diagnose ectopic pregnancy. The diagnostic procedure followed should show 
th a t the patien t is pregnant and whether the foetal-placental tissue is 
located outside its norm al position in the uterus.
Bischof et a l. (1989) have reported th a t PAPP-A levels are depressed in 
ectopic pregnancy with the finding th a t depressed levels in the m aternal 
blood occur from day 30 onwards. They found it  to be an  excellent 
prognostic param eter for ectopic or in trauterine abortion w ith a sensitivity 
of 87.5% and a predictive value of 100%. They concluded th a t PAPP-A can 
be used to monitor post-implantation embryo viability following IVF-ET. 
Sinosich et a l, (1985) have also found th a t in conjunction w ith a positive 
pregnancy test and clinical history, th a t severely depressed or undetectable 
serum  PAPP-A was indicative of suspected ectopic pregnancy.
A larger study of 207 women with suspected ectopic pregnancy 
(W estergaard et a l. 1988) also bears out the use of PAPP-A to detect ectopic 
pregnancies, but they also suggested th a t it was not the ideal te s t prior to
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8 weeks. Sauer e ta l, (1989) also came to the conclusion th a t a single PAPP- 
A m easurem ent was of little value in determining norm al from abnormal 
pregnancies prior to 8 weeks gestation. The need for early diagnosis of 
ectopic pregnancy seem therefore to exclude PAPP-A as a biochemical 
param eter for it diagnosis, however Tornehave et ah (1987) have also shown 
th a t the syncytiotrophoblast tissue staining for PAPP-A matches its 
m aternal serum  levels. Ectopic tissues studied had PAPP-A values all 
below the lO^1 centile, with PAPP-A levels being implicated in this 
pathological condition by m easurem ents a t both local (tissue) and a t the 
periphery (blood). Its use therefore as a diagnostic tool for the diagnosis of 
ectopic pregnancy has not yet been ruled out.
1.4.7.3 Pre-eclam ptic toxaem ia
Pre-eclamptic toxaemia (PET) occurs in  3 - 5% of pregnancies, the cause 
has not yet been elucidated. I t  is characterised by a raised blood pressure, 
proteinuria and oedema. Eclampsia is a severe degree of PET and if 
un treated  leads to the death of the patient.
PET is one of the earliest recognised disorders being observed over 100 
years ago and is present in about 7% of pregnancies, three quarters develop 
hypertensive pregnancies during the last trim ester of pregnancy, it is 
responsible for over half of all perinatal m aternal deaths seen in  the USA 
(Blazer et ah 1991). Surgical intervention in the form of caesarean section 
has led to the m ortality rate  being reduced to 1% in  some clinics. Sm ith et 
al, (1979) observed th a t m aternal levels of PAPP-A rose in  those patients 
th a t suffered from PET and th a t th is rise often preceded any overt signs of 
this condition, the significance of this still has to be determined.
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1.4.7. 4 C o rne lia -de-L ange  S y n d ro m e
This is a rare  syndrome with an estim ated occurrence of 1: >10,000 live 
births. I t  is known as the Cornelia de Lange (CL) syndrome w ith the first 
published account by this Paediatrician in 1933, the condition was also 
described by Dr Brachm ann in  1915 (Opitz, 1985). I t is a serious syndrome 
producing severe m ental retardation  in the infant and has characteristic 
facial and limb dysmorphic features; with small stature, hypoplastic middle 
phalanx of the index fingers and gastroesophageal reflux. I t  is not always a 
fatal syndrome and current diagnosis relies upon recognising the 
dysmorphic features. Early recognition is essential as dietary changes 
combined with surgical treatm ent for the gastroesophageal reflux has been 
seen to reduce morbidity and m ortality in children w ith th is syndrome 
(Sataloff et ah 1990 and Rosenbach et a l. 1992). The lack of foetal m arkers 
makes antepartum  diagnosis difficult but it has been suggested (Bruner 
and Hsia, 1990) th a t a diagnosis is possible by comparing the triad  of:
• Abnormally low m aternal serum AFP.
• Symmetrical In trau terine  growth retardation.
• U ltrasound exam inations for foetal abnorm alities in  the second
trim ester.
I t  has also been suggested th a t hormonal derangem ent may play a role 
in the m anifestations of this syndrome (Sataloff et a l. 1990). CL has a 
relatively poor prognosis as relatively few patients survive into adulthood. 
Some familial transm ission has been seen, however the m ajority of CL cases 
are sporadic. An autosomal dominant mode of inheritance has been 
suggested, bu t no clear chromosomal region has been identified. The only 
candidate regions th a t have been seen were a balanced 3; 17 chromosomal 
translocation and ring 3 and 9 chromosomes. No consistent chromosomal 
abnorm ality has been observed in CL cases. PAPP-A levels have been 
suggested as another biochemical indicator as they have been dem onstrated 
to be undetectable in the m aternal serum  or trophoblastic tissues of 
patients w ith this rare  syndrome (W estergaard et a l. 1983c). This combined 
with the observation th a t the locus for PAPP - A is on Chromosome 9
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(S ilahtaroglu et a l, 1993) and one case of CL has been associated with a 
ring 9 chromosomal abnorm ality (Opitz, 1985) suggests th a t PAPP-A may 
be implicated in the aetiology of this syndrome but fu rther studies are 
needed to define it’s role.
1.4.7.5 D ow n S y n d ro m e
John Down in 1866 described a series of patients w ith w hat is now 
defined as Down Syndrome (DS). The cause of th is phenotype was found to 
be trisomy of chromosome 21 in 1959. Approximately 1 in  600 - 800 live 
births are born with DS (Hernandez and Fisher, 1996). A range of clinical 
features seen with this syndrome are described in Table 1.8.
T ab le  1.8 Clinical Features of DS
1C lin ica l F e a tu re s F re a u e n c v  o f F e a tu re s  S een  in  DS P a t ie n ts
M ental Retardation 992>3 %
Neonatal Hypotonia 1003 %
Dysmorphology - 902 % Flattened facial features.
- 502 % Speckled Iris.
AD H istopathology 1003 % by the age of 35 years 
(30% have AD-dementia by age of 40.)
Cong. H eart Defects 40 - 602’3 %
Growth Retardation 314 % below 10th centile a t term .
Acute Leukaemia 13 %
[Legend: AD: Alzheimer Disease. Cong.: Congenital. 1Clinical Features: These are not a 
comprehensive list but represent a selected range of features; A comprehensive listing of DS 
features can be found in: 2: Buyse, 1990. 3: Hernandez and Fisher, 1996. 4:Cuckle and 
Wald, 1992.]
I t  is the most common form of aneuploidy seen in Man; the observation 
th a t a m aternal serum  m arker (alpha-fetoprotein, AFP) is reduced in DS 
pregnancies (Cuckle et a l. 1987) led to the possibility of screening for this 
aneuploidy. Wald (1988) suggested the use of the biochemical m aternal 
serum  triple test assaying for AFP, Total hCG and Unconjugated free in  
Oestriol between 15 and 22 weeks of pregnancy and th is is now established 
m any countries.
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1.4.7.5a M a te rn a l S e ru m  S c re e n in g  fo r DS in  th e  2nd  T r im e s te r
A multi-centre evaluation of m aternal serum  screening methods (Ward, 
1994) dem onstrated th a t the m easurem ent of unconjugated Oestriol adds 
little to the risk  assessm ent (probably because it includes a m aternally 
derived component, Cuckle and Wald, 1992). A superior assessm ent of risk 
is obtained by m easuring levels of free p-Chain of hCG and AFP (Table
1.9).
T ab le  1.9 Detection Rates for DS in the 2nd Trim ester when analysing
different m aternal serum  analytes.
A n a lv te  m ea su re d : % d e t e c t i o n  ra te :  % 2F a lse  p o sitiv es :
3AFP + Free phCG 63.8 5.9
3AFP + T o tal hCG 55.3 6.5
3AFP + ThCG + UE3 55.1 7.1
[Legend: h Given as proportion of affected pregnancies with positive results. 2: Given as 
proportion of unaffected pregnancies with positive results. 3: Figures given were derived 
from Ward, 1994.]
PAPP-A levels have been shown not to be significantly different in  Down 
syndrome pregnancies when compared to norm al unaffected pregnancies in 
the second trim ester (Knight et a l. 1993), I t is thus not a useful m aternal 
serum m arker in  the second trim ester. PAPP-A m easurem ents in  the first 
trim ester of pregnancy are significantly lower in trisomic foetuses th an  in 
norm al controls (Wald et ah 1992). This may therefore form the basis of an 
effective first trim ester screening program.
1.4.7.5b M a te rn a l S e ru m  S c re e n in g  fo r DS in  th e  1st T r im e s te r
I t  has been dem onstrated th a t m aternal serum  PAPP-A levels are 
reduced in chromosomally abnormal foetuses (Wald et a l. 1992). Bersinger 
et a l. (1994) and Bram bati et a l. (1994) have also raised the possibility of 
m aternal serum  screening in the first trim ester with the indication th a t a 
combination of age and PAPP-A levels offer a higher aneuploidy detection 
ra te  when compared to phCG and m aternal age alone.
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The conclusion of m ulti-centre tria l assessing first trim ester screening for 
DS aga inst a panel of seven m aternal serum  m arkers concluded th a t 
m aternal serum  screening for DS is now a practical proposition in  the first 
trim ester of pregnancy. The most discriminatory m arkers appeared to be a
combination of P-hCG and PAPP-A (Wald et al, 1996, Table 1.10).
Approximately 50 % of DS pregnancies abort between the first trim ester and 
term . I t  is likely th a t the m aternal biochemistry a t the tim e of CVS may 
reflect the process of miscarriage, Stabile et al. (1988) have shown th a t the 
m aternal levels of PAPP-A in pregnancies th a t go on to m iscarry are 
reduced. Thus screening for DS during the first trim ester will also detect 
pregnancies th a t would not have proceeded to term.
T ab le  1.10 Comparison of m aternal serum DS screening during first
and second trim ester of pregnancy
F ir s t T r im e s te r S econd T r im e s te r
iS_z 14 w ks) (1 5 - 22 w ks)
^ n a l v t e s  m ea su re d : % 2DR % 3FP % 2DR % 3F P
4PAPP-A,p-hCG+ mat. age 62 5 54 5
5Triple Test n d n d 59 5
6Quadruple Test n d n d 727: (657) 5
8Nuchal translucency (NT) 86 5 n d n d
NT + Serum M arkers8 91 5 n d n d
[Legend: h Maternal serum markers used for DS screening. 2: Detection rate as defined 
in Table 1.9. 3: False positives as defined in Table 1.9. 4: Figures derived from Wald et al. 
1996. 5: Triple test as defined by Wald (1988) and listed above. 6: Quadruple test as defined 
by Wald et al. 1995. 7: Percentage detected if gestational age determined by ultrasound 
dating (Percentage detected if gestational age based on LMP dates). 8: Data taken from 
Wald et al. 1995. Note: Mat.: Maternal nd.: Not determined/or reported.]
I t  has been proposed by Wald et a l. (1995) th a t by combining ultrasound 
examination of nuchal translucency during the first trim ester w ith a 
biochemical screening program will increase the detection ra te  to >80% and 
reduce the false positive rate  to < 5%, bu t this will have to aw ait a combined 
control trial.
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1.4.7.6 T he  u se  o f  B io ch em ica l T es ts  To A ssess F o e ta l  W ell-being
I t  has been suggested th a t biochemical tests indicating foetal well-being 
have fallen into disfavour (KLopper, 1987). This has m ainly been because 
they have a large norm al range, thus making it difficult to separate normal 
from pathological conditions in pregnancy. The situation is further 
compounded in th a t most of the new placental proteins have no ascribed 
function. This class of proteins may have a role in an tenatal monitoring, 
PAPP-A can now be used as a biochemical indicator for first trim ester 
screening of Down syndrome (section 1.4.7.5).
1.4.8 In -V itro  B io log ical R oles A ttr ib u te d  To PA PP-A
During the period since PAPP-A’s isolation several biochemical effects 
have been a ttributed  to PAPP-A (Table 1.11).
1.4.8.1a Im m u n o su p p re s s io n
M artin-du-Pan et a l. (1983) did not dem onstrate th a t PAPP-A inhibited 
PHA induced lymphoblastogenesis as they used sem inal plasm a and 
correlated levels of PAPP-A with the degree of immunosuppression seen. 
Bischof et a l. (1983) used PAPP-A th a t was contam inated w ith other serum  
proteins th a t were immunosuppressive. Thus the contradictory findings 
th a t PAPP-A does not inhibit PHA induced lymphoblastogenesis by 
McIntyre et a l. (1981) and Sinosich et a l. (1984) confirm th a t it is unlikely 
th a t PAPP-A is involved in immune suppression.
1.4.8.lb /c  In h ib it io n  o f  C om plem ent(b ) a n d  F ib rin o ly tic (c )  sy s tem s
PAPP-A was shown to inhibit complement fixation and throm bin induced
coagulation (Bischof, 1979a. Meisser et a l, 1985) whereas others could not
show this (Gore et a l. 1984, Sinosich et a l. 1990). Meisser et a l. (1988a,
1988b) dem onstrated th a t the initial activity attribu ted  to PAPP-A was an
artefact and both the reported inhibitory actions were likely to be due to the
presence of heparin th a t is known to inhibit both the complement and
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fibrinolytic systems. The initial m aterial and effect noted by Bischof in  1979 
used PAPP-A th a t was not contaminated with heparin. The initial inhibition 
dem onstrated was probably due to the purity  of PAPP-A used as this 
m aterial has been subsequently shown to be contam inated w ith other serum 
proteins. PAPP-A has not been shown to convincingly inhibit e ither of these 
two systems.
1.4.8.Id  P roteo ly tic  Inh ib ition
Bischof (1979a) dem onstrated inhibition of plasm in bu t as already 
described the m aterial used was contam inated with other serum  proteins 
and others (Gore et al. (1984), Sinosich (1990)) did not dem onstrate an 
inhibition of plasmin. I t  is thus unlikely th a t PAPP-A inhibits either of 
these two pro teases.
I t  has been suggested by Sinosich et_al,(1982a, 1991) th a t PAPP-A is a 
specific inhibitor of hum an granulocyte elastase (HGE). O ther investigators 
have suggested th a t this inhibition is due to a heparin contam inant (Bischof 
et al. 1990) th a t is responsible for the inhibition of HGE. Oxvig et a l. (1994) 
have found th a t the described inhibition is non-specific in  na tu re  (Table 
1.12). The inhibition of HGE by PAPP-A is considered below.
Bischof et a l. (1990) found th a t HGE was inhibited by heparin  sepharose 
column washings in absence of PAPP-A under hypotonic (>0.15 M NaCl) 
conditions, w ith suggestion th a t the reported inhibition of HGE by PAPP-A 
was due to a leeched heparin  contam inating component. In  contrast 
Sinosich and Zakher (1991) found PAPP-A’s inhibition of HGE was labile, 
inactive PAPP-A did not to inhibit HGE a t isotonic or hypertonic NaCl 
concentrations. In  contrast heparin th a t was found to inhibit HGE under 
isotonic conditions bu t not a t hypertonic (>0.15M NaCl) conditions. PAPP-A 
inhibition could be shown to specifically inhibit HGE under hypertonic 
conditions where heparin was shown to have no inhibitory affect.
Contradictory findings were observed by Oxvig et a l, (1994) who 
suggested th a t the inhibition is likely to be due to electrostatic interactions 
between the glycosaminoglycan on proMBP linked to PAPP-A in  their
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purified PAPP-A and a set of Arg-residues located near the active site of 
HGE.
T ab le  1.12 Type of HGE Inh ibition observed with PAPP-A
In v e s tig a to r  (s) T ype o f 
In h ib it io n
in h ib i t io n  
(<0.15M N aCl)
in h ib i t io n  
(>0.15M NaCl)
Sinosich et al, (1982a) Non-Competitive
(Specific) n d n d
Sinosich et al, (1990) Non-Competitive
(Specific) n d n d
Sinosich/Zakher (1991) n d
(Specific) ++ ++
Oxvig et al, (1994) Competitive,
(Non-specific)3 ++ -
[Legend: nd: not determined (or reported). ++: Inhibition positive. -: Inhibition negative, 
h Reaction performed under hypotonic NaCl conditions. 2: Reaction performed under 
hypertonic NaCl conditions. 3: Cathepsin-G competitively inhibited.]
A possible explanation of the contradictory results obtained by Sinosich 
et ah (1982a, 1990, 1991) and Oxvig et a l. (1994) for the inhibition of HGE 
by PAPP-A could be due to differences in composition of PAPP-A purified by 
these two groups. I t  has been dem onstrated th a t proMBP binds to heparin 
and is purified by affinity chromatography to this m atrix (Popken-Harris et 
al, 1994). Sinosich et a l. (1987) use a heparin affinity m atrix and negative 
immunoaffinity against non-pregnancy heparin binding proteins. Thus it is 
possible th a t this antibody removes the PAPP-A/proMBP complexes th a t 
have been described by Oxvig et a l. (1994) to yield PAPP-A free of proMBP. 
The discrepancy in type and specificity of inhibition of HGE by PAPP-A 
found by these two groups is a t present unresolved.
1.4.8.2 S p e rm  M otility
I t has been seen th a t the levels of PAPP-A found in sem inal plasm a 
correlate w ith sperm motility (Bolton et a l. 1986), w ith increased PAPP-A 
levels found in samples in which the sperm had  a motility >60%. I t  is not 
known w hether this represents an effect on sperm motility, or is due to the
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presence of increased accessory gland secretions th a t have been noted to 
have an affect on sperm motility. The significance of this observation is a t 
present unknown.
1.4.8.3 C a r r ie r  P ro te in
Sinosich et ah (1983) noted th a t PAPP-A interacted and chelated, Zinc. 
They also dem onstrated th a t PAPP-A has an absorption maximum a t 214 
nm th a t is characteristic of an interaction for a zinc carrier protein. An 
analysis of PAPP-A cDNA (Kristensen et ah 1994) reveals the presence of a 
putative Zinc binding site th a t is characteristic of metalloproteinases. Thus 
PAPP-A binds Zinc, the function of which is a t present unknown.
1.4.8.4 In -V ivo  B io log ical fu n c tio n  o f PA PP-A
T hat such a diverse set of ascribed functions has been a ttribu ted  to 
PAPP-A In-Vitro th a t have been confirmed and refuted by different 
investigators is probably a reflection on the purity  of the PAPP-A m aterial 
th a t was used. The biological function of PAPP-A in-vivo has probably yet 
to be elucidated.
1.5 A im s o f The Study
The aim of th is study was to further characterise the PAPP-A molecule; 
to this end a molecular approach was undertaken. This necessitated an 
assessm ent of the antibodies available for PAPP-A and involved the 
isolation of the PAPP-A protein in a homogeneous form th a t enabled 
prim ary sequence information to be generated for PAPP-A. This information 
allowed the production of PAPP-A specific oligonucleotide probes th a t were 
used to screen a placental cDNA library. The isolation of a pure PAPP-A 
monomer allowed a further characterisation of the PAPP-A monomeric sub­
unit.
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CHAPTER
TWO
Chapter Two 
M aterials And M ethods
2.1 M aterials and G eneral E quipm ent
A detailed list of m aterials, equipment and suppliers used in this study 
can be found in Appendix 1. Unless otherwise indicated all other chemicals 
were of BDH A nalar’ grade or its equivalent. The preparation of stock 
reagents and buffers is described in Appendix 2. The distilled w ater referred 
to as dH2 0  in  the text was glass-distilled, de-ionised and filtered (0.2 pm)
nanopure grade (>16.7 Megaohms).
Aseptic techniques were performed as described in  Sambrook et al 
(1989). General sterilisation of plasticware and solutions (unless otherwise 
indicated) was achieved by autoclaving a t 15 lbs. pressure for 15 minutes. 
F ilter sterilisation where required was through 0.22pm syringe filters 
(Sarstedt).
Blood samples were obtained in  collaboration w ith Dr T.C. Lee, Jessop’s 
hospital, Sheffield. M aternal blood was obtained from women a t term  with 
their informed consent. All blood samples were collected as either EDTA or 
C itrated Plasm a unless otherwise stated  (section 2.7.2, Chapter 2).
An International Reference serum  78/610 was used initially as a 
standard for PAPP-A. I t  was assumed th a t this contained 110 pg/ml (Pinto- 
Furtado et a l,1984) of PAPP-A. This was a kind gift of the International 
Agency for Research on Cancer, 150 Cours Albert-Thomas, Lyon, France.
Monoclonal antibodies to PAPP-A were produced and kindly provided by 
Ms E.A. Mowles, D epartm ent of Biology and Biochemistry, University of 
E ast London.
Heparin-Sepharose (pre-1984) was kindly donated by M r R. Stoker, 
D epartm ent of Biology and Biochemistry. University of E ast London.
Partially  purified PAPP-A used initially for radioiodination was kindly 
supplied by Miss K. Price, The Royal London Hospital, W hitechapel.
Allesheria terrestris culture supernatant was a kind gift of Dr E. 
Kvesitadze, Republic of Georgia.
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2.2. S erv ices U sed  D uring This Study:
2.2.1 C u sto m  O lig o n u c leo tid e  S y n th e s is
These were produced in - house using PAC phosphoramidites on a 
Pharm acia LKB Gene Assembler Plus by M r P. Loxley. De-protection and 
end-processing was as described in Appendix 2.
2.2.2 P ro te in  S e q u e n c in g
• Dr K. Lilley, D epartm ent of Biochemistry, University of Leicester.
• M r J. Gilroy, D epartm ent of Biological Sciences, University of Durham.
• Dr A. Moir. D epartm ent of Molecular Biology and Biotechnology, 
University of Sheffield.
2.2.3 A m ino A cid  A nalysis
• Dr A. Moir. D epartm ent of Molecular Biology and Biotechnology, 
University of Sheffield.
2.3 G eneral M ethods
2.3.1 T he D e te rm in a tio n  o f  P ro te in  C o n c e n tra tio n
Protein concentration can be estim ated by spectrophotometric methods 
either directly by absorption of UV light a t 280 nm or following the addition 
of chemicals th a t in teract with proteins leading to the form ation of a 
coloured complex with a maximum of absorption within the visible range. 
The am ount of protein in an  unknown sample can then be determ ined by 
comparing its absorbance with th a t of the standard. Two methods were 
used in this study, one based on the colour change when CBB dye binds to a 
protein (Bradford, 1976). The other utilised protein interaction w ith BCA, 
as originally described by Sm ith et a l. (1985).
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2.3.1.1 Bradford P rotein  A ssay
When the Dye CBB G-250 binds to basic and aromatic amino acids 
(Compton and Jones, 1985) there is a shift in  the absorption maxima of the 
dye from the red form to the blue form th a t can then  be used as a measure 
of the am ount of protein present. The microassay procedure as described in 
the Bio-Rad Protein Estim ation k it was used, using BSA as the standard 
protein. Briefly, 800 pi of sam ples/standards diluted in  PBS were mixed 
w ith 200 pi of Bio-Rad dye concentrate by vortexing. The samples were left 
for 10 m inutes and then  the absorbance was read a t 595 nm.
The m ain problem with this assay was due to the dependence of dye 
binding on the num ber of basic and aromatic amino acids, leading to 
differences in binding due to the protein prim ary structure. I t  was also seen 
to suffer from interference by buffer components th a t in teract w ith the 
protein or dye components. However the assay components were very stable 
over time and it was used mainly to determine protein levels when loading 
electrophoresis gels.
2.3.1.2 BCA protein  assay
Proteins are known to reduce alkaline Cu(II) to Cu(I) (Lowry, 1951). 
Bicinchoninic acid has been shown to be a specific chromogenic reagent for 
Cu(I), on interaction it  forms a purple complex whose resulting absorbance 
is directly proportional to the protein concentration. The BCA assay and its 
composition is essentially th a t of Sm ith et al (1985). A modified BCA assay 
was used using a microtitre plate format. Briefly 20 pi of sample (or 
standard) was placed in a microtitre plate well, 20 pi of 0.1 M NaOH and 
200 pi of BCA reagent was then added to each well. The microtitre plate was 
mixed a t RT for 60 m inutes using a Denley well-mix . I t  was found th a t a 
modification of an  alkali addition to this micro-assay did not resu lt in  a 
change in  levels m easured in the protein standard  (BSA) used , Figure 2.1. 
I t  did however resu lt in less variation in  protein levels th a t were found and 
m easured during the purification of PAPP-A. The m easured levels were 
closer to the levels observed using other methods of protein estim ation such 
as the absorbance a t 280 nm and integration of elution profiles. This
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modified BCA microtitre plate assay was used to monitor protein levels 
found during the purification of PAPP-A.
0.01
100 1000 
Pro te in  C o n ce n t ra t io n  (BSA. jug/ml)
f i g u r e  2.1
The BCA protein micro-assay (+/- alkali addition) with BSA used as the
protein standard.
[Legend: All points were in triplicate. (■); indicates standard plus alkali addition, 
r2 = 0.992. (A); indicates PBS in place of alkali addition, r2 = 0.996],
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2.3.2 E lectrop horetic  M ethods
Electrophoresis is a method whereby charged molecules m igrate in 
response to the application of an  electric field. Proteins are amphoteric, so in 
a solution whose pH is above the proteins iso-electric point then  the protein 
will have a net negative charge. Nucleic acids are negatively charged a 
broad range of pH, so under these conditions macromolecules will m igrate 
towards the anode.
2.3.2.1 H orizontal A garose Slab Gel E lectrop horesis o f  DNA
Aaij and Borst (1972) dem onstrated th a t the electrophoretic mobility of 
DNA molecules in agarose and polyacrylamide gels is inversely proportional 
to the log of their molecular weight. By varying the agarose concentration 
and buffer composition it is possible to separate DNA in the size range 20bp 
- lOKbp. Submerged horizontal electrophoresis was performed as described 
in Sambrook et a l. (1989). In  brief an  X% (w/v) agarose gel (low EEO) was 
prepared in  Tris-Acetate buffer, on cooling ethidium  bromide was added to 
a final concentration of 1 pg/ml. This was then poured into a horizontal gel 
former (Biometra) and a comb positioned. The gel was allowed to set for a 
minimum of 30 m inutes and was subsequently submerged in  Tris-Acetate 
buffer. The submerged gel allows quick dissipation of any h ea t generated 
during electrophoresis, so reducing any band distortion. Samples were p re­
treated  by adding 0.2:1 (v/v) of sample buffer:sample (Appendix 2) and 
loaded into gel slots. Electrophoresis was performed a t 120 V (constant 
voltage) until the BPB front was approximately 2/3rds the length of the gel 
and visualisation was by exposure of the gel to UV - light.
2.3.2.2 SDS-PAGE
A modified Laemmli (1970) SDS PAGE system was used, which has the 
following essential features:
•  A modification of th a t originally described by O rnstein (1964) who 
outlined the theory and its practical application, as described by Davis 
(1964) for a discontinuous system th a t has a non-restrictive large pore 
stacking gel th a t is layered on top of a resolving gel. Each of these gels was
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made w ith a different buffer, the tank  buffers was also of a different 
composition from th a t present in the gel. This ensured th a t the protein 
loaded m igrates a t an  interm ediate ra te  th a t was determ ined by the 
mobility of the buffer ion in  the stacking gel (leading ion) and the mobility of 
the buffer ion in  the upper tank  (trailing ion). When electrophoresis starts 
then  the ions and proteins s ta rt to m igrate into the stacking gel. The 
proteins then  concentrate into a very th in  zone, the stack between the 
leading and trailing ions. This continues until they reach the resolving gel 
and results in a loading of a sharp band onto the resolving gel.
•  The majority of proteins have been shown to bind 1.4 g of SDS per lg. 
of protein (Reynolds and Tanford,1970), this ensures th a t proteins in effect 
become negatively charged rods th a t have equal charge densities over their 
entire length. If electrophoresis occurs through a m atrix w ith a constant 
pore size, separation will occur as function of size as molecular sieving will 
take place. This slows down the migration ra te  of a larger protein when 
compared to its sm aller counterpart, thus resulting in  an  inverse linear 
relationship when plotting the log Mr of the protein Vs its relative mobility.
A highly uniform gel structure with a consistent pore size is produced by 
polymerising acrylamide under controlled chemical conditions using an  
initiator which produces oxygen free radicals (e.g. ammonium persulphate) 
from a base catalyst (e.g. TEMED). Oxygen acts as an  inhibitor of 
polymerisation so the top of the resolving gel is covered w ith w ater 
sa turated  n-Butanol to lim it this effect and reduce any meniscus effects a t 
the top surface of the resolving gel.
2.3.2.2a The Laem m li (1970) SDS-PAGE System
This system with the following modifications was used:
• Samples were diluted 1:1 (v/v) in sample buffer (Appendix 2) and then  
boiled for 2 minutes, centrifuged briefly and loaded onto the gel. Prior to 
sample loading the stacking gel slots were washed with running  buffer to 
remove any unpolymerised acrylamide.
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• A 5% (w/v) polyacrylamide (30%T: 2.7% C) separating gel was cast using 
Tris-HCl a t pH 8.6, w ith the stacking gel a t pH 6.8. Both gels contained 
a final concentration of SDS of 0.1% (Table 2.1).
• The in itiator and catalyst of polymerisation were ammonium 
persulphate and TEMED respectively.
• The tank  stock running buffer (Appendix 2) was diluted tenfold with 
distilled w ater to give a 2.5 mM Tris/190 mM glycine buffer a t pH 8.6 
containing 0.1% SDS .
• Electrophoresis was a t a constant voltage of 50 Volts overnight.
T ab le  2.1 Composition of Laemmli SDS-polyacrylam ide gels.
C o m n o n en ts S ta c k in g  Gel R eso lv in g  Gel
Volume(ml) 10 40
30 %Acrylamide/Bis(ml) 1.5 6.6
10 % SDS(ml) 0.1 0.4
1 M Tris-HCl(ml) (pH 6.8) 1.25 (pH 8.6) 15
10 % APS(ml) 0.1 0.4
dH20(m l) 7 17.4
TEMED (ml) 0.01 0.04
Volume sufficient for one 14 x 20 cm gel
2.3.2.2b M o d ifica tio n s  to  SDS-PAGE S y stem  i f  sam p le  w as to  b e  N- 
te rm in a lly  seq u en ced .
• The resolving gel was cast and left to age overnight prior to use.
• The stacking gel was cast a t least 3 hours prior to use.
• The upper tank  buffer included 0.2 mM sodium thioglycolate, which was 
pre-run for 1/2 hour prior to the samples being loaded.
2.3.2.2c SDS L in e a r  G ra d ie n t Gel E le c tro p h o re s is .
The SDS-PAGE system described above was used for monitoring the 
purification procedure, however a separation system was needed which 
yielded sharper bands over a wider size range than  th a t obtained w ith the 
described SDS-PAGE system. A linear gradient of increasing acrylamide
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concentration (%T) produces a gel th a t introduces the elem ent of size 
selection on the basis of a decreasing pore size, thus also size fractionating 
proteins th a t were loaded. A gradient mixer system as described by Hames 
(1991) was used to cast these gels bu t as they were going to be used to 
separate proteolytic digests of PAPP-A. A modified buffer system as 
originally described by Schagger and Von-Jagow (1989) was used th a t 
enabled a greater size range of proteins to be separated. The inclusion of a 
glycerol gradient also aided in the preparation of a reproducible gradient 
system. The gel composition was as given in Tables 2.2 and 2.3.
T ab le  2.2 The standard  linear gradient SDS-PAGE gel system
C o m n o n en ts  o f  re so lv in g  gel A cry lam id e  C o n c e n tra tio n
5%T. 20%T.
Volume(ml) 17.5 17.5
30 % Acrylamide/Bis (ml) 2.9 11.7
10 % SDS (pi) 175 175
3 M Tris-HCl (pH 8.8, ml) 2.2 2.2
Glycerol (ml) (1%) 0.175 (10%) 1.75
dH20 (ml) 12 1.6
20 % APS (pi) 31 31
TEMED (pi) 6 6
C o m n o n en ts  o f  s ta c k in g  gel 
Volume(ml) 10
30 % Acrylamide/Bis (ml) 1.5
10 % SDS (pi) 100
1 M Tris-HCl (pH 6.8, ml) 1.25
dH20 (ml) 7.1
20 % APS (pi) 50
TEMED (pi) 10
Volume sufficient for one 14 x 20 cm gel
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T ab le  2.3 The modified linear gradient SDS-PAGE gel system
M od ified  g ra d ie n t  sy s tem  u s in g  S c h a g g e r a n d  V on-Jagow  B u ffers
C o m n o n en ts  o f  re so lv in g  gel A cry lam id e  C o n c e n tra tio n
5% 20%
Volume(ml) 17.5 17.5
30 % Acrylamide/Bis (ml) 2.9 11.7
Peptide gel buffer (Appendix 2, ml) 3.5 3.5
Glycerol (ml) (1%) 0.175(10%) 1.75
dH20 (ml) 10.8 0.45
10 % SDS (pi) 70 70
20 % APS (pi) 31 31
TEMED (pi) 6 6
C o m n o n en ts  o f  s ta c k in g  gel
Volume(ml) 10
30 % Acrylamide/Bis (ml) 1.35
10 % SDS (pi) 25
Peptide gel buffer (Appendix 2, ml) 2.5
dH20 (ml) 5.9
20 % APS (pi) 50
TEMED (pi) 10
Volume sufficient for one 14 x 20 cm gel
The tank  running buffer for the standard gradient system  was as 
described in  section 2.3.2.2a. The modified system had different anodic and 
cathodic running buffers (Appendix 2) but were briefly a 0.1 M Tris/Tricine 
SDS cathodic buffer and 0.2 M Tris-HCl (pH 8.9) as the anodic buffer. As 
was seen from Figure 2.2 the modified gel system used in  th is thesis:
• Extended the size range of proteins th a t can be separated.
• Yielded a wider linear range for the of proteins th a t were separated.
I t  was thus a suitable system to separate lim ited proteolytic digestions of 
PAPP-A. (Chapter 6).
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■
h
N
,4 ,5,3
Mr
F igure 2.2
L inear Gradient SDS-PAGE
(The standard  grad ient system Vs modified system developed in  th is thesis)
[Legend: %T: This was calculated as a function of expected linear gradient with known 
start (5%) and finishing points (20%) of the gradient. Mr: Size from use of molecular weight 
marker standards. Molecular weight standards were the high, medium and peptide 
markers from BDH (Appendix 1); These were taken as Myosin (205 kDa), P-Galactosidase 
(116.3 kDa), Phosphorylase-b ( 97.4 kDa), Ovotransferrin (77 kDa), Albumin (66.3 kDa), 
Glutamate dehydrogenase (55.5 kDa), Ovalbumin (42.7 kDa) Carbonic anhydrase (30 kDa), 
Myoglobin, (Equine 17.2 kDa), Myoglobin (horse-heart, 16.95 kDa), Myoglobin peptide 
fragment I (14.4 kDa), Cytochrome-c (12.3 kDa), Myoglobin peptide fragment II (8.16 kDa), 
Myoglobin peptide fragment III (6.2 kDa) and Myoglobin peptide fragment IV (2.5 kDa). 
Standards were run in duplicate. ( A ) samples/standards were run in standard gradient 
system. ( ■  ) Samples/standards were run in modified system described in this thesis, 
section 2.3.2.2c.]
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2.3.2.2d P rote in  D etection: CBB Sta in in g  o f SDS-PAGE G els
General protein staining of SDS-PAGE gels was performed as described 
by Wilson and Yuan (1989), In  brief, the gel was incubated in 0.04% pre­
warmed (42°C) G-250 reagent (Appendix 2) for 60 m inutes a t 42°C. The gel 
was then  destained in  5 % acetic acid for about 30 m inutes and stored in 
sealed plastic bags.
2.3.2.2e P rote in  D etection: S ilver S ta in in g  o f SDS-PAGE Gels
SDS-PAGE gels were silver stained using a method first described by 
M erril et ah (1981). A Bio-Rad silver staining kit was used. Briefly, the gels 
were fixed in Fixer 1 for 30 minutes. They were then  fixed in Fixer 2 for 2 X 
15 m inutes. The gel was then  placed in an oxidiser (yellow) for 5 m inutes 
and then  washed in multiple changes of distilled w ater until all visible 
traces of yellow within the gel have disappeared. The gel was then  placed for 
20 m inutes in silver reagent, briefly washed with distilled w ater and then 
the gel was placed in  pre-warmed developer (37°C). The developer was 
replenished every five m inutes and development stopped by incubating the 
gel in 5% acetic acid for a t least 5 minutes. The gels were stored in  sealed 
plastic bags. This silver sta in  procedure was very sensitive to any im purities 
present in distilled water, so all preparation of reagents and m anipulations 
were carried out in  clean distilled w ater washed glass apparatus.
2.3.3 M easurem ent o f C hitinase A ctiv ity
Chitinase activity was assessed by the m easurem ent of the N-acetyl 
amino sugars th a t were released from chitin. I t  was performed essentially 
as described by Thomas (1981). Crude chitin was also purified as described 
by Thomas (1981) using a method th a t was described in  Appendix 2. An 
aliquot (0.5 ml) of a stock suspension of purified chitin was incubated a t 
30°C with 0.1 ml of chitinase standard  (or sample). The reaction was 
term inated by removing an aliquot (0.1 ml) and adding it  to 0.1 ml of 0.8 M 
potassium tetraborate, pH 9.2, th is was boiled for 3 m inutes and the N- 
acetyl-glucosamine (NAG) content was m easured (section 2.3.4).
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2.3.4 M e a su re m e n t o f  N -A cety l-g lucosam ine (NAG)
The NAG content was determined using the method cited from Reissig et 
al (1955) w ith modifications as described by Thomas (1981). The stopped 
reaction from section 2.3.3 after cooling to RT was incubated w ith 1 ml of 
DMAB reagent (Appendix 2) a t 37°C for 20 minutes. The absorbance a t 585 
nm was read and compared to a set of NAG standards th a t were prepared 
in PBS (Figure 2.3).
2.0 1
0.0 0.2 0.4 0.6 0.8
N - A c e ty l - G lu c o s a m in e  (m g/a l iquot)
F ig u re  2.3
Standard calibration curve for N-acetyl-glucosamine using DMAB reagent
[Legend: The calculated absorbance was plotted as standard value minus the value at 0.12 
mg/aliquot of NAG. Standards and samples were run in duplicate and as outlined in 
sections 2.3.3 and 2.3.4.]
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2.3.5 A ssessm ent o f G eneral P roteo lytic  A ctiv ity
Proteolytic activity can be assessed by a variety of methods. The 
advantages and disadvantages of each method have been described by 
Sarath  et a l, (1989). The assay developed here had  the advantage th a t it 
was quick and required no special equipment. I t  utilises the protease’s 
ability to digest a standard protein (BSA) and then  the discrimination 
between the digested m aterial and native protein by TCA precipitation. The 
products of digestion th a t were present in the supernatan t were determined 
using the protein assays described in this Chapter (sections 2.3.1.1 and 
2.3.1.2).
0.30
E 0.25 - c
O
£  0.2 0 - 
4-»
CO
0 0.15-
o  c (0
■Q 0 .1 0  -L. o(/>A<  0.05 - 
0.00  -
0 50 100 150 200 250
Time [Minutes)
Figure 2.4
The general protease assay with detection using the BCA protein assay
[Legend: ( ■  ) 25 Units (Appendix 1) of standard protease/aliquot. (The standard protease 
used was chymotrypsin, Appendix 2), protein measurement was as described in section 
2 .3.1.2).]
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Briefly; 1 ml of a 1% BSA solution in PBS (Appendix 2) was pre­
incubated a t 37°C. Aliquots (50 - 100 pi) of sample (or standard  protease, as 
detailed in legend of Figure 2.4) were added and incubated a t 37°C. At 
various times, a 100 pi aliquot was removed and placed in 900 pi of TCA 
reagent (Appendix 2), which was heated to 90°C for 3 m inutes. This was 
then  centrifuged and an aliquot of the supernatant removed and assayed for 
the protein concentration th a t was present (Figure 2.4) as outlined in 
section 2.3.1.2.
2.3.6 M easurem ent o f  T osyl-arginine m ethyl ester (TAME)
The m easurem ent of this ester is based upon the quantitative 
colorimetric reaction th a t was described by Castellano and Sodetz (1969). 
TAME reacts w ith hydroxylamine to yield hydroxamic acid, the 
concentration of this acid can be m easured by the conversion of ferric 
chloride to a ferric ion-hydroxamic acid complex th a t can be determined 
using a colorimetric m easurem ent of this complex a t 525 nm.
Briefly a 50 pi aliquot containing the TAME substrate (Appendix 2) was 
mixed w ith 40 pi of Reagent A (Appendix 2) and incubated for 30 m inutes a t 
RT. Hydroxam ic acid formation was complete after 30 m inutes and was 
m easured by the addition of 80 pi of a TCA solution (Appendix 2) and 800 pi 
of a ferric chloride solution (Appendix 2), this was mixed and the absorbance 
a t 525 nm was determined for each sample.
2.4 M iscellaneous M em brane A ssociated  T ech n iqu es
2.4.1 Sem i-Dry E lectrob lotting  (W estern b lotting)
Proteins present in an SDS-PAGE resolving gel can be transferred  onto 
a membrane by electroblotting. The choice of a blotting m em brane was 
dictated by the purpose of the blot. Nitrocellulose (Schleicher and Schuell), 
was used if the blot was to be probed with antibodies or lectins. Immobilon - 
P (Millipore) or a modified PVDF (Fluorotrans, Pall) were used if the blot 
was to be stained for proteins or used for N-term inal protein sequencing.
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A sem i-dry method of protein transfer as outlined by Kyhse-Andersen 
(1984) was used. Blotting m embranes were allowed to equilibrate for a t 
least 10 m inutes in transfer buffer prior to electroblotting. If PVDF 
mem branes were used they were pre-wetted in  100% m ethanol and then 
equilibrated in  transfer buffer. The gel was equilibrated in  transfer buffer 
on an electroblotter (Biometra) as a sandwich shown in Figure 2.5. The 
blotter was cooled by the passage of cold w ater through the base of the 
electroblotter. Electroblotting was carried out a t 5 mA/cm2 for 10 m inutes 
followed by 10 mA/cm2 for 20 minutes.
Whatman 
3MM 
Filter Paper
Polyacrylamide Gel
Whatman 
3MM 
Filter Paper
Transfer Membrane
F igure 2.5
Schematic illustrating semi-dry electroblotting sandwich.
2.4.2 D etection  o f P rotein  on PVDF B lots
After blotting the membrane was rinsed briefly in distilled water, 
followed by 100% methanol and then  stained with CBB-Stain (Appendix 2). 
The protein bands were visible in  about 1 minute. The blot was then
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destained w ith frequent changes of destain (Appendix 2), rinsed with 
distilled w ater and left to a ir dry.
2.4.3 P robing W estern B lots
The efficient transfer of proteins from a gel to a m em brane allows the 
blot to be probed by a variety of molecules. The technique of probing the blot 
for specific antigens using antibodies was first described by Towbin et al 
(1979). The bound antibody can then  be detected by a variety of detection 
systems. In  th is study an avidin/biotin-enzyme system was used for all 
W estern blots. The blocking step was overnight incubation a t 4°C in 5% 
(w/v) Marvel™ in TBS buffer. All subsequent steps were performed a t RT 
with shaking. The blot was washed 3 times in TBS-T (Appendix 2) for 12 
m inutes and then  incubated for 3 hours in TBS-TM containing a dilution of 
the prim ary antibody (dilutions of the prim ary antibody are indicated in the 
relevant Figure legend). The blots were washed as indicated above and then  
incubated with a 1:100 dilution of biotinylated secondary antibody 
(Appendix 2) in  TBS-TM for 1 h r a t RT. After washing to remove the 
secondary antibody the blot was incubated with a 1:100 dilution of 
Steptavidin-HRP (Appendix 2) in TB-MT for 1 h r a t RT. The blot was then  
washed for 3 x 6 m inutes in TB-T and 3 x 6  m inutes in  TB (Appendix 2). 
Detection was obtained by mixing colour reagent-A with B (Appendix 2) ju st 
prior to use and applying to the blot. The reaction was stopped by washing 
in distilled w ater and the blot was dried between paper towels.
2.4.4 L ectin  P robing
Proteins present on the blots were probed with lectins to determ ine the 
glycan component as described by Kijimoto-Ochiai et a l. (1985), the 
following lectins were used:
• Bandeiraea simplicifolia lectin - II (BSL-II).
• Datura stramonium  lectin (DSL).
• Erythina cristagalli lectin (ECL).
• Artocarpus integrifolia (Jacalin).
• Lycopersicon esculentum  lectin (LEL).
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• Solanum tuberosum  lectin (STL).
• Vicia villosa lectin (W A).
These were provided in a k it from VECTOR laboratories (Appendix 1). 
When lectins were used as a probe then  the blot was trea ted  as described 
in section 2.4.3 except th a t it was blocked with TBS-G (Appendix 2) and the 
prim ary antibody was replaced by a biotinylated lectin in TBS-GT 
(Appendix 2). Briefly, a 1:100 dilution of each lectin in TB-GT (Appendix 2). 
was used and the blots were incubated for 1 hour a t RT, (washing was as 
described in  section 2.4.3). They were then treated  with a 1:100 dilution of 
Streptavidin-HRP in  TB-GT and then  as described in  section 2.4.3.
2.4.5 P eriod ate C hem ical T reatm ent o f  N itrocellu lose  B lots.
The antigenicity of the glycan component of PAPP-A was studied using 
the chemical cleavage method th a t by periodate oxidation th a t was 
originally described by Woodward et a l. (1985). I t  was used to further 
examine the glycan components of PAPP-A antigenic determ inants th a t 
were known to bind to a sub-group of paratopes present in the polyclonal 
PAPP-A antisera (Chapter 3). The blot was incubated in  TBS (Appendix 2) 
or sodium periodate a t 2 - 10 mM in Buffer A (Appendix 2) for 1 hour a t RT. 
It was then  incubated with 50 mM sodium borohydride in PBS for 1/2 hour 
a t RT and washed 5 times in PBS-T (Appendix 2). The blot was then 
probed with DAKO anti-PAPP-A antibodies (as described in section 2.4.3).
2.4.6 Enzym e D igest T reatm ent o f  P rotein s E lectrob lotted  Onto 
N itrocellu lose.
The blots were prepared as described in section 2.4.1. After blocking and 
washing the membrane twice with TBS-T, they were incubated for 2 hours 
a t RT in TBS-M w ith/without 0.5 units of chitinase (see P late 3.4 legend, 
Chapter 3) th a t had been pre-incubated with an  aliquot of a protease 
inhibitor cocktail 1 hour prior to use (Appendix 2) and then  w ith another 
aliquot of this cocktail ju st before use. Following washing, the 
immunodetection with polyclonal anti-PAPP-A antibody was performed as 
described in section 2.4.3. The effect th a t the protease inhibitor cocktail had
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on the glycosidic activity and the level of contam inating proteolytic activity 
of the chitinase preparation was m easured using the methods described in 
sections 2.3.3 and 2.3.5.
2.4.7 E nzym atic D eglycosy lation  and Subsequent D etection
Selective removing of the glycan components by glycosidic enzymes is one 
tool th a t can be used to examine their structure. A review of glycosidic 
enzymes th a t have been used for this purpose can be found in  Maley et a l. 
(1989). In  this study the N-linked glycan groups were removed with 
recom binant N-Glycanase™ (PNGase F: EC 3.5.1.52, Appendix 1) which has 
a wider specificity th an  Endo-H. I t  was also free of contam inating proteases 
and it is known to be unaffected by presence of sulphated residues or 
substituted N-linked residues th a t have been shown to inhibit Endo-H. O- 
linked groups were selectively removed by treatm ent of the protein w ith 0- 
Glycanase™ (Appendix 1). The inclusion of detergents is required as it has 
been dem onstrated (Hasselbeck and Hosel, 1988) th a t they not only prevent 
denaturation of the glycosidic enzymes used to digest the glycan p a rt of a 
molecule bu t also aid in the removing of these groups. Non-ionic 
detergents such as Triton X-100 and Nonidet P-40 are efficient a t protecting 
these enzymes bu t they need to be removed prior to fractionation of the de­
glycosylated protein by SDS-PAGE, therefore a glucoside (MEGA-10) was 
used as it had  the same protective effect bu t did not have to be removed 
prior to electrophoresis.
The enzymatic treatm ent were performed as described by Patterson  and 
Bell (1990) except th a t an enriched PAPP-A fraction and the control 
proteins, HSA (Grade V, Appendix 1), Fetuin (Type IV, Appendix 1) and 
Ovalbumin (Appendix 1) were used as the protein substrates. Prior to 
deglycosylation an aliquot of the proteins were boiled for 2 m inutes w ith an 
equal volume of sample buffer (Appendix 2) and equilibrated to pH 7.2 w ith 
phosphate buffer containing 0.5 % MEGA-10 (Appendix 1). This was then  
boiled for 2 m inutes and after cooling, deglycosylated as described below:
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• N-Glycanase treatm ent: 1 U n it of N-glycanase/10 \ig of protein substrate 
was incubated in  20 mM phosphate buffer, pH 7.2 in  capped Eppendorf 
tubes overnight a t 37°C.
• Neuram inidase (Clostridium perfringens., appendix 1): Proteins were 
equilibrated in 25 mM phosphate/citrate buffer, pH 5.8 and incubated 
w ith 1 m Unit of enzyme/pg of protein substrate for 2 hours a t 37°C in 
capped Eppendorf tubes.
• O-Glycanase (Endo-alpha-N-Acetyl-D-galactosam inidase, Appendix 1) 
treatm ent: Any substitution on the core disaccharide results in inhibition 
of this enzyme, therefore prior to incubation with th is enzyme, proteins 
were de-sialated by treatm ent with neuram inidase (as above). After de- 
sialation they were incubated w ith 1 m Unit of O-Glycanase/10pg of 
protein substrate  for 6 hours a t 37°C in capped Eppendorf tubes.
All enzyme reactions were stopped by boiling for 2 m inutes and the 
samples were stored frozen. The fractionation of the deglycosylated proteins 
was as described in the legends on Plates 7.2 and 7.3 (Chapter 7).
2.5 M aterials and M ethods S ection  for cDNA S creen in g
A Clik Clontech hum an cDNA library (mRNA source: 34 week Placenta 
with a cDNA insert size range of 0.8 - 3.6 kb: Appendix 1) was used. Buffers, 
reagents and media are described in detail in  Appendix 2.
2.5.1 Screen in g  A P lacen ta l cDNA Library
2.5.1.1 S torage and P reparation  o f C om petent B acteria l C ells for  
P hage In fection
E. coli (strain: Y1090) was stored freeze dried in vials and used to 
prepare slopes for inoculation into TB medium (Appendix 2). 10 ml 
containing 100 pg/ml of ampicillin in sterile universals. The cultures were 
shaken overnight a t 37°C.
2 -20
2.5.1.2 P re p a ra t io n  o f  A gar P la te s  U sed  fo r  S c re e n in g
Autoclaved agar (Appendix 2) was poured into sterile Petri dishes 
(Northum bria Biologicals) and allowed to set. On cooling the plates were 
inverted and allowed to dry before use. The poured plates were stored at 
room tem perature.
2.5.1.3 In fe c tio n  o f  E .co li (s tra in : Y1090) W ith  B a c te r io p h a g e  (^ g t l l )
Two different Petri dish sizes (90 and 140 mm diameter) were used and 
their size determined the volume of infected bacterial culture and top 
agarose th a t was used to accommodate phage plaques. A dilution of library 
in lam bda phage diluent (Appendix 2) was used for infection th a t would give 
an estim ated num ber of plaques per plate as illustrated in  Table 2.4.
T ab le  2.4 The relationship of num ber of plaques to Petri dish diam eter.
P e tr i  d ish  d iam e te r: 90 mm. 140 mm.
V olum e o f c u ltu re  used : 200 pi 600 pi
V olum e o f to p  a g a ro se  used : 3.3 mis. 9.9 mis.
E s t im a te d  n u m b e r  o f p la q u e s1: 8,000 20,000
[Legend: u. The cDNA library was diluted to give the estimated number of pfu’s for the 
given size of Petri dish as described in section 2.5.1.]
The diluted library was incubated w ith bacterial culture in a w ater ba th  
a t 37°C for 20 m inutes to allow infection to take place. Top agarose 
(Appendix 2) which had been equilibrated to 50°C was then  added and 
mixed by gentle inversion. I t  was then  swirled onto plates and allowed to set 
for 10 minutes.
2.5.1.4 T itr a t io n  o f  T he L ib ra ry .
The library was diluted with lam bda phage diluent in  sterile capped 
polypropylene tubes to a 10*7 dilution. Then 10, 20 and 30 pi of the diluted 
library was used to infect E. coli as described in Section 2.5.1.3. Inoculated 
plates were inverted and incubated for 3 hours a t 42°C, followed by 3 hours 
a t 37°C. The num ber of plaques detected per plate is illustra ted  in  Table 3.1 
(Chapter 3).
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2.5.1.5 The R atio o f R ecom binant/V ector P hage in  The Library.
A 10 pi aliquot of 10*6 dilution of library was added to the top agarose as 
described in  section 2.5.1.3, except th a t the top agarose also contained 9 
mM iso-propyl-P-D-galactoside (IPTG) and 10 pM X-gal. The plates were 
incubated a t 37°C overnight (Plate 3.2, Chapter 3).
2.5.1.6 P laque Form ation.
Plates were prepared as in section 2.5.1.3. and incubated a t 42°C for 3 
hours, followed by 1 hour a t 37°C. They were then overlaid with a 
notched/numbered 0.45 pm nitro-cellulose filter membrane th a t had  been 
im pregnated (Appendix 2) w ith IPTG. The plates were fu rther incubated for 
3 hours a t 42°C. The membranes were always handled wearing latex gloves 
and forceps were used to carefully remove the membrane overlay from the 
plate so as to avoid disturbing the top agarose lawn and lim it any tearing of 
the membrane. The membrane orientation was m arked on the plate and 
inverted plates were stored a t 4°C.
2.5.1.7 B lock in g  o f  N itrocellu lose  O verlays and Im m unodetection .
Filters prepared as described in section 2.5.1.6 were placed back to back 
in a plastic bag and 3 (9) mis of TBS-TB added for a 90 (140) mm filter. Air 
bubbles were removed and the bag was sealed and left overnight a t 4°C. The 
filters were then  washed three times for 10 m inutes each in TBS-T and 
placed in  a plastic bag with a 1:300 dilution of DAKO anti-PAPP-A in TBS-T 
for 3 hours a t room tem perature. Following washing (as above) the filters 
were transferred into a plastic bag with a 1:100 dilution of biotinylated an ti­
rabbit IgG (SIGMA Extra-3 kit, Appendix 1) in  TBS-T for 1 hour a t room 
tem perature w ith rocking. They were then washed (as above) and sealed in 
plastic bags w ith a 1:100 dilution of avidin-horseradish peroxidase conjugate 
(SIGMA Extra-3 kit, Appendix 1) in TBS-T and incubated for 1 hour a t room 
tem perature with rocking. The filters were washed in  TBS (3 times, 10 
m inutes each wash). Components (A and B, Appendix 2) of a chromogenic 
substrate were prepared ju st before use and approximately 5 (15) ml were 
applied to each 90 (140) mm filter. The colour was allowed to develop for
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approximately 20 minutes. The filters were blotted dry and examined for 
coloured areas.
2.5.1.8 I so la tio n  o f  P u ta tiv e  R e co m b in a n t P h a g e  P la q u e s .
Filters containing coloured areas (a positive immunoblot) were aligned 
w ith the Petri dish using the notch and filter outline on the dish as a guide. 
The agar/agarose containing the plaque th a t corresponded to the coloured 
area was removed using a sterile P asteur pipette tip. This agar plug was 
placed into a sterile capped polypropylene tube and 
vortexed w ith 50 pi of chloroform to lyse the bacterial cells. 1 ml of lambda 
phage diluent was then  added and it  was incubated for 1 hour a t 37°C. The 
lysate was diluted 103 fold and 50 pi of this was used to infect E. coli cells for 
re-screening as described in  section 2.5.1.3.
2.6 M aterials and M ethods S ection  for The Q uantitative  
M easurem ent o f PAPP-A
2.6.1 R o ck e t Im m u n o e le c tro p h o re s is
RIE was performed as originally described by Bischof et a l. (1979) bu t 
with the following modifications. Litex HSA agarose a t a concentration of 
0.75% (w/v) in  Tris-barbital buffer containing a 1:40 dilution of anti- PAPP- 
A antibody (DAKO) and 2% (w/v) PEG 6000 were cast onto coated glass 
plates (Appendix 2) and allowed to set for 1 hour a t RT. Wells were cut out 
and 5 (10) pi of sam ple/standards were loaded (as shown on the individual 
plate captions). The RIE was performed in  a Pharm acia LKB electrophoresis 
system a t 10 Volts/cm (constant voltage) as m easured by a voltage probe 
across the plate. The electrophoresis system was cooled to 10°C and run  
for a minimum of 14 hours. Visualisation of the rockets required each plate 
to be pre-treated (Appendix 2) prior to staining with Coomassie Brilliant 
Blue.
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2.6.2 R a d ia l Im m u n o d iffu s io n
SRID was performed as originally described by M ancini et al (1964), 
except for the following modifications. Litex HSA agarose a t a concentration 
of 0.75% agarose (Appendix 2) was prepared containing a 1:75 dilution of 
anti-PAPP-A antibody (DAKO) and poured into sealable plastic SRID plates 
(Appendix 1). The agarose was allowed to set and then wells were cut out 
and the plates allowed to equilibrate for a t least 24 hours a t 4°C before use. 
The SRID Plates were stored a t 4°C and allowed to equ ilibrate a t room 
tem perature before use. Sam ples/standards were diluted in assay diluent 
(Appendix 2) containing 5 pi of male (Citrate) plasma, (the salt 
concentration present in  the loaded sample/agarose was as described in the 
appropriate Figure legend). The plates were sealed and left a t room 
tem perature for a minimum of 24 hours. Visualisation and quantification of 
the precipitin rings were the same as th a t for RIE, except a longer wash 
pre-treatm ent prior to CBB staining was required (Appendix 2). 
Quantification was achieved by comparison of unknown sample w ith a 
standard  reference serum  (WHO 78/610) . A typical calibration curve is as 
illustrated  in  Figure 2.6.
2.6.3 S a n d w ic h  ELISA  fo r  PA PP-A
2.6.3.1 P re p a ra t io n  o f  PA PP-A  F (a b ’)2  F ra g m e n ts
A pepsin digest of the DAKO anti-PAPP-A was performed as described by
Am aral et_al,(1966). Briefly a calculated am ount of IgG (7 mgs in  0.5 ml) 
was mixed with 0.5 ml of 0.2 M sodium acetate buffer a t pH 4.5 containing 
50 pg (175 U) of pepsin. This was left to incubate overnight a t 37°C. The 
digestion was stopped by raising the pH to 8.6 w ith 3 M Tris. This stock 
digest was diluted to a final concentration of 2.5 mg/ml and stored in 
aliquots a t -70°C.
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2.6.3.2 ELISA C oating and B lock ing o f  Solid  Phase
A 100 pi aliquot of antibody (see Figure legend in text for type and 
concentration) in ELISA coating buffer was applied to the wells of a Falcon 
3915 microtitre plates. This was sealed w ith Clingfilm and left overnight a t 
4°C n  a hum id chamber. The plates were then  washed w ith PBS and
60 i
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P A P P - A  C o n c e n t r a t i o n  (jug/ml)
Figure 2.6
C alibration curve for PAPP-A SRID
[Legend: ( ■: Sample was loaded in assay diluent containing male (citrate) plasma, plate 
was made in assay diluent, r2 = 0.994 ). (A: Sample was loaded in assay diluent with a final 
concentration of 1M salt and containing male (citrate) plasma, plate was made in assay 
diluent, r2 = 0.996). The assay was performed as outlined in section 2.6.3.3.].
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subsequently 300 jxl of ELISA blocking buffer was dispensed into all wells. 
The plates were covered with Clingfilm and left for 2 hours a t RT. The 
plates were then  washed 3 times (as before) bu t w ith ELISA w ash buffer.
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B u f fe r  T y p e  U se d  In C o a t i n g  P l a t e s
F ig u re  2.7
Determ ination of optimum conditions for coating PAPP-A F(ab’)2 fragm ents 
onto Falcon 3915 plates.
[Legend: 1: 0.25 M Tris-HCl (pH 8.8). 2: 0.01 M Tris-HCl (pH 8.8). 3: 0.25 M Carbonate 
Buffer (pH 9.6). 4: 0.25 M Acetate/Citrate Buffer (pH 5.6). 5: 0.01 M Acetate/Citrate Buffer 
(pH 5.6). ^Results were expressed as mean +/- standard deviation (n=9)) Note: F(ab’)2 
fragments were detected by performing the ELISA as described in section 2.6.3.3 with all 
wells being incubated with assay diluent containing a 1:5 dilution of a late pregnancy 
plasma pool as described in section 2.6.4. Anti-PAPP-A was used at a 1:2.5 K dilution in 
assay diluent and detected with a 1:1K dilution of protein-A-HRP conjugate in assay 
diluent.]
The most efficient buffer for coating the PAPP-A F(ab’)2 fragm ent to 
Falcon microtitre plates was found to be 0.25 M Carbonate buffer (pH 9.6). 
The optimum concentration of the fragm ent for this type of plate was then  
determined (Figure 2.8).
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Determ ination of optimum concentration of F(ab’)2 for coating Falcon 3915 
plates.
[Legend: x( Results were expressed as Mean +/- standard deviation ( n=9 )) Note: 
The F(ab’)2 fragments were detected as described in Figure legend 2.7]
The optimum dilution of anti-PAPP-A F(ab’)2 fragm ent to coat th is type 
of plate was found to be a 1:750 dilution (Figure 2.8). A lOOjil aliquot a t this 
dilution was subsequently used to coat the wells of m icrotitre plates by 
incubation overnight a t 4°C as described in  section 2.6.3.2. These plates 
were then  wrapped in Clingfilm and stored a t 4°C in PBS until required.
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2.6.3.3 The ELISA A ssay P rocedure
The sam ples/standards were diluted in  ELISA d iluent (Appendix 2) and 
then  100 pi aliquots were placed into the microtitre plate wells and 
incubated for 1 hour a t RT. The plates were washed three tim es in  ELISA 
wash buffer (Appendix 2) and then  incubated with 150 pi of second stage 
antibody (see Figure legends 4.3 and 4.4 in  Chapter 4 for the type and 
concentration of antibody th a t was used) in ELISA d iluent for 1 hour a t RT. 
The plates were washed (as above) and then  incubated w ith a Protein-A 
HRP-conjugate (See Figure legends 4.3 and 4.4 in Chapter 4 for the 
concentration of conjugate) in ELISA diluent for 1 hour a t RT. They were 
then  washed (as above) and then were given a final wash, three tim es in 
PBS and blotted dry.
2.6.3.4 C olorim etric D etection  and R eading o f R esu lts
200 pi of ELISA colour reagent (Appendix 2) was added to all wells and 
incubated a t room tem perature for approximately 15 m inutes a t RT. The 
colour development was stopped by adding 75 pi of ELISA stop reagent 
(Appendix 2) and the plates were read a t 450 nm.
2.6.4 The PAPP-A R adioim m unoassay
A num ber of radioimmunoassay procedures have been described for 
PAPP-A (Bischof et a l. (1981b), Sinosich et a l. (1982) and Anthony et a l. 
(1983)), however the RIA procedure chosen in th is study was one developed 
originally by Pinto-Furtado et a l. (1984) and it was used w ith some 
modifications.
An iodination grade enriched PAPP-A preparation th a t had  been derived 
from m aternal serum  was kindly supplied by Miss K. Price, th is preparation 
was used in the original iodinations. This m aterial was present a t a 
concentration of 400 pg/ml with each aliquot containing 4 pg and it was 
stored a t -70°C until use. Initial calibration was against the reference serum  
(WHO 78/610), bu t la ter a plasm a (C itrate and EDTA) pool from the late 
3rd trim ester of pregnancy was calibrated against th is and stored in
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aliquots of 100 pi a t -70°C. Each set of standards was used only once and a 
second set of working standards for use in the assay was prepared by 
dilution in  assay diluent buffer with a concentration range of 4 - 4000 pg/1. 
The antisera used was polyclonal anti-PAPP-A (DAKO, Appendix 1).
2.6.4.1 T he  C h lo ram ine-T  M ethod  F o r  Io d in a tio n  o f  PA PP-A
The method used to iodinate PAPP-A was as described (Pinto-Furtado et 
al, 1984) except th a t 5 pg of PAPP-A was used for a 0.5 mCi iodination with 
5 pg of chloramine-T . The labelled protein was separated from the other 
products of iodination by de-salting on a disposable G-25 column (Sephadex- 
G25 fine grade, Appendix 1). Before separating the products of iodination 
th is column was pre-blocked by running an aliquot of a 30% BSA solution 
made in assay diluent (Appendix 2). The PAPP-A tracer th a t was produced 
had  a m ean specific activity of 29 pCi/pg.
2.6.4.2 A ffin ity  P u r if ic a tio n  o f T ra c e r  F o r  U se in  T he  PA PP-A  RIA.
The process of iodination can lead to damage of the m aterial th a t has 
been labelled (Bolton, 1981). Pinto-Furtado et a l. (1984) dem onstrated th a t 
a further affinity purification of the PAPP-A tracer prior to it’s usage in an 
RIA increased the percentage of tracer th a t bound to the PAPP-A antibody. 
A disposable heparin-affigel (Bio-Rad, Appendix 1) column was used to 
affinity isolate the PAPP-A tracer, the tracer was eluted from the gel with 
assay diluent containing 0.8 M NaCl (Figure 2.9). The affinity purified 
tracers binding to the PAPP-A antibody was significantly improved by this 
affinity purification. A maximal binding of only 50% was seen a t excess 
antibody concentrations, this was probably due to the sample th a t was 
used for iodination containing proteins other th an  PAPP-A th a t were 
iodinated but did not bind the PAPP-A antibody. The presence of other 
proteins in the sample used for iodination was confirmed using N-term inal 
sequencing (Chapter 6). This method of iodination and the affinity 
purification of the PAPP-A stock tracer ju s t prior to it’s use, produced a 
tracer th a t was used in a PAPP-A RIA (Chapter 4, section 4.3.3).
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2.6.4.3 A ntibody T itration  Curves
Serial two fold dilutions of anti-PAPP-A antisera (DAKO) were prepared 
from 1:4 K - 1:512 K in  the assay diluent buffer. 100 pi aliquots of the 
appropriate dilution was added to plastic tubes (LP4, Appendix 1). 100 pi 
of PAPP-A tracer (2 ng/ml) and 100 pi of assay diluent was added to all 
tubes.
50 i
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20  -
P A P P -A  Antiserum Dilution
Figure 2.9
PAPP-A antiserum  titration  curve.
[Legend: (A): 2 ng/ml crude PAPP-A tracer that had not been affinity purified. (■): 2 ng/ml 
affinity purified tracer. 1(103 represented a 1:1000 dilution of anti-PAPP-A antiserum 
(DAKO)). %Tracer bound was plotted as (Bound CPM - NSB CPM)/(Total CPM - NSB 
CPM). The titration curve was produced as outlined in section 2.6.4.3]
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The assay was performed in duplicate and non-specific binding was 
assessed using assay diluent in the place of the PAPP-A antiserum . All the 
tubes were vortexed, covered and left to incubate overnight a t room 
tem perature. Separation of the bound and free antigen was by a solid phase 
magnetic system (Amerlex-M anti-rabbit, Appendix 1) w ith the bound/free 
phases separated by centrifugation and aspiration.
2.6.4.4 T he  PA PP-A  RIA
Affinity purified tracer was used a t a concentration of 2 ng/ml and a 
working anti-PAPP-A antibody dilution of 1:45 K. At th is antibody dilution 
approximately 35% of the PAPP-A tracer was bound. 100 pi of tracer and 
antibody was added to 100 pi of standards (see above) or samples. Except 
the non-specific binding (NSB) control in which the PAPP-A an tisera was 
replaced by assay diluent. All tubes were vortexed, covered and incubated 
overnight a t RT. Separation was achieved as described in section 2.6.4.3. 
The percentage tracer bound plotted against the PAPP-A concentration. The 
RIACALC (Pharmacia) system was used to plot the results using a 
smoothed spline function, results were interpolated from the standard  
curve (Figure 4.7, Chapter 4).
2.6.5 D e n s ito m e try
It has been noted by Merrill (1990) th a t a linear relationship exists 
between the band intensity of stained proteins as m easured by densitom etry 
when compared to the protein concentration of these proteins separated by 
SDS-PAGE and visualised by protein staining. The stained band intensity  
was obtained using a BioRad model 620 video densitom eter (Appendix 1) 
and ID analyst capture software. By plotting the in tensity  of the band 
stained as a function of the area of the band (Absorbance per mm2) against 
the protein concentration, a calibration curve was obtained (Figure 4.8, 
Chapter 4). H igh molecular weight m arkers (BDH, Appendix 1) or purified 
myosin were used as standards against which the concentration of PAPP-A 
and other proteins were compared.
2-31
2.7 M aterials and M ethods Section  for The Iso la tion  Of 
PAPP-A for M icrosequencing
2.7.1 T he  FP L C  S y stem  u se d  in  th e  iso la tio n  o f PA PP-A
The FPLC system (Pharmacia) was composed of two solvent delivery 
pumps (P-500), sample injector valve (MV-8) fitted with a 10 ml supa-loop, 
a UV-M detector and system controller (LC-500) connected to an  IBM 
compatible PC running the FPLC m anager software (Appendix 1). The 
starting  equilibration buffer was always in  buffer reservoir A, referred to in 
Figure legends as buffer A. A gradient was obtained by the controller mixing 
pump B buffer w ith pump A buffer, it was assum ed th a t the final mixture 
given as a percentage of Pump B buffer was as sta ted  by the FPLC 
controller. The individual running conditions for each step are given with 
the appropriate Figure legend illustrating th a t step.
2.7.2 T he  P re p a ra t io n  O f S o u rce  B io log ical M a te r ia l
Blood samples were obtained by either venupuncture from pregnant 
women in their 2nd/3rd trim ester of pregnancy and collected as EDTA or 
C itrate Plasm a. Blood was also collected into EDTA when lost via the 
vagina a t delivery, this m aterial underw ent a degree of haemolysis and 
clotting prior to collection. Many thanks are due to the nurses working on 
the m aternity  ward a t Jessop hospital for Women who collected and pooled 
samples of blood lost a t delivery. The pre-treatm ent of samples was a 
modification of th a t originally described by Sutcliffe e t a l. (1980) for the 
preparation of filtered serum. All plasm a samples were centrifuged a t 40K 
x g. for 30 m inutes a t 4°C. This removes particulate m atter and allowed the 
lipid content to be reduced, as it forms a white scab layer th a t after 
centrifugation was separated from the plasm a by careful decanting and 
filtering through glass wool. The filtered plasm a was stored a t - 70°C.
2.7.3. A m m onium  S u lp h a te  P re c ip i ta t io n  A nd  D ia ly sis
As illustrated in Table 1.2 (Chapter 1), PAPP-A in term  m aternal blood 
is present a t 0.07 - 0.16% of the initial protein. When the protein of in terest
2-32
is less than  1% of the sta rting  m aterial, methods based on a proteins 
differential solubility are frequently used. Salt fractionation was chosen 
using ammonium sulphate precipitation, with a guide to its concentration 
taken  from work originally described by Lin et ah (1974a) and Sutcliffe et 
al, (1980). A description of the technique th a t was used is given below:
Precipitation was carried out a t 4°C. The concentration of ammonium 
sulphate (pH 7.1) was adjusted to 28% saturation. Then it was gently rocked 
for 45 m inutes and centrifuged a t 35K x g for 30 minutes. The supernatan t 
was ad justed to 60% saturation  w ith ammonium sulphate, gently rocked for 
45 m inutes and the precipitate collected by centrifugation (as above). The 
precipitate was resuspended in 10 mM potassium  phosphate, pH  7.2. This 
was then dialysed against 5 litres of 10 mM potassium  phosphate, pH 7.2 
containing 50 mM NaCl a t 4°C. Prior to dialysis, the buffer was pre­
incubated for 1/2 hour w ith PMSF at a concentration of 0.1 mM and then 
ju st prior to the dialysis of the resuspended precipitate another aliquot of 
PMSF was added. After 3 changes of the dialysis buffer, the  dialysed 
sample was centrifuged a t 35K xg for 60 m inutes and the su p e rn a tan t was 
used immediately or stored a t -70°C. The combined application of 
centrifugation w ith pre-treated filtered plasm a/serum  was advantageous as 
it removed particulate m aterial th a t was likely to clog chrom atographic 
columns and shorten the life of chromatographic separation media.
2.7.4 H e p a r in  A ffin ity  C h ro m a to g ra p h y
H eparin is a naturally  occurring mucopolysaccharide th a t is composed of 
equimolar quantities of glucosamine and glucuronic acid, linked by a-1,4 
glycosidic bonds. The common repeat unit is illustrated  in Figure 2.10.
OSC.ONa
CH;
Na0.0 OH HC.
NH
NaOSO-
F ig u re  2.10
The common repeat unit found in heparin.
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The m ain characteristic of heparin is the large num ber of sulphated 
amino groups th a t allow heparin to act as a high capacity cation exchanger 
or by virtue of its structural form acts as affinity ligand for coagulation 
factors (Walton, 1955). Since the initial observation by Sinosich et a l. (1981) 
th a t PAPP-A interacted with heparin this has subsequently been used as a 
method to affinity purify PAPP-A from other blood components (Davey and 
Teisner, 1982).
H eparin Affi-gel (Bio-Rad, Appendix 1), heparin-Sepharose (Pharmacia: 
Pre-1984 and Post-1988) and heparin-Ultrogel A4R (Reactifs IBF, Appendix 
1) were obtained and packed into a column (0.8 x 10 cm). Elution was 
monitored by absorbance a t 280 nm. Initial work was carried out using the 
heparin-Sepharose (Pharmacia) and running conditions were as described 
by Sinosich et al (1987) except th a t 10 mM potassium phosphate (pH 7.2) 
was used as the buffer.
In itial work with the heparin Affi-gel (Figure 5.3) dem onstrated th a t 
little or no protein bound when a salt concentration higher th an  0.3M NaCl 
was used. This situation was not improved by using Tris-based buffers th a t 
Sinosich (1987) dem onstrated improved the binding capacity of PAPP-A to 
this affinity matrix.
Information received from the supplier (Pharmacia) noted th a t heparin 
affinity gels post - 1984 were produced by a different supplier w ith two key 
differences noted in th a t the heparin was:
• From a different species.
• The linkage chemistry used to a ttach  heparin to the support was
different to the m atrix th a t was produced pre - 1984.
The supplier of the original affinity gel (pre - 1984: Reactivs-IBF, 
Appendix 1) was located and this affinity m atrix produced the expected 
elution profile, w ith enrichment of PAPP-A in the m aterial eluted a t 0.6 M. 
The high affinity (>0.6M NaCl) heparin bound PAPP-A (Figure 2.12) was 
used as p a rt of a heparin based scheme, purification scheme 2 (Figure 5.3, 
Chapter 5).
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Elution profile from heparin-Affigel affinity column (P la te  in s e t  2.11: 
represented a 5% SDS-PAGE of fractions indicated).
[Legend: *: indicated off-scale absorbance. Size m arkers were as indicated by arrows, the 
num ber represented the size in KDa. Note: Buffer A was 10 mM potassium  phosphate, pH 
7.2; Buffer B was as buffer A but included 1 M NaCl. The column used was as outlined in 
section 2.7.4]
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Elution profile from heparin-affinity column (Reactivs-IBF)
[Legend: *: indicated off-scale absorbance. Buffer conditions were as described in Figure 
2.11. The column was loaded with an aliquot from the DEAE bound material as described 
in section 2.7.6. The bound material that was eluted from this column at 0.3 and 0.6 M 
NaCl was loaded onto the gel filtration column as described in section 2.7.11].
2.7.5 S u lp h a te d  D e x tra n  C h ro m a to g ra p h y
Sulphation of polysaccharides has been shown to confer on them  some 
heparin-like activity (Miletich et a l. 1980). Therefore th is could offer 
another alternative to heparin. A column, 0.8 x 10 cm was loaded with 
sulphated dextran th a t had been equilibrated w ith 10 mM potassium  
phosphate (pH 7.2) containing 0.1 M NaCl at a flow rate  of 1 ml/min. A step 
gradient elution system was used. This procedure enriched PAPP-A 
considerably (Figure 2.13)
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F igure 2.13
Elution profile from a sulphated dextran affinity matrix. P la te  In s e t  2.13 
represented a 5% SDS-PAGE gel of the fractions indicated
[Legend: *: indicated off-scale absorbance. Buffer A and B were as described in Figure 
2.13. The size m arkers were as indicated by arrows and represented the size in KDa. The 
PAPP-A m arked was determined by its size and W estern blotting followed by immuno­
detection with a polyclonal anti-PAPP-A.]
Although this affinity step did enrich PAPP-A, changes in the salt 
concentration produced dram atic fluctuations in volume of m atrix  th a t often 
resulted in the column being blocked or the increased pressure resulting in 
the m atrix m aterial being pushed through the frit of the column. The m atrix 
effect th a t was seen with changing salt concentrations made this an 
unsuitable m atrix for further work. However this affinity compound 
attached to a more rigid support such as Cellufine sulphate (Amicon) would 
probably have produced a usable m atrix but th is was not required as the 
heparin affinity m atrix from Reactifs IBF was seen to enrich PAPP-A 
(Figure 2.12).
2.7.6 DEAE Io n  E x ch a n g e  C h ro m a to g ra p h y
Ion exchange chromatography has been used by a num ber of 
investigators as p a rt of their purification schemes (Lin et a l.(1974a, 1974b), 
Bischof, (1979a,1979b), McIntyre et_al,(1981) and Sutcliffe et a l. (1980). A 
column of 2.4 x 15 cm was packed with DEAE-Trisacryl (Reactivs IBF, 
Appendix 1), equivalent to a bed volume of approximately 70 mis. Buffer A 
was 10 mM potassium  phosphate, pH 7.2. Buffer B was buffer A bu t also 
containing 1M NaCl. A gradient was obtained by a pump mix of reservoirs, 
A and B. The column was loaded and run  a t 2 ml/min. Initially the column 
was equilibrated in 10 mM potassium phosphate buffer containing 50 mM 
NaCl. Gradients salt elution was tried as shown in Figure 2.14. The DEAE 
bound fraction was eluted with buffer containing 0.5 M NaCl.
As shown in  Figure 2.14 and also as found by the investigators listed 
above, PAPP-A was eluted from the column over a wide range of salt 
concentrations, possibly as a result of heterogeneity in  the carbohydrate 
portion of the PAPP-A molecule. A factor th a t has been seen to produce a 
sim ilar heterogeneity in other proteins (Gerrard, 1990). The salt elution 
profile was optimised to give maximum binding of PAPP-A binding to this 
column using a simple isocratic gradient (Table 2.5). The optimal conditions 
for loading the ion exchange column were achieved using 10 mM potassium  
phosphate containing 0.075 M NaCl, elution was w ith a sa lt increase to 
0.5 M NaCl.
T ab le  2.5 Optimisation to yield maximum recovery of PAPP-A from DEAE
ion exchange column using an isocratic gradient elution.
1Column loading %PAPP-A bound %Protein Bound
conditions (detection by an RIA) (Absorbance a t 280 nm)
50 mM NaCl 99.5% 28%
75 mM NaCl 99% 24%
100 mM NaCl 84% 13%
[Legend: 1 Column loading conditions were represented by the sample loaded in 10 mM 
Buffer A (section 2.7.6) containing x mM Salt. Elution was with Buffer A containing 500 
mM Salt. 2% Protein bound was determined from the integration of the elution profile of the 
absorbance at 280 nm using the FPLC manager software. The sample loaded was a dialysed 
resuspended aliquot of a 28/60% ammonium sulphate precipitate prepared as described in 
section 2.7.3.]
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2.7.7 D ye A ffin ity  C h ro m a to g ra p h y
It was noted by Gore and Sutcliffe (1984) th a t PAPP-A did not bind to 
the dye, Cibachron-Blue. Sinosich et a l. (Cited from 1988b) also found th a t 
the inclusion of the dye, Red-120 in an  interm ediate gel in crossed 
immunoelectrophoresis resulted in  the PAPP-A imm unoprecipitate being 
abolished. Thus suggesting th a t PAPP-A was interacting w ith th is dye. 
Using these observations a tandem  Cibachron blue to Red-120 dye column 
system was tried. A Column of 2.4 X 15 cm was packed w ith Cibachron-Blue 
3GA (Appendix 1) and Read-120 (Appendix 1) was packed to a column 
height of 4 cm. The columns were equilibrated in  10 mM potassium  
phosphate (pH 7.2) containing 0.075M NaCl (Buffer A). The sample was 
loaded onto the columns a t a flow ra te  of 2 ml/min. The flow through from 
the Cibachron-Blue column was loaded directly onto the Red-120 column. 
The Blue-dye column was removed and the protein was eluted from the Red- 
dye column with Buffer A th a t contained 1 M NaCl.
The Cibachron-Blue column did not significantly separate PAPP-A from 
its contam inants (Figure 2.15) and the red dye column significantly 
increased the Contam inant X-group of molecules (Figure 5.4, Chapter 5). 
This group of molecules exist as single chain entities running  a t 
approximately 210 - 260 kDa as determined by SDS-PAGE (as described in  
section 2.3.2.2) and from the volume they elute from a calibrated gel 
filtration column (as described in section 2.7.11).
2.7.8 L -A rg in ine  A garose  A ffin ity  C h ro m a to g ra p h y
The rationale behind the use of L-Arginine as an  affinity m atrix  for the 
purification of PAPP-A was th a t PAPP-A is a glycosaminoglycan (GAG). 
GAG’s have been shown to in teract w ith basic proteins (Sampson et a l. 
1985). Therefore PAPP-A should in teract w ith the basic amino acid, 
Arginine. A column, 0.9 x 1.5 cm was packed with L-Arginine agarose 
(Appendix 1) and equilibrated in 10 mM potassium  phosphate (pH 7.2) 
containing 0.075M NaCl. The sample was loaded and eluted from the 
column by increasing the salt concentration to 1 M NaCl. (Figure 2.16).
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Elution profile from Cibachron-blue affinity column
(P la te  In se t 2.15: 1. PVDF CBB stained sample from peak A ru n  on a 5% 
SDS-PAGE gel. 2. W estern of peak A with imm unodetection using 
polyclonal anti-PAPP-A. 3. Silver stained 5% SDS-PAGE gel of the bound 
m aterial, peak B.)
[Arrow indicated molecular weight m arker with the size in kDa. Buffers and the sample 
loaded were performed as described in section 2.7.7]
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Elution profile from a L-Arginine affinity column (P la te  In s e t  2.16: 5% 
SDS-PAGE gel of bound fraction)
[Legend: The arrow indicated the molecular weight m arker with the size in kDa. The band 
marked as PAPP-A was determined by W estern blotting followed by imm uno-detection with 
polyclonal anti-PAPP-A. Buffer conditions were as described in section 2.7.8, the sample 
loaded was an aliquot from the DEAE bound fraction, section 2.7.6]
2.7.9 L ec tin  A ffin ity  C h ro m a to g ra p h y
The extent and type of glycosylation can be used as an aid in the 
purification of a protein (Gerrard, 1990). PAPP-A is glycosylated (Chapter 1, 
section 1.4) there was therefore the possibility th a t the carbohydrate groups 
present could be used to separate PAPP-A from its contam inants. Lectins
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are a class of molecules th a t have defined specificities for particular 
carbohydrate side chains. Bischof (1979b) used Con-A as an  affinity m atrix 
to aid in the purification of PAPP-A. Experiments th a t used PAPP-A 
electroblotted onto a membrane with subsequent incubation w ith lectin and 
appropriate carbohydrate (Chapter 7) revealed th a t the lectin th a t seemed 
to offer the best specificity for PAPP-A compared to its contam inants was 
Lycopersicon esculentum. A 2 ml column was packed agarose bound 
Lycopersicon esculentum  lectin (Appendix 1). The lectin/PAPP-A interaction 
on the solid phase blots was not transferable to a chromatographic method 
as in the absence of detergents used on the blots the Lectin did not 
dem onstrate the same specificity for PAPP-A th a t was observed on the blots.
2.7.10 M etal C helate C hrom atography
Immobilised m etal ion chromatography (MCAC) separates proteins 
according to the presence of histidine, tryptophan and cysteine on the 
protein surface. These amino acids bind to m etal ions th a t are complexed to 
chelating groups on the chromatographic medium. Sinosich et_al,(1983) th a t 
PAPP-A interacts with Zinc and found th a t elution from a Zn MCAC 
column using EDTA did not resolve PAPP-A from its m ain plasm a 
contam inants (Alpha -2- macroglobulin, PZP and fibronectin). A decreasing 
pH grad ient did not separate these proteins, bu t PAPP-A was 
immunologically denatured as to be no longer immunologically m easurable 
by crossed immunoelectrophoresis. This is in contrast to the stated, pH 
stab ility of PAPP-A by Lin (1974b) who observed immunological stability a t 
a pH range of 2 - 12. I also observed th a t a physico-chemical change 
occurred to PAPP-A after Zn-MCAC, in  th a t the protein separated tended to 
precipitate and was difficult to re-solubilise after elution from th is column. 
Although detectable by RIA after elution (Figure 2.19) w ith >95% recovery 
of the PAPP-A loaded onto the column, in the indicated peak fraction (•). 
Because of the difficulties in keeping the protein in  solution after elution 
from this column, it was not used as a step in  the isolation of PAPP-A. The 
MCAC m atrix (Appendix 1) was loaded to a bed volume of approxim ately
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5 mis, and the m atrix  charged by running 20 mis of 0.1 M Zinc Sulphate in 
distilled w ater through the column a t a flow rate  of 0.5 ml/min. It was then 
equilibrated w ith 100 mM acetate buffer (pH 6.3) containing 0.5 M NaCl 
(Appendix 2), PAPP-A was eluted with a step gradient to 30% of 100 mM 
acetate buffer (pH 4) containing 0.5 M NaCl (Appendix 2) a t a flow rate  of 
2 ml/min.
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Elution profile from Zinc-MCAC column
[Legend: An aliquot of the DEAE bound fraction from section 2.7.6 was loaded onto this 
column, buffer conditions were as described in section 2.7.10. PAPP-A was detected by the 
RIA as previously described in section 2.6.4.5]
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2.7.11 Gel F il t ra t io n
Gel perm eation chromatography (gel filtration) is a form of partition 
chromatography th a t separates molecules by partitioning them  between the 
solvent and a defined porous stationary phase. Protein aggregates can elute 
before the void volume, by being sterically hindered from diffusing between 
beads. Smaller molecules can enter the stationary phase and move through 
the column a t a slower ra te  th an  larger molecules th a t will then  elute first. 
Separation is then  on the basis of shape and m ass of a particu lar molecule. 
A pre-packed superDex-200 (Pharmacia, Appendix 1 w ith a bed volume of 
305 mis) was equilibrated in 10 mM potassium  phosphate buffer (pH 7.2) 
containing 0.15 M NaCl. The column was run  a t 4 ml/min and 5 ml fractions 
were collected (Figures 2.18 and 2.19).
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Calibration curve for the SuperDex-200 gel filtration column.
[Legend: Volume eluted/Void volume plotted against proteins of a known molecular weight 
(Appendix 1) taken to be Blue dextran (2000 kDa), Fibrinogen ( 340 kDa), IgG (150 kDa), 
Albumin (66 kDa) and Ovalbumin (45 kDa). r2= 0.997.]
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A typical elution profile from the superDex 200 gel filtration column (P la te  
in se t  2.19, represented a silver stained 5% SDS-PAGE gel of fractions 
indicated.)
[Legend: *: indicated off-scale absorbance. The arrow indicated molecular size m arkers 
with the num ber in Kda. The m aterial indicated as PAPP-A in the plate were confirmed by 
western blotting and immunodetection with anti-PAPP-A antibodies. An aliquot from the 
m aterial bound on the L-arginine m atrix was loaded onto this column, buffer conditions 
were as described in section 2.7. 11]
2.7.12 E lu t io n  o f  P ro te in s  F ro m  Gel Slices
Samples were reduced w ith 2-mercaptoethanol and run on an SDS-PAGE 
gel as described in section 2.3.2.2. Experim ents indicated th a t m ajor losses 
occurred a t the post-gel sta ining/destaining stage using the s tandard  CBB
2 -46
sta ining method (section 2.3.2.2d). If the protein was to be recovered from 
the gel, 1.5 mis of 2% CBB-R250 in methanol was added to the top 
electrophoresis reservoir. This allowed in-gel staining of proteins and the 
recovery of protein from the gel by excising the visualised band (It was 
frozen a t -70°C). After thaw ing the gel slice was cut into small pieces and 
incubated for 3 h rs a t 37°C with 300 pi of gel elution buffer (Appendix 2). 
This was then  spun through siliconised glass wool and the gel fragm ents 
were washed with 150 pi aliquots of elution buffer until the elution buffer 
had no traces of CBB. The fractions were pooled, freeze dried and finally 
reconstituted in sterile distilled water. Recoveries were calculated by re ­
running sample on an  SDS-PAGE gel and video-densitometry as described 
in section 2.6.5. Recoveries for the in-gel staining were approximately 40% 
compared to a recovery of only 10% when post gel staining/destaining was 
used prior to the recovery of protein from the gel slices.
General concentration of samples (if required) was achieved using 
Centriprep-100 (Amicon, Appendix 1) as described by the m anufacturers.
2.8 M aterials and M ethods S ection  For A M olecular  
Approach: Tow ards The PAPP-A Gene-II
2.8.1 A ssessm ent o f  P rotein  E lution  M ethods from  B lottin g  
M em branes
Protein ((standard proteins, 0C2M or purified myosin) and PAPP-A) were 
electroblotted onto nitrocellulose, immobilon-P as described in section 2.4.1. 
This m aterial was then  eluted from these mem branes using a variety of 
solvents (Appendix 2) as described by these investigators:
• 5% Tween (Leykan and Strahler, 1992).
• 20 - 100% M ethanol (Charbonneau, 1991).
• Hexafluoroisopropanol, HFIP (Morris, 1992).
The eluted m aterial was recovered by freeze-drying the m aterial and 
reconstituted in sample loading buffer (Appendix 2). I t  was subsequently 
analysed by SDS-PAGE followed by densitom etry as described in  section
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2.6.5). More th an  80% of the standard protein was recovered from the 
mem branes bu t PAPP-A could not be detected after using any of the 
suggested elution methods.
2.8.2 So lid-P hase C yanogen Brom ide (CNBr) D igestion
Cyanogen bromide specifically cleaves proteins a t the methionyl peptide 
bond (cited from Gross et ah 1962). Methionine residues are less frequently 
present in  proteins th an  other amino acids, so cleavage a t th is site usually 
produces a lim ited num ber of large peptides.
The procedure described in the probe-design k it was followed (Promega, 
1990). The PAPP-A monomer was electroblotted onto immobilon-P 
membrane or nitrocellulose (Luo et a l. 1990). The blotted m aterial was 
incubated overnight a t RT with 50 - 100 pi of 70% formic acid containing 10 
mg/ml CNBr. The CNBr solution was then  transferred to a new sterile 
screw-top Eppendorf tube (eluted peptide vial). The peptides were eluted 
from the membrane by submerging it in  200 ul of peptide elution solvent 
(Appendix 2) for 2 hours. This process was repeated again and the eluted 
peptides combined in  the eluted peptide vial and dried down using a 
nitrogen stream  directed a t the liquid in a well ventilated fume hood. The 
peptides were reconstituted in  distilled w ater and loaded onto the RP-HPLC 
colum n.
2.8.3 RP-HPLC Separation  o f P ep tid es
The mechanism by which proteins/peptides adsorb to a RP column as 
proposed by Geng and Regnier (1984) is th a t the hydrophobic amino acids in 
a peptide or protein are retained on a reverse-phase surface by single or 
multi-point adsorption and the retention time on th is surface can be 
predicted from the ratio of polar/non-polar amino acids in  the molecule. The 
protein/peptide entering the column displaces the mobile phase organic 
modifier on the surface of the reversed phase support. The protein rem ains 
adsorbed until a critical concentration of mobile organic modifier is reached 
and is then  desorbed. Large molecules in teract w ith the surface of the
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support by an  adsorption type mechanism, which is highly dependent upon 
their protein conformation. Thus separation of a protein/peptide m ixtures 
can be achieved. The use of TFA in the solvent protonates carboxyl groups 
on peptides thus increasing their affinity for the RP surface.
Briefly, the CNBr peptide digest was loaded onto a 250 x 4 mm RP-18 
column (5 pm Merck) linked to a Pharm acia HPLC system (Appendix 1). I t 
was eluted a t a flow ra te  of 0.5 ml/min with a four-step gradient as 
illustrated in  Figure 6.3, Chapter 6.
Solvent A: distilled w ater containing 0.06% TFA.
Solvent B: 80% Acetonitrile containing 0.06% TFA.
Detection was by absorbance a t 214 nm, or using a diode-array detector 
(Appendix 1) and amino-acid analysis (Appendix 3) was used to determ ine if 
peaks contained protein th a t was suitable for microsequencing (Figure 6.3, 
Chapter 6).
2.8.4 V a p o u r P h a se  CNBr C leavage O f PA PP-A  In  G el S lices
This was performed by a modification of the method originally described 
by Zingde et a l. (1985). TFA under reduced pressure was used instead of 
formic acid as this encouraged vapour formation and led to the production 
of an  acidic CNBr atmosphere. The vapour phase method ensured th a t 
cleavage was likely to occur a t methionine residues and not a t the acid 
labile, Asp-Pro bonds. The use of a vapour also m eant th a t extensive 
equilibration procedures were not needed prior to peptide separation thus 
reducing protein losses th a t occur a t these stages. All procedures involving 
CNBr were carried out in a well ventilated, externally vented fume hood.
In-gel stained PAPP-A bands as described in section 2.7.12 th a t had  been 
separated on 5% SDS-PAGE gels as described in section 2.3.2.2a were 
incubated in  a quik-fit chamber containing 3 mis of a 20 mg/ml cyanogen 
bromide in  70% TFA. The gel slices were suspended above the CNBr 
containing TFA, care was taken th a t liquid did not splash gel slices. The 
vessel was flushed with nitrogen and placed under a vacuum until the TFA 
boiled. I t  was then  sealed, covered in foil and left overnight a t RT. The gel
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slices were then  freeze dried and washed in sample buffer (Appendix 2) until 
the buffer rem ained a blue colour (dye sensitive to pH changes). The gel 
slices were boiled in 50 pi of sample buffer for 3 m inutes and loaded onto a 5 
- 20% peptide separating gel as described in section 2.3.2.2c). After 
electrophoresis the proteins present in the gel were electroblotted onto a 
PVDF mem brane as described in section 2.4.1 and sent for autom atic 
sequencing.
T ab le  2.6
Proteolytic enzymes suitable for limited proteolytic cleavage in the
Cleveland SDS-PAGE gel environment
Proteolytic Enzyme 1Cleavage
Site
Reaction conditions O ther
Information
Endoproteinase Glu-C -Glu 2X 50 mM Ammonium Active in
(from Staphylococcus bicarbonate (pH 7.8) presence o f :
aureus; V8 protease.) Or - 0.2% SDS.
50 mM Ammonium - 2M Urea,
acetate (pH 4.0) - 2M Guanidine-
HC1.
-Glu 2X 50 mM Sodium 50% activity in
or phosphate, (pH 7.8) 4M urea.
-Asp 2X M r 28,000 d.
Endoproteinase Lys-C Lys-3X 100 mM Ammonium Active in
(Type XXXIII-A from bicarbonate (pH 8.5) presence of:
Lysobacter enzymogenes) - 2M urea
- 0.1% SDS
Mr33,000 d.
[Legend: 1Cleavage site: Specific cleavage site as determined by enzyme and reaction 
conditions. 2X: Where X is any amino acid but not glutamic acid or proline. 3 X: Where X is 
any amino acid.]
2.8.5 L im ited  P ro te o ly tic  C leavage in -gel S lices (C leve land )
The Cleveland method (Cleveland et a l. 1977) enables in-gel proteolytic 
digestion of proteins. The method th a t was used was a modification of the 
Cleveland technique described by Andrews (1989). In-gel stained PAPP-A 
slices (Chapter 5) were cut in squares and equilibrated for 15 m inutes a t RT 
in stacking layer buffer (Appendix 2), they were then  gently pushed into the 
wells of a 5 - 20% gradient SDS-PAGE system as described in section 
2.3.2.2c. These gels were cast with a 5 cm stacking gel layer to allow the
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protease and protein to be stacked together and facilitate proteolytic 
digestion. The gel slices were overlaid with stacking layer buffer containing 
10% glycerol, a proteolytic enzyme (see Table 2.6, the concentration and 
type of protease th a t were used can be seen in the legends in  Figures 6.4 
and 6.5, Chapter 6) and 0.001% Bromophenol blue as dye m arker. The gel 
was then  run  a t 55 V (constant) until m arker dye was 2 cm into stacking 
layer. Then the power was turned off and the samples were left to digest for 
60 to 90 minutes. Subsequently electrophoresis was resumed, the 
fractionated digest was then  electroblotted onto a PVDF mem brane as 
previously described (section 2.4.1).
2.8.6 N -te rm in a l m ic ro se q u e n c in g
The m aterial produced on PVDF blots was sent to commercial sequencing 
services (services used were described in  Chapter 2) which used an Applied 
Biosystems 477A Protein Sequencer. The sequences produced by these 
services are identified as p a rt of the legend to Figures 6.4 and 6.5, Chapter 
6. A full outline of the sequencing results can be found in  Appendix 3.
2.8.7 O lig o n u c leo tid e  S y n th e s is  a n d  P o s t S y n th e s is  P ro c e s s in g
Oligonucleotides were produced in-house by M r P. Loxley. The 
phosphoramidite version of the phosphite triester method was carried out on 
a solid phase support. De-protection and concentration of oligonucleotides 
were as described in  Appendix 2. The following oligonucleotides were used 
as PCR prim ers (Table 2.7).
T ab le  2.7
Oligonucleotides synthesised from PAPP-A sequences obtained in  th is study.
5’- AAA GCIAGA GGI GCIACI GAA -3’ :N-PAPP-1.
5’- G C G G -3’ :N-PAPP-2.
5’- GA(A/G) GCI (A/C)G(A/G) GGI GCI ACI GA(A/G) GA(A/G) C -3’ :PA PP-4 
5’- ICC ICC (G/A)TC IGC (A/G)TT (A/G)AA (A/G)TG -3’ :cPA PP-3________
[Legend: Bracketed figure indicates 50% wobble with nucleotides indicated at that 
position. N-PAPP-1/2 were two oligonucleotide pools produced from the first N-terminal 
sequence obtained for PAPP-A (K. Lilley, Appendix 3). PAPP-4 was the consensus N- 
terminal region for PAPP-A obtained from sequencing information (Table 6.3, Chapter 6) 
and PAPP-3 was a complementary strand to a putative internal stretch obtained from a V8 
digestion of PAPP-A, Figure 6.5, Chapter 6. The synthesis of these primers is further 
outlined in Appendix 3.]
2 -51
2.8.8 Polymerase Chain reaction (PCR)
The PCR reaction is an  in-vitro DNA amplification process th a t occurs 
during a series of repeated cycles. Each cycle consists of three tem perature 
dependent steps:
• D enaturation carried out a t 90 - 95°C.
• Prim er annealing carried out a t 35 - 65°C.
• Extension a t 70 - 75°C.
The tem perature a t which denaturation is performed is somewhat 
dependant upon the DNA tem plate. The annealing tem perature is 
dependent upon the individual primers present in  the assay and the 
extension tem perature is a function of the therm ostable DNA polymerase. 
By cycling these three steps the polymerase extends the prim ers in  a 5’ -> 3’ 
direction and allows amplification of the original tem plate. A more complete 
description of the PCR reaction and factors th a t influence th is reaction can 
be found in  Ehrlich, (1987) and Bej et a l. (1991).
H ighly degenerate prim ers were used (Table 2.7) and as suggested by 
Williams (1989) in such cases, it is best to use a low annealing tem perature 
in the first cycle and then gradually increase it, giving a ram ped PCR cycle. 
This type of program (Table 2.8) was the one th a t worked best a t amplifying 
cDNA from the placental library these degenerate primers.
T ab le  2.8 Ramped PCR program for use with prim ers listed in Table 2.7:
5.1 95°C Program  paused after 9 m inutes and 2.5 U nits of Taq 
added, (H ot-S tart) R estart, 1 m inute a t 95°C.
5.2 50°C 1 m inute
5.3 72°C 2 m inutes
5.4 95°C 1 m inute
5.5 550C 1 minute
5.6 72°C 2 m inutes
5.7 95°C 1 m inute
5.8 60°C 1 m inute
5.9 72°C 2 m inutes (Repeat x 28 from step 5.7).
5.10 72°C 10 m inutes
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The standard  PCR was performed using 2.5 U of therm ostable DNA 
polymerase (from Thermus aquaticus, s tra in  YT2, (Appendix 1)). A 10X 
reaction buffer was used th a t consisted of 100 mM Tris-HCl, pH 8.3 (at 
25°C), 500 mM KC1 and 15 mM M gC h. The standard  PCR reaction volume 
was 5 0 p l, w ith substrate dNTP's th a t were used a t a final concentration of 
200 pM each. The reaction mixture also contained 100 pmoles of each 
prim er and 5pl of the cDNA library tem plate (Appendix 1) a t a 1:100 
dilution. The PCR products were analysed (see Plate 6.1, Chapter 6) on a 2% 
agarose gel in  TAE as described section 2.3.2.1.
2.9 M aterials and M ethods Section  for S tu d ies on An In teraction  
B etw een  R educed M onom eric PAPP-A and The E ndop rotein ase  
Arg-C.
Limited in-gel slice digestion was performed as described in section 2.8.5. 
Purified monomeric PAPP-A (see Plate Inset 5.3, Chapter 5) was used. A 
reduced SDS treated  BSA (Appendix 1) which was prepared and eluted from 
gel slices in the same way as PAPP-A as described in  section 2.7.12 was 
used as a control (a sim ilar molar concentration of BSA and PAPP-A were 
used assum ing th a t monomeric PAPP-A has a molecular weight of 195 kDa 
and BSA, 66 kDa). Protein sequencing grade endoproteinase Arg-C 
(Appendix 1) was used. The effect of PAPP-A or the control protein (BSA) on 
the esterolytic activity of endoproteinase Arg-C was m easured. Briefly, 30 
pi of endoproteinase Arg-C (for concentration see Figure legends 7.2 and 7.3, 
Chapter 7) were pre-incubated with 15 pi of buffer A (Appendix 2) and 15 pi 
of protein (PAPP-A, BSA or buffer A for the protein concentration see 
legends in  Figures 7.2 and 7.3, Chapter 7) for 1/2 hour a t RT and then  0.44 
ml of pre-warmed (37°C) buffer A and 1 ml of pre-warm ed (37°C) TAME 
substrate (Appendix 2) were added. After 30 m inutes of incubation a t 37°C, 
50 pi aliquots were removed and the TAME was m easured as described in 
section 2.3.6.
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CHAPTER
THREE
Chapter Three
A M olecular Approach: T ow ards The PAPP-A G ene I
3.1 In trod u ction
The m ain classical strategies by which a gene may be cloned are:
• Direct selection is an  approach whereby the cloned gene product confers 
a recognisable phenotype on the host cells. However in the case of PAPP- 
A the gene is a p a rt of a complex genome and its product does not have a 
known function.
• Screening a DNA library in  which the gene (or cDNA) itself or its 
transla ted  product is identified.
The screenings of DNA libraries require the use of an efficient host/vector 
system. Molecules of DNA with one origin of replication function as units of 
replication and are called replicons. So if replication of a DNA fragm ent is 
required then  the obvious solution is to attach  it to a suitable replicon. Such 
replicons are called vectors and examples are plasmids and bacteriophages 
in which the exogenous DNA can be either:
• Inserted a t a unique restriction site w ithin the vector (Insertion Vectors).
• Used to replace phage DNA a t a specific site as it contains a pair of 
specific restriction sites flanking both sides of a particu lar region 
(Replacement Vectors).
The original wild type bacteriophage lambda is not suitable as a cloning 
vector because it contains too many restriction sites, some of which are 
located within regions essential for the replication of the phage. However by 
a series of m anipulations m utant bacteriophage strains have been produced 
th a t are suitable cloning vehicles for cDNA inserts. The use of 
bacteriophage vectors requires an understanding of the phage structure 
and its interaction w ith its bacterial host. To illustrate  th is interaction I 
have chosen the bacteriophage X gtll and its bacterial host, E. coli. (a
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derivative of K12, strain: Y1090). This system was used to screen for the 
PAPP-A clone using an antibody directed against PAPP-A as a probe and is 
described in  this Chapter (Figure 3.1).
E. coli has the following advantages when used as the host organism:
• Gene expression is largely controlled a t the level of in itiation of 
transcription.
• I t  is a well studied organism th a t can be easily grown in a well defined 
media.
• The work can be carried out safely using standard  microbial techniques 
as described by Bainbridge (1991) and needed no special precautions as 
E. coli is classified as a low risk category organism.
The double stranded DNA of the lam bda phage genome is encapsulated 
in an  icosahedral head from which a single tail fibre is projected. Infection is 
in itiated by the adsorption of the tail fibre to the receptor sites in  the outer 
membrane of the bacterium  (this site is encoded by the E. coli, lamB gene). 
Receptors are produced when E. coli cells are grown in a medium th a t 
contains maltose as the host’s carbon source. The adsorption is facilitated by 
the presence of magnesium ions.
After infection the phage can follow a productive (lytic) or tem perate 
(lysogenic) pathw ay depending upon physiological conditions. In  a lytic 
cycle, early to late transcription events take place th a t resu lt in  the 
production of virion proteins and the phages genomic m aterial is packaged 
to generate bacteriophages. This type of replication eventually leads to the 
host cell lysis w ith the release of phages th a t can infect other host cells..
A lysogenic cycle results in the integration of the bacteriophage genome 
into the host chromosome and results in  the phage (prophage) being 
replicated as p a rt of the host, E. coli chromosome.
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The H ost/V ector System  U sed In T his Study  
B a c te r ia l  H ost: Escherichia co li, strain: Y1090 with the following
genotype:
• lacU l69............Deletion that prevents endogenous generation of
functional P-galactosidase protein product.
• Ion*...................  Deletion of Ion protease, which reduces proteolysis
of expressed fusion proteins.
• araD l39 Cannot use arabinose as a carbon source.
• strA.................... Resistance to the antibiotic, streptomycin.
• supF...................Results in the insertion of Tyrosine at UAG
codons.
• trpC22.............. Requires Tryptophan for growth.
• (pMC9)..............Contains a plasmid that is a derivative of pBR322
which has the LacI gene that encodes the lac 
repressor. It also confers resistance to ampicillin and 
tetracycline.
• hsdR (rk-, mk+) Restriction minus, modification positive: Thus 
allowing material to be cloned into the host 
without cleavage of DNA by endogenous 
restriction endonucleases that are present.
V ector: The tem perate bacteriophage, Xgl l  has the following stated
features with the insertion site for exogenous DNA in a unique EcoRI site, 
53 bp from the 3’ term inus of lacZ gene; thus proteins are expressed as 
fusion products with p-galactosidase.
• Sam 100...........Mutation renders the phage lysis-defective, so it cannot
make plaques in hosts that lack the SupF supressor gene product.
• N in5................ A deletion that removes a transcription terminator.
• cI857............... Encodes a temperate repressor protein (see below)
F ig u re  3.1 Vector/host interactions.
The Y1090 stra in  contains the pMC9 plasmid th a t carries the  LacI gene 
which encodes a protein repressing the Lac promoter carried by the A,gtll 
phage so enabling a control of the production of a protein specified by the 
DNA insert. Y1090 is also Ion- and so lacks a protease th a t is responsible for 
degrading abnormal proteins. The cI857 gene encodes a repressor protein,
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which is inactive a t 420C (active a t 300C), and unable to shu t off early 
phage promoters, this leads to a lytic response. The nin5 deletion (Figure
3.1) allows enough leaky readthrough to occur th a t when the amber 
m utation is suppressed it enables plaques to be formed.
Insertion of foreign DNA within the LacZ gene, results in a phenotypic 
change from LacZ+ to LacZ- , thus when plated onto an appropriate host 
which is LacZ- in the presence of IPTG (a synthetic inducer of the lac 
repressor) and X-Gal (a chromogenic substrate for p-galactosidase) the 
parental A,gtll produces blue plaques. Recombinant phage produce 
colourless plaques as the inserted DNA in terrupts the coding sequence of 
the LacZ gene.
The described host/vector system makes it possible to synthesise a 
foreign protein in the host, E. coli thus enabling th is host to produce a 
polypeptide th a t is specified by the cDNA present (Young and Davis, 1983).
Screening of this cDNA library for a clone of in terest can then  be 
achieved by one of two methods:
• Nucleic acid hybridisation; with the cDNA itself being identified, bu t in 
the case of PAPP-A, no prim ary sequence information was available 
therefore this method could not be used initially to identify a PAPP-A 
clone.
• Immunological detection; with the transla ted  product of the gene being 
immunologically identified, hence the use of an  antibody directed against 
PAPP-A being used as an  immunological probe.
This chapter describes the initial studies th a t were undertaken to study 
the structure and expression of the PAPP-A gene by searching for its cDNA 
in a bacteriophage expression library th a t had  been prepared commercially 
from mRNA derived from placental tissue. Placental tissue has been shown 
to be a likely source of PAPP-A (Chapter 1, section 1.4.3) and thus a viable 
source of PAPP-A mRNA.
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3.2 M aterials and M ethods
The reagents, methods and techniques th a t were used to generate the 
results described in th is chapter are described fully in  Chapter 2, section 
2.5.
3.3 R esu lts and D iscu ssion
An antibody to PAPP-A was needed for the screening of a cDNA 
expression library th a t would recognise a denatured form of this protein. 
The host, E. coli has an in ternal cellular environment th a t does not allow 
the formation of disulphide bridges (Young and Davis, 1983). Thus 
proteins produced by this system are not able to fold into their native state. 
The ability of a particular antibody to detect a denatured protein can be 
assessed in W estern blotting where reduced and unfolded proteins are 
studied. The monoclonal and polyclonal (DAKO) antibodies directed against 
PAPP-A th a t were available in this study were assessed for their ability to 
detect a denatured monomeric PAPP-A protein (Plate 3.1)
The monoclonal PAPP-A antibody did not recognise the monomeric 
reduced form of PAPP-A but did recognise the PAPP-A dimer (Plate 3.1(B)) 
or the proposed PAPP-A/proMBP dimer (Oxvig et a l. 1993). This is discussed 
further in Chapter 7 , section 7.2. This monoclonal antibody’s paratope was 
thus directed a t a PAPP-A epitope th a t was related to the molecule’s 
tertiary  structure and so was unlikely to be useful for isolation of a cDNA 
clone for PAPP-A from this type of expression library.
The polyclonal antibody recognised m any more epitopes on the 
unreduced PAPP-A th an  on the reduced sample as it was dem onstrated by 
the intensity of staining (Plate 3.1(A)) when the same am ount of th is protein 
th a t was loaded into each lane. The polyclonal antibody did recognise 
PAPP-A in a denatured and unfolded form, so it was decided to use this 
antibody as a probe to isolate a PAPP-A clone from the placental cDNA 
expression library.
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P la te  3.1
W estern blots of PAPP-A prepared using DAKO polyclonal antibody (A) and 
anti-PAPP-A monoclonal (B).
[Legend: W estern Blotting was performed as described in chapter 2, section 2.4.1. The 
polyclonal antibody was used at a 1:600 dilution and the monoclonal ascites tap  a t a 1:25 
dilution. (+): Indicates th a t the protein sample was reduced with 2-mercaptoethanol prior to 
SDS-PAGE. (-): Indicates th a t protein sample was not reduced prior to SDS-PAGE. SDS- 
PAGE was carried out as described in Chapter 2, section 2.3.2.2a. The arrow indicates the 
position of the 205 kDa molecular weight size m arker (Appendix 1) on the blotted 
membrane.]
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In itial screening was performed on 90 mm plates, however th is was soon 
changed to 140 mm plates as it allowed a larger num ber of clones to be 
screened a t one time. If we assume th a t PAPP-A is encoded by a 
relatively infrequent species of mRNA then  assum ing a 99% probability of 
isolating this clone, a library m ust contain a t least 9
x 105 independent clones to identify a clone th a t is represented by a 
relatively rare  species of mRNA (Sambrook et a l. 1989). The library was 
titra ted  and it  was estim ated th a t 3.4 x 1010 clones were present in 1 ml of 
this library (Table 3.1).
T ab le  3.1 T itration of the placental cDNA library.
Volume of a 1 0 7 Dilution of librarv used Number of nlaaues/nlate
10 pi 20
20 pi 78
30 pi 130
[Legend: Results of cDNA library titration performed as described in Chapter
2, section 2.5.1.4.]
This was close to the figure obtained from Clontech of 9 x 109 clones/ml, 
w ith the difference being probably due to the error in diluting the library 
from neat to a 10*7 dilution. From this value of the num ber of plaque 
forming units (PFU’s), a dilution was taken in subsequent work to give 8000 
(20000) PFU’s per 90 (140) mm plate. This num ber of plaques per plate 
enabled large num bers of clones to be screened and also allowed the 
identification of individual plaques th a t could be picked out and re-screened 
when a putative positive clone was found. Therefore to identify a rare  clone 
it is necessary to screen a large num bers of clones. To th is end an  estim ated 
1.2 million plaques were screened in an a ttem pt to identify a clone for 
PAPP-A. No clone for PAPP-A was identified using the DAKO polyclonal 
antibody. A further assessm ent of the characteristics of the library  and the 
polyclonal antibody used was now made.
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P la te  3.2
An Assessment of Vector/Recombinant Phages present in the placental 
cDNA library used in this thesis.
[Legend: The plate was prepared as described in Chapter 2, section 2.5.1.4. The small 
white dots were bacterial contamination th a t were seen on extended storage of the plate 
and were not present on the plates th a t were used to screen for the PAPP-A clones.].
One possibility was th a t the library contained a large num ber of non­
recombinant vector bacteriophages as this would have reduced the num ber 
of recombinants th a t had been screened. As can be seen from Plate 3.2 less 
than  5% of the plaques were blue in the presence of X-Gal (a chromogenic 
substrate for the p-galactosidase gene product). This indicates th a t the 
placental library had a large num ber of recombinant bacteriophages and is 
well above the widely accepted 60% level for expression libraries (Huynh et 
al, 1985).
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A positive control for the screening system used was obtained by 
infecting the host, E. coli cells with recombinant phage containing an 
ovalbumin insert and detecting the products of the expression with an an ti­
ovalbumin antibody. The ovalbumin cDNA clones were detected very 
efficiently using this system dem onstrating th a t the host/vector system was 
capable of transcription of the cDNA insert with subsequent production of a 
polypeptide (Plate 3.3). Therefore the inability to identify a clone th a t was 
representative of PAPP-A using the DAKO polyclonal anti-PAPP-A as a 
probe was not due to a failure of:
• The avidin/biotin end-detection system.
• Or the host/vector system th a t produced an expressed polypeptide.
P la te  3.3
Positive control of the expression library/screening system
[Legend: Control ovalbumin cDNA clones were used to infect the host, E. coli. as described 
in Chapter 2, section 2.5.1.3 The clones were detected with a 1:5000 dilution of rabbit 
(Appendix 1) anti-ovalbumin antibody, detection was as described in Chapter 2, section 
2.5.1.7].
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Assum ing th a t PAPP-A was present in the placental cDNA library the 
negative result could have been due to another characteristic of the 
prokaryotic system, th a t is the lack of post-translational modifications (e.g. 
glycosylation and phosphorylation) of proteins. The PAPP-A molecule has a 
significant carbohydrate component th a t would not have been added to the 
polypeptide chain produced in this system. The expression of a partial 
PAPP-A monomer was also likely as incomplete cDNA molecules would 
have been present in this library (insert size quoted as being 0.8 - 3.6 kb) 
which would also result in less epitopes being present for PAPP-A. To 
investigate the effect of removing the carbohydrate moiety from native 
PAPP-A was achieved by incubating PAPP-A th a t was blotted onto a 
nitrocellulose membrane w ith an enzyme preparation th a t would remove 
the glycan component of PAPP-A.
The enzyme preparation th a t was chosen was a crude chitinase 
preparation from Aspergillus niger as th is has been shown to contain a 
mixture of glycosidic enzymes capable of de-glycosylating proteins (Maley et 
al, 1989). Although this preparation was efficient a t removing the glycan 
moiety it had a disadvantage in th a t it was shown to be contam inated w ith 
a lim ited am ount of proteolytic enzymes (Figure 3.2) and any change in 
ability of the antibody to recognise PAPP-A could have been due to 
proteolytic digestion, ra ther than  the removal of the glycan component. The 
subsequent treatm ent with a protease inhibitor cocktail has however 
dem onstrated th a t the contaminating proteases were successfully inhibited 
(Figure 3.2) and th a t this protease inhibitor cocktail did not affect the 
activity of the glycosidic enzymes of this preparation (Figure 3.3).
F urther treatm ent of the blot from an SDS-PAGE gel w ith 
chitinase and subsequent probing with the DAKO anti- 
PAPP-A antibody revealed th a t the band previously detected was no longer 
visible (Plate 3.4). This suggested th a t the polyclonal serum  
used to screen the library for the PAPP-A clone has a num ber 
of paratopes th a t are directed a t . epitopes on the glycosylated p a rt of the
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F igure 3.2
Calculated general proteolytic activity present in  the chitinase enzyme 
preparation (before/after incubation of this preparation w ith a protease 
inhibitor cocktail).
[Legend: Percent calculated protease activity was obtained using the general protease 
determination as described in Chapter 2 , section 2.3.5) and these values were related to the 
mean level found in the chitinase preparation (1) after 16 hours at 37°C. 1: Results were 
expressed as mean calculated activity +/- range for samples in triplicate. (1): 0.5 units 
(Appendix 2) of a chitinase preparation pre-incubated in TBS prior to assessment of 
proteolytic activity. This preparation of chitinase had been shown to be contaminated with 
an estimated 0.75% of proteolytic enzymes as measured by the general proteolytic assay 
described and compared to a standard protease preparation. (2): 0.5 units of the chitinase 
preparation pre-incubated for 1 hour with a protease inhibitor cocktail in TBS prior to the 
assessment of general protease activity present.]
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F ig u re  3.3
The calculated chitinase activity before and after incubating this enzyme 
preparation with a protease inhibitor cocktail.
[Legend: Percent calculated chitinase activity was obtained by comparing the values 
of the mean activity for the chitinase preparation (1) after 19 hours at 30°C as 100% and 
others plotted as a percentage of this value, h all values were expressed as mean +/- range 
for each preparation in triplicate. (1): 0.5 units (Appendix 2) chitinase preparation in TBS 
(Appendix 2). (2): 0.5 units chitinase preparation (pre-incubated for 1 hour with a protease 
inhibitor cocktail in TBS). (3): 0.5 units chitinase preparation (pre-incubated for 1 hour and 
supplemented with another aliquot of protease inhibitor cocktail in TBS, just prior to being 
assessed for chitinase activity as described in Chapter 2, section 2.3.3).]
PAPP-A molecule or to the tertiary  structure th a t is held in place by the 
glycan component of the PAPP-A molecule. The hypothesis th a t the lack of 
recognition of PAPP-A by this antibody was due the removal of glycan and 
not proteolysis of PAPP-A by proteases th a t were present in this crude 
enzyme preparation was further strengthened by experiments with 
electroblotting a control protein BSA, th a t is not glycosylated. Incubation of 
the BSA blots w ith the chitinase enzyme preparation did not diminish the 
intensity of immunodetection with an anti-BSA antibody when compared to 
the intensity on blots which had not been treated  with this enzyme.
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Subsequently a culture supernatant from Allesheria terrestris grown in 
conditions giving a lim ited proteolytic component (the general protease 
component present was determined as described in Chapter 2, section 2.3.5 
and was shown to have 37 fold less protease th an  the chitinase preparation) 
was used to trea t the W estern blots for PAPP-A and BSA. Sim ilar results to 
th a t found with the chitinase preparation with regard to immunodetection 
of these proteins were observed.
I t  has been shown th a t the polyclonal anti-PAPP-A antibody used under 
the described conditions detects a single band on the W estern blot from an 
SDS-PAGE gel. This band corresponds in size to values a ttribu ted  to PAPP- 
A by other investigators (Bischof, 1979. Sinosich et a l. 1990). I t  also had a 
disulphide bridged tertiary  structure as reported. I t  was however noted th a t 
a higher concentration of salt was required to produce a specific single band 
on a W estern blot. Non-specific interactions of antibodies with other 
macromolecules are often electrostatic (Kabat,1976) therefore a t an 
increased ionic strength  these non-specific interactions are reduced as 
electrostatic charges are shielded by the increased concentration of ions. 
This thus lim ited the immunodetection to PAPP-A and may explain why a 
haptoglobulin related protein was not isolated in th is study, in  contrast to 
Kuhajda et al (1989) who isolated a cDNA encoding this protein using the 
DAKO antibody th a t was used in this study. Therefore it is likely th a t the 
failure to isolate a PAPP-A clone from this placental cDNA library using the 
DAKO polyclonal antibody was a function of the PAPP-A structure in th a t 
the antibody used under the described conditions did not have m easurable 
levels of paratopes with a strong enough affinity to in teract solely with 
PAPP-A’s polypeptide chain or p a rt of th a t chain th a t was available to form 
recognised epitopes. I t  was therefore decided to isolate the PAPP-A clone(s) 
using nucleic acid probes. No such prim ary sequence information was 
available for PAPP-A a t the time, so it was necessary to obtain the PAPP-A 
protein in a form suitable for N-term inal amino acid sequencing (Chapter 5) 
and in sufficient quantities for lim ited proteolytic digestion to produce 
peptides for sequencing from which nucleic acid probes could be designed.
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CHAPTER
FOUR
Chapter Four
The Q uantitative M easurem ent o f PAPP-A
4.1 In troduction
An assay is a system of m easurem ent for a defined m aterial, which is 
based around a m aterials physico-chemical properties. The defined m aterial 
in this case was PAPP-A and an assay was required to monitor the 
purification of PAPP-A from other blood plasm a components. Assays th a t 
are based around a m aterials structure can be divided into two distinct sub- 
types (Ekins, 1981):
• Non-competitive, reagent excess (Figure 4.1A).
• Competitive, reagent limited (Figure 4.IB).
A class of th is type of assay are the immunoassays th a t use an antibody 
as the structurally  specific reagent. The m ain problem in these types of 
assay is how to distinguish the free from the bound sta te  and th is is depicted 
in Figure 4.1. One method to resolve this problem is to use a labelled 
component (a tracer) in the depicted reaction th a t can be used to monitor 
the free/bound state. The types of tracer and label commonly used in 
immunoassays are illustrated in Table 4.1.
A) R e a g e n t (A ntibody) E xcess
Analyte + Antibody [Analyte-Antibody Complex] + Residual Antibody
(Free) (Free) (Bound) (Free)
[The bound complex is directly proportional to the am ount of analyte
present.]
B) R e ag e n t (A naly te) L im ited
Analyte + Antibody -» [Analyte-Antibody Complex] + Residual Analyte
(Free) (Free) (Bound) (Free)
[The ratio of bound complex to free unreacted analyte is proportional to the
original amount of analyte present.]
F ig u re  4.1
The principle of reagent excess (A) and reagent lim ited assays (B)
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Table 4.1
Features of s tan d ard immunoassays that have been adapted for use in the measurement of PAPP-A.
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[NOTE: 1Time: Time required from setting up the assay to obtaining a quantitative result. 2 Sensitivity: Approximate level of assay sensitivity. 3 Technica  
Level: S (simple), M (moderate) and C (Complex), includes factors such as assay development and laboratory equipment required. A mor 
detailed examination of these assays can be found in Bolton and Hunter (1986), Axelsen (1983) and Tijssen (1985)]
A num ber of types of immunoassay for the m easurem ent of PAPP-A 
were available, but the choice of assay used was lim ited by a num ber of 
factors. The immunometric assays require a constant pure source of specific 
antibodies directed against PAPP-A th a t could be labelled, th is supply was 
unavailable a t the time when this work was being performed, so the IRMA 
was not considered a viable choice of an  assay to m easure PAPP-A. The 
radioimmunoassay requires a supply of pure antigen th a t obviously was 
unavailable a t the s ta rt of a purification, a RIA was eventually used and 
this was as described by Pinto - Furtado et a l. (1984). The immuno- 
-precipitation methods of RIE and SRID only requ ired a specific antibody; 
of which one was commercially available (DAKO). I t  was also possible to 
design a sandwich ELISA for PAPP-A using this antibody and it was these 
techniques th a t were used to monitor the PAPP-A purification procedure. A 
further technique of W estern blotting and densitometry could also be used 
to semi-quantify PAPP-A bu t only when it was enriched to a level as to be 
visible as a distinct band on an SDS-PAGE sta ined gel.
4.2 M aterials and M ethods
An individual description of the M aterials and Methods th a t were used 
in this chapter can be found in Chapter 2, section 2.6.
4.3 R esu lts and D iscu ssion
As has been seen in Chapter 1 the analysis of the PAPP-A protein
produced during pregnancy has produced an array  of conflicting information
with investigators during the past 20 years finding little common ground.
These results seem to be due to a variety of factors w ith differing results
due to artefacts in the assay system (Pledger and Nicol, 1983), the quality of
the prim ary reagents e.g. The pure PAPP-A preparations containing
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contam inants and the antisera used not being monospecific (Chemnitz et al, 
1986. Bueler and Bersinger, 1989). Coagulation of the sample used to 
m easure PAPP-A has also been seen to play a role, w ith detection in male 
patients and non-pregnant females being dependant upon where the 
components used to make the immuonoassay system were acquired (Bischof 
and Meisser, 1988).
4.3.1 T he  PA PP-A  ELISA
The ELISA used in  this thesis (Figure 4.2B) differed from the ELISA 
described by Pledger and Bellfield (1983, Figure 4.2A) in  that:
• The microtitre plate was coated with F(ab’)2 fragm ents instead of 
complete antibody molecules.
• The PAPP-A bound was detected by utilising the affinity of Protein-A for 
a binding site on the Fc portion of the Ch2 and Ch3 domains of IgG 
molecule (Langone, 1982 and Lian et a l. 1991) as illustrated  in Figure 
4.2B.
This ELISA design removed the need to specifically label the PAPP-A 
antibody and so reduced any damage th a t may have occurred to the 
antibody during enzyme labelling. I t  also m eant th a t a lot less tim e was 
required to prepare assay components, as the protein-A conjugate was 
available commercially. Surprisingly, the am ount of the m aterial bound by 
the capture F(ab’)2 and directly detected with the Protein-A conjugate was 
the same as th a t detected when the second stage PAPP-A antibody was 
included. A significant level of PAPP-A was found in male serum  (Figure 
4.3) using this assay, it  could not be determined w hether PAPP-A or a 
plasm a contam inant was binding to the protein-A enzyme conjugate.
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( A )
F ig u re  4.2
Schematic representation of PAPP-A ELISA design
[Legend: (A) Design used by Pledger and Bellfield (1983). DAKO PAPP-A antiserum was 
used as the capture phase and detected with HRP conjugated to DAKO PAPP-A antiserum. 
(B) Design for PAPP-A ELISA used in this thesis. DAKO PAPP-A antiserum F(ab’)2 
fragments were used as the capture phase. DAKO PAPP-A antiserum was used as the 
second phase antibody with detection by a protein-A HRP conjugate.]
However the results th a t were found using the ELISA procedure 
described detected PAPP-A in male plasma, therefore it was likely th a t 
either the antiserum  was detecting a normal serum  component to the same 
extent as PAPP-A or th a t PAPP-A is in a complex with a serum  component 
th a t binds protein-A. I t  is not known w hether the recent observation th a t
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PAPP-A is complexed w ith proMBP (Oxvig et al. 1993) has an  affect, or 
w hether i t  was proMBP present in  the male serum  was the component th a t
binds protein-A.
0.45
L.
0.15
Male Plasma Level A t A 1 /5  Dilution
0.001 0.01 0.1 
L ate  P re g n a n c y  P lasm a  Dilution
F ig u re  4.3
Unmodified ELISA +/- 2nd phase PAPP-A antibody w ith detection by a 
Protein-A enzyme conjugate
[Legend: (■) Wells were incubated with 1:2.5K dilution of DAKO Anti-PAPP-A antibody. 
(A) Wells were incubated with PBS in place of the second stage antibody. All wells then 
incubated with a 1:1000 dilution of protein-A enzyme conjugate. Other conditions were as 
outlined in Chapter 2, section 2.6.3. Note: 0.1 represented a 1:10 dilution of a late 3rd 
trimester plasma pool prepared as outlined in section 2.1 and 2.6 (Chapter 2). Initial 
experiments used Male (Lithium Heparin) Plasma as the negative control as illustrated 
above, this was replaced with Male (Citrate) Plasma in the subsequent experiments.]
In  an  attem pt to use th is ELISA to m easure PAPP-A several 
modifications were made:
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• The standards and unknown samples were incubated in  diluent th a t 
contained male plasm a (Initially Li-Heparin was used bu t th is was 
changed to the C itrate anticoagulant in subsequent experiments).
• The second antibody was pre-incubated in diluent th a t contained horse
serum.
100
P A P P - A  C o n c e n t r a t i o n  ( j jg /ml)
F ig u re  4.4
Modified PAPP-A ELISA w ith detection via a protein-A enzyme conjugate.
[Legend: Standards/Unknowns were incubated in ELISA diluent containing 5% Male 
Plasma (Citrate). A parallel duplicate set were run for each sample, one set (■) was 
incubated with a 1:2.5K dilution of PAPP-A antiserum in ELISA diluent containing 5% 
horse serum and the parallel set (A) were incubated in ELISA diluent containing 5% horse 
serum. Detection was with a 1:1000 dilution of Protein-A enzyme conjugate. Other 
conditions were as outlined in Chapter 2, section 2.6.3. The PAPP-A concentration given 
was calculated from an in-house late 3rd trimester plasma pool that had been calibrated 
against the WHO 78/610 reference pool as described in section 2.1 (Chapter 2).]
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Male Plasma Level A t A 1 /5  Dilution
P A P P - A  C o n c e n t r a t i o n  (jug/ml)
F ig u re  4.5
The modified PAPP-A ELISA
[Legend: (■) The modified Absorbance was plotted as values that were obtained from (■, 
Figure 4.4) minus their mean corresponding values, (A, Figure 4.4). Male (Citrate) plasma 
was used as the negative control as illustrated above. All other conditions were as described 
in the legend for Figure 4.4]
Using these modifications, a difference in levels was observed when the 
second antibody was used ( Figure 4.4). Therefore by incorporating these 
modifications an observable difference was seen in the presence (or absence) 
of second phase antibody. Thus these modifications enabled PAPP-A to be 
distinguished from the undefined m aterial th a t was interfering w ith this 
assay. This undefined m aterial did also seem to increase during pregnancy, 
bu t by comparing matched samples with/without the second phase antibody,
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an assay was produced which did not detect PAPP-A in male plasm a (Figure 
4.5).
Because of the non-specific effects th a t were seen during the 
development of this assay and the lack of knowledge as to w hat non-specific 
component of blood was being m easured, or w hat the effect on the ELISA 
would be of varying ratios of PAPP-A to this non-specific cross reactan t th a t 
would be seen during a purification procedure, this assay was not used to 
monitor PAPP-A concentrations. I t  is interesting to note th a t Pledger and 
Bellfield (1983) also found increased levels in haemolysed samples with a 
suggestion th a t their assay may also be m easuring a red cell component. 
Pro-MBP has also been shown to be linked to PAPP-A (Oxvig et ah 1993), 
however it is unknown if either of these two factors is responsible for the 
non-specific effect th a t was observed during the development of th is assay.
4.3.2 Im m unoprecip itation  M ethods
These methods are dependant solely on the quality of the antiserum  used 
w ith m igration of antigen via electrophoresis in RIE and diffusion in SRID, 
both types of assay have sim ilar levels of sensitivity and precision.
As seen from the results represented in Figures 2.6 (Chapter 2) and 
Figure 4.6, the composition of the m atrix has a distinct affect on the level 
of PAPP-A detected. These effects have also been observed by B jerrum
(1983) who found they were produced by the dissociation of sub-units, 
aggregation or denaturation of the antigen due to exposure to conditions 
such as high tem perature, high salt, or extremes of pH. The 
imm unoprecipitate th a t was produced being increased (or decreased) 
dependant upon which of these described factors was present. An increase 
in the size of precipitin ring (or rocket height) is probably due to a loss of 
antigenic determ inants, so th a t migration through the gel is over a longer 
distance before the complexes are large enough to be retained  w ithin the 
agarose network. A decrease can be due to partial unfolding of the protein or 
loss of antigenicity by some of the molecules involved. However it  has been 
established th a t using the RIE and SRID under constant conditions for all
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the samples m easured then  a level of PAPP-A could be determ ined when 
monitoring the purification scheme.
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P A P P -A  C oncen tra t ion  (jug/ml)
F ig u re  4.6
PAPP-A SRID illustrating the effect of salt concentration on the assay. 
[Legend: ( ■: The samples were loaded in assay diluent containing male plasma, the plate 
was made in assay diluent containing a final concentration of 1 M salt, r2 = 0.997). (A: The 
samples were loaded in assay diluent at a final concentration of 1M salt (containing male 
plasma, Appendix 2), the plate was made in assay diluent containing a final concentration 
of 1M salt, r2 = 0.994). Other conditions were as outlined in Chapter 2, section 2.6.2. The 
PAPP-A concentration was calculated against the WHO reference pool, 78/610. ].
4.3.3 T he  PA PP-A  RIA
The PAPP-A assay described by Pinto-Furtado et al (1984) was less
prone to effects of anti-coagulants on the assay and it  also gave a linear
correlation of values obtained when compared against an  IRMA th a t used
the DAKO polyclonal and a monoclonal antibody directed against PAPP-A
(Mowles et a l. 1986) thus im parting to this assay a greater specificity for
PAPP-A. However this does not exclude the possibility th a t the monoclonal
antibody is directed a t an antigenic component other th an  PAPP-A as it has
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been shown th a t it only binds to un-reduced PAPP-A (Chapter 3, Plate 3.1). 
PAPP-A has been shown to be linked to pro-MBP (Oxvig et a l. 1993).
The advantage to this assay of affinity purifying the PAPP-A tracer on a 
heparin column was illustrated in Figure 2.9 (Chapter 2) w ith less than  
23% of the tracer bound to excess antibody prior to chromatography. This 
compares favourably w ith a level of 30% observed by Pinto-Furtado et al.
(1984). After affinity chromatography a greater than  two fold increase in 
tracer bound in excess antibody was observed. The low level of tracer 
binding to PAPP-A antiserum  could have been due to damage produced 
during the iodination procedure or to the presence of other proteinaceous
m aterial in the iodination grade PAPP-A preparation (Chapter 6, Table 6.2).
-q  100 -
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20  -
10 100 1000 
PAPP-A Concentra tion (ng/ml)
10000
F ig u re  4.7
A typical PAPP-A RIA calibration curve.
[Legend: Results were expressed as 1 Percent tracer bound: (Bound CPM - NSB)/(B0 - NSB) 
Vs PAPP-A standard, the curve was fitted using RIACALC as described in Chapter 2, 
section 2.6.4.5]
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The PAPP-A RIA (Figure 4.7) had a detection limit as defined from its 
precision profile of 15 ng/ml and an upper lim it of 500 ng/ml a t a level of 
precision level as m easured by a coefficient of variance of 10% or less. This 
compared favourably to a detection limit of 10 - 15 ng/ml and an  upper limit 
of 600 ng/ml th a t was seen by Pinto-Furtado et ah (1984) using the 
described RIA procedure.
As seen from Table 4.2, the PAPP-A tracer undergoes changes with time 
th a t reduce its ability to bind heparin. This reduction in binding is the factor 
th a t lim its the life of the tracer to about four weeks. As seen from Figure 
2.9 (Chapter 2) it  was essential to use the heparin  bound fraction of PAPP- 
A tracer for the RIA. This assay was used to monitor development of a 
PAPP-A purification scheme.
T ab le  4.2 Percentage of PAPP-A tracer bound to a heparin affinity column.
T im e A fte r Io d in a tio n  (days)
0 7 14 M
P e r c e n ta g e  o f  T o ta l
PA PP-A  t r a c e r  B o u n d  47% 25% 13% 10%
[Note: h The table represents the proportion of PAPP-A tracer bound Vs The age of PAPP- 
A tracer when separated using a heparin affinity column. The results are expressed as a 
percentage of total tracer applied that were bound to this affinity matrix under the 
conditions described in section 2.6.4.2 (Chapter 2).]
4.3.4 Q u a n tif ic a tio n  b y  D e n s ito m e try
This method can be used once the PAPP-A has been enriched to a level 
where it can be visualised by protein staining and a discernible band could 
be distinguished from other serum /plasma components. I t  should be noted 
however th a t the levels found using this method are for the monomeric 
chain of PAPP-A (as seen under reducing conditions of SDS-PAGE).
A linear relationship was found to exist between the intensity  of staining 
and the protein concentration for CBB staining from 0 . 5 - 2 0  pg and 0.02 - 
2.0 ng/mm2 for silver staining. (Merril, 1990).This compared favourably 
with the results th a t were obtained in this thesis of a linear relationship 
between 1 - 8 pg/mm2 for CBB staining as was illustrated  in  Figure 4.8.
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Therefore th is method was used subsequently to calculate the recovery of 
monomeric PAPP-A protein levels from SDS-PAGE gels (Chapter 5).
2.5
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A m o u n t  O f  M y o s i n / B a n d  In M i c r o g r a m m e s
figure 4.8
A typical calibration curve of protein levels seen using video densitometry. 
[Legend: The calculated area/absorbance, (Chapter 2, section 2.6.6) was plotted Vs the 
amount of myosin loaded onto an SDS-PAGE gel. The gel was stained with CBB, as 
described in Chapter 2, section 2.3.2.2d.]
To summarise, the PAPP-A assays were found to be affected by a 
variety of factors from:
• The prim ary quality of the individual assay components.
• The individual assay design with affects due to molecular characteristics 
of PAPP-A.
These factors have undoubtedly affected the in terpretation  of the 
various clinical studies th a t were undertaken to see if PAPP-A could be used 
to monitor foetal well-being (Chapter 1, section 1.4.7). The assays developed 
and illustrated  here were however sufficient for the purpose of m onitoring a 
PAPP-A purification/enrichment procedure th a t is outlined in  C hapter 5.
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CHAPTER
FIVE
Chapter Five
The Iso la tion  o f PAPP-A for M icrosequencing
5.1 In troduction
The immunological approach to screening for the cDNA encoding PAPP-A 
did not give the expected results for the reasons th a t were discussed in 
Chapter 3. The biological activity of PAPP-A is unknown, so the only other 
approach to the identification of the PAPP-A cDNA required some prim ary 
sequence information of the PAPP-A protein. Thus allowing the preparation 
of nucleic acid probes th a t could be used for screening cDNA libraries 
(Huynh et a l. (1985) and Sambrook et a l. (1989). This information was 
unavailable a t the time the practical work of this thesis was undertaken, 
therefore it was necessary to purify, or enrich PAPP-A so it  would be in a 
form suitable for microsequencing. Such a purified product should then  give 
an unambiguous N-term inal sequence, if it was not N-term inally blocked. 
This would then  provide prim ary sequence information th a t would aid the 
isolation of PAPP-A cDNA (and hence the gene) and define its exact reading 
frame. I t  has been estim ated th a t between 50 - 90% of eukaryotic proteins 
are N-terminally blocked and are thus refractory to the Edm an chem istry 
(Brown and Roberts, (1976) and Stone et a l. (1989). Taking th is factor into 
account along with the large size of the PAPP-A protein (monomeric 
polypeptide chain is 160 - 180 kDa), it was also probable th a t in ternal 
stretches of amino acid sequence would be needed, not only to verify any 
putative clones identified but also to aid the isolation of this cDNA.
The design of a purification scheme for PAPP-A needs to take several 
factors into consideration and these are sum m arised in  Figure 5.1. The 
purification schemes th a t have been used to isolate PAPP-A over the past 
two decades are illustrated in Table 1.1 (Chapter 1).
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Key Q uestions A nsw ers in  rela tion  to  PAPP-A
1) Define the aim of the 
protein isolation in  term s of 
its final:
- Purity  ? And
- Yield ?
— ^
2) W hat is the most suitable 
and available source ?
— ^
><
3) W hat is known about the 
protein to be isolated?
>
4) How to m easure a 
successful purification ?
5) W hat techniques should be 
employed ?
Over the past two decades a 
num ber of investigators have 
described physico - chemical 
properties (Chapter 1) of PAPP-A
A guide to w hat has proved 
successful in the past to isolate 
PAPP-A should enable a scheme 
to be devised (Table 1.1, Chapter
A num ber of methods to monitor 
and m easure PAPP-A levels have 
been produced (Chapter 4), a 
final criterion is to obtain a 
single N-term inal sequence by 
the scheme used to isolate PAPP- 
-A.
Purpose: To obtain PAPP-A in a 
form suitable for protein 
sequencing, therefore the final 
purity  was a more im portant 
factor th an  the yield. W ith these 
aims in mind it was also not 
necessary to m aintain  PAPP-A 
in its native state.
M aternal plasm a from late th ird  
trim ester is when PAPP-A is a t 
its highest level in relation to 
other blood plasm a components 
th a t have been seen to co-purify 
with PAPP-A1*2 (Chapter 1). As it 
was not needed in  its native 
form, blood lost a t delivery could 
also be used.
Figure 5.1
Factors involved in the design of a purification scheme w ith particu lar 
reference to PAPP-A.
[Note: h Sutcliffe et al. (1980). 2: Sottrup-Jensen and Sand (1985).]
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The schemes outlined in Tables 1.1 and 1.2 (Chapter 1) represent the 
major purification schemes for PAPP-A and other published procedures were 
based around these described schemes. The previous work by other 
investigators in  th is field (discussed in Chapter 1) helped in the 
development of a scheme to isolate PAPP-A in a form th a t was suitable for 
microsequencing.
A complication arose in th a t there appeared to be an apparent change in 
the binding of PAPP-A to heparin which was shown to enrich PAPP-A and 
separate it from it’s major contam inants, (Sinosich et a l. 1987) PZP and 0C2- 
macroglobulin. This change in binding to heparin was investigated and it 
also made necessary a more thorough exam ination of the methods th a t could 
be used to purify PAPP-A. The development of purification schemes th a t 
yielded a single N-term inal sequence for PAPP-A are described in this 
chapter.
The isolation of a protein in a homogenous form suitable for Edman 
degradation has frequently been achieved by utilising a final step of RP- 
HPLC or separation under reducing conditions on SDS-PAGE and 
electroblotting onto a membrane suitable for solid phase sequencing 
(PVDF). These approaches have been shown to be successful in  producing 
amino acid sequence information from a variety of different proteins 
(Charbonneau, (1991), Cleveland et a l. (1977), M atsuidaira, (1990) and 
Stone et a l. (1989).
5.2 M aterials and M ethods
All chromatographic procedures unless otherwise sta ted  were carried out 
using a Pharm acia FPLC system. The methods used to monitor the 
purification are described in Chapter 4 of this thesis. The m easurem ent 
method th a t was used to monitor PAPP-A levels is sta ted  in the appropriate 
Figure legend. The overall purification schemes produced th a t were used to 
isolate PAPP-A are sum m arised in the following Results and Discussion 
section. Individual chromatographic steps are described in the appropriate 
section of the M aterials and Methods in Chapter 2 (section 2.7).
5 - 4
5.3 R esu lts and D iscu ssion
A wide variety of methods were employed to separate PAPP-A from other 
blood components. Not all methods were successful but they did however 
serve to illustrate  some of the biochemical features of PAPP-A and blood 
contam inants th a t co-purified with PAPP-A. They have been included for 
this purpose and the schemes described in this section are a reflection of the 
most successful routes th a t yielded an enriched form of PAPP-A.
I t  was beneficial to s ta r t w ith a biological source th a t contained PAPP-A 
in increased amounts, therefore m aternal blood a t term  was used as the 
source m aterial. The major contam inants th a t investigators have found 
difficult to separate from PAPP-A (Chapter 1, Table 1.2) were a 2- 
macroglobulin and pregnancy zone protein th a t are present a t a level of 2 - 
4 mg/ml (Sutcliffe et a l. 1980) and 1 -1 .4  mg/ml respectively in term  plasm a 
(Sottrup-Jensen and Sand, 1985). So by using term /late 3rd trim ester blood 
the concentration ratio of PAPP-A to (X2M/PZP was maximised.
As it was shown in Chapter 1 the use of the affinity of PAPP-A for 
heparin was a useful way to separate PAPP-A from other contam inants th a t 
often had  been seen to contaminate PAPP-A preparations produced using 
the classical methods of protein purification. W ithout the use of the heparin 
affinity matrix, PAPP-A was frequently not separated from other m aternal 
blood components such as (X2M, PZP and fibronectin. The heparin/PAPP-A 
interaction and purification of PAPP-A are discussed fu rther in Chapter 7, 
section 7.4.
5.3.1 P u rifica tion  Schem es That Were S u ccessfu l in  E n rich in g  
PAPP-A
As sta ted  in the introduction to this chapter, the aim of the isolation of 
PAPP-A was to use th a t m aterial for N-term inal microsequencing, A 
scheme (Figure 5.2) th a t utilised an affinity of PAPP-A for the amino acid 
L-arginine combined with steps described by other investigators (Table
1.1, Chapter 1) yielded PAPP-A enriched to approximately 30% of the 
proteins present in the final preparation. The only other major protein
5 - 5
As illustrated  in the plate inset 2.19 (Chapter 2), PAPP-A could not 
easily be separated from an unidentified contam inant th a t was present as a 
single chain form with an Mr of approximately 210 - 240 kDa. This 
contam inating m aterial (hereafter nam ed group-X) was immunodetected 
using an antiserum  directed against norm al serum  components. I t  also co­
eluted with PAPP-A in all the methods used to isolate PAPP-A which are 
described in Chapter 2, section 2.7. The only method th a t was successful in 
removing it, was on a basis of its size by gel filtration. The m aterial 
prepared by th is scheme was separated from 0C2M by SDS-PAGE under 
reducing conditions. I t  was electroblotted onto a PVDF mem brane th a t is 
suitable for use in  microsequencing (Plate inset 5.2). The PAPP-A band 
indicated by ( ★  ) yielded a single N-term inal sequence (Chapter 6, Table
6.2) thus confirming th a t the PAPP-A isolated had  been separated  from 
other contam inating serum proteins.
The second scheme th a t was successful in  enriching PAPP-A utilised the 
described affinity of PAPP-A for heparin and is illustrated in  Figure 5.3. 
The heparin  bound fractions (0.3 and 0.6 M) shown in Figure 2.12 (Chapter
2) were subjected to gel filtration (Figure 7.4, Chapter 7) and the fractions 
containing PAPP-A were identified as described (Plates 5.1 and 5.2).
The heparin  based scheme (Figure 5.3) as illustrated in  P lates 5.1 and
5.2 significantly enriched the PAPP-A present and separated PAPP-A from 
its m ain contam inant seen in scheme 1 (Figure 5.2), th a t of (X2M. I t  however 
failed to separate PAPP-A from the unidentified X-contaminant. This 
contam inant has also been observed by Davey et a l. (1983) who noted th a t 
it could be removed if a 0.4 M NaCl step was substituted between the 0.3 
and 0.6 M NaCl steps during the heparin affinity chrom atography stage. 
This did however resu lt in a considerable reduction in the yield of PAPP-A 
and the m aterial was still contaminated with other serum  proteins. Sinosich 
et al. (1990) removed these by negative affinity immunoadsorption. In  this 
study it was chosen to purify a single chain PAPP-A by elution from a gel 
slice as described in Chapter 2, section 2.7.12. This method yielded a pure 
monomeric PAPP-A molecule (Plate inset 5.3).
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(G ro u p  X) < 205
P la te  5.1
A CBB stained 5% SDS-PAGE gel of fractions from heparin  based
purification, Scheme 2.
[Legend: All samples were reduced w ith 2-mercaptoethanol before separation on this gel. 
The 0.3 and 0.6 M bound fractions from the heparin affinity column were loaded onto a gel 
filtration column (see text). The 0.3 M heparin bound fractions separated on the gel 
filtration column were (1): Fractions 1 - 4. (2): Fractions 5-6. (3): Fractions 7-8. (4): 
Fractions 11 - 12. (5): The high molecular weight m arkers (Appendix 1) with the arrow 
indicating the 205 kDa marker. The 0.6 M heparin bound fractions separated  on the gel 
filtration column (see text) were (6): Fractions 1 - 4. (7): Fractions 5 - 8. The PAPP-A band 
marked was determined by western blotting and subsequent detection with anti-PAPP-A 
antibodies. The group-X contam inant was also marked.]
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P la te  5.2
A CBB stained 5% SDS-PAGE gel illustrating the disulphide bridged
structure of the proteins separated by the heparin based purification scheme
[Legend: ( +  ) indicated samples were reduced with 2-mercaptoethanol, ( - ) indicated 
samples were treated  with sample buffer th a t did not contain 2-mercaptoethanol. The 
samples separated were from the heparin affinity column and then  loaded onto the 
superDex gel filtration column (see text): (1): 0.3 M bound heparin column, fractions 1 - 4 
from gel filtration column. (2): 0.6 M bound heparin column, fractions 1-4 from gel filtration 
column. (3): 0.6M bound heparin column, fractions 5 - 8 from gel filtration column. (4): The 
high molecular weight m arkers (Appendix 1) with the arrow indicating the 205 kDa 
marker. The PAPP-A m arked band was determined by western blotting and subsequent 
detection with anti-PAPP-A antibodies. The group-X contam inant was also marked.]
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F ig u re  5.3
The heparin based purification, scheme 2. P la te  In s e t  5.3, Pure 
monomeric chain PAPP-A.
[Legend: k Biological source m aterial was composed of a pool of late 3rd trim ester plasma 
and blood lost during delivery at term  th a t had been treated  as described in section 2.7.2, 
Chapter 2. The plate inset was a CBB stained 5% SDS-PAGE gel as described in section 
2.3.2.2.a of the gel-slice eluted m aterial (described in Chapter 2, section 2.7.12) from this 
purification scheme was illustrated in Plate 5.1. This preparation yielded a pure monomeric 
chain. PAPP-A. Note: (1): Represented eluted pure monomeric PAPP-A. (2): Represented 
high molecular weight m arkers (Appendix 1) with size illustrated  in kDa.]
5.3.2 A S chem e T h a t S ig n if ic a n tly  E n r ic h e d  th e  U n d e fin e d  (G roup - 
X) C o n ta m in a n t
Sinosich (1988) using CAIE w ith the dye, Red-120 observed th a t the 
PAPP-A immunoprecipitate was removed if this dye was included in an 
interm ediate gel, suggesting th a t it might be possible to isolate PAPP-A by 
dye affinity chromatography. A scheme incorporating this dye was devised 
(Figure 5.4).
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Red-120 Dye A ffin ity  
C h ro m a to g ra p h y
C ib ac h ro n  B lue Dye 
A ffin ity  C h ro m a to g ra p h y
28/60 % A m m onium  
S u lp h a te  C u t 
(0.52% PAPP-A)
b io lo g ic a l  S o u rce  M a te r ia l 
65 m g/m l 
(0.09% PAPP-A)
DEAE Io n  E x ch an g e  
C h ro m a to g ra p h y  
(2% PAPP-A)
90% Y ield
L -A rg in ine  A ffin ity  
C h ro m a to g ra p h y
F ig u re  5.4
Enrichment scheme for group-X contaminant. (P la te  In s e t  5.4 represented 
electroblotted m aterial purified using this scheme.)
[Legend: h Biological source m aterial was composed of a pool of late 3rd trim ester plasma 
and blood lost during delivery at term  th a t had been treated  as described in section 2.7.2, 
Chapter 2. The steps used in this purification were carried out as described in Chapter 2, 
section 2.7. The m aterial in the final step was reduced with 2-mercaptoethanol and 
separated on a 5% SDS-PAGE gel, it was electroblotted on a PVDF m em brane as 
previously described in Chapter 2, sections 2.3.2.2c and 2.4.1 and stained with CBB. Note: 
The arrow indicated molecular weight m arker with the size in kDa. The W estern blotted 
m arked band (Group -X) did not dem onstrate an affinity for anti-PAPP-A antibodies using 
the conditions previously described. The protein present in this band was sequenced by Dr 
A. Moir (Appendix 3).]
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Surprisingly the Red-120 dye did not enrich the PAPP-A component but 
the group-X contaminant. This was an  uncharacterised group of proteins, 
which in  N-term inal microsequencing generated more th an  one N-term inal 
amino acid. The amino acids present did not correspond to the N-term inal 
sequence th a t had  been obtained for PAPP-A prepared by the purification 
scheme 1 (Chapter 6). T hat the CAIE technique yields different results to 
th a t obtained by chromatography was also seen when the LEL lectin was 
used for purification. A further analysis of the implications of this 
contam inating group is given in Chapter 7.
The PAPP-A isolated and defined by the schemes described in this 
chapter produced a monomeric form of PAPP-A th a t was free of pro-MBP 
and yielded a single N-terminus (Chapter 6, Table 6.3). This m aterial was 
thus suitable both as a substrate for lim ited chemical/proteolytic cleavage to 
obtain further prim ary sequence information (Chapter 6) and provided a 
source of pure monomeric PAPP-A th a t was used to study some of the 
physico-chemical properties of the PAPP-A molecule (Chapter 7).
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CHAPTER
SIX
6 - 1
Chapter Six
A M olecular Approach: Tow ards th e PAPP-A G ene II
6.1 Introduction:
The possible strategies for identifying a cDNA encoding PAPP-A have 
been described in Chapters 3 and 5 and as it was shown the best available 
approach was to produce nucleic acid probes using the prim ary sequence of 
the PAPP-A protein. The prim ary sequence of PAPP-A was unknown a t the 
time the practical work of this thesis was undertaken. In  order to obtain it, 
PAPP-A was enriched by the methods described in Chapter 5 and finally 
isolated as a monomeric chain by SDS-PAGE. Its identity was confirmed by 
immunological detection on W estern blots using polyclonal antibodies 
directed against PAPP-A. The reduced monomeric PAPP-A was prepared on 
membranes, or cleaved (enzymatically or chemically) and microsequenced. 
PAPP-A in gel slices was cleaved using the method described by Cleveland 
et al. (1977) to produce a limited proteolytic digest needed to obtain amino 
acid sequence of the in ternal regions of the PAPP-A molecule. The 
approaches th a t were applicable to the PAPP-A m aterial th a t was produced 
are listed in Figure 6.1 and described in the relevant sections in  this 
Chapter.
Prim ary protein sequence information can be obtained by N-term inal 
sequencing of proteins using the method described by Edm an (cited from 
Edman, 1950). Briefly the chemical sequencing cycle consists of the protein 
fragm ent being allowed to react with PITC to yield a phenylthiocarbormoyl 
peptide, then  under anhydrous HC1 conditions the labelled amino acid 
undergoes cyclisation to yield a free PTH-am ino acid and a protein 
polypeptide chain th a t is n-1 residues shorter. The PTH labelled residue is 
identified and the n-1 polypeptide chain is put through another cycle (Figure 
6 .2).
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Edman
degradation
microsequencing
Design of 
degenerate 
probes
CNBr vapour 
phase chemical 
cleavage
Protein sequence 
refractory (blocked)
Limited proteolytic 
cleavage
2Solid Phase CNBr 
chemical cleavage 
approach_____
Separation of 
products of digestion 
and microsequencing
Electroblotted 
protein on PVDF 
membrane
Protein in  SDS- 
PAGE gel
C leveland in-gel slice cleavage approach
Separation of products of cleavage via 
Gradient SDS-PAGE and electrobiotting 
onto PVDF membrane
F ig u re  6.1
Approaches to producing prim ary sequence information w ith identified 
outcomes.
[Legend: 1 Cleveland in gel slice approach was as originally described by Cleveland et al, 
(1977) and discussed in more detail in Chapter 2, section 2.8.4: 2Solid phase CNBr digestion 
was as described by Promega probe design kit (Promega) in Chapter 2, section 2.8.2.]
The m anual process originally described by Edm an has now been 
autom ated (Findlay and Geisow, 1990) and techniques for protein transfer 
from a gel onto a th in  uniform support m atrix (usually a membrane) has 
been developed. This transfer procedure is referred to as blotting. (Bers and 
Garfin, (1985) and Stott (1989). A polymer based m em brane prepared from 
polyvinylidene difluoride (PVDF) and introduced in 1987 has the advantage 
of being mechanically strong, easy to handle and chemically inert; so the 
Edman chem istry can be applied to a protein blotted onto it (M atsuidaira, 
1989).
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Cr-^CO-rNHgCHR-jCO-Rg- etc. 
i (N -A c e tv la te d  p ro te in )  \M  = C=S  
P IT C
NH^CHR-jCO P.2 - el:c* p ro te in  r e f ra c to ry« i ■ 1 ■ -\  (P ro te in )
x h c o - r2
P T C -o ro te in
cycle  r e p e a ls
P ro te in  (n-1 p e p tid e )  chaJn. C leavage
C o n v e r te d
T h ia z o lin o n e -a m in o  a c idfree  P T H -a m in o  ac id
F ig u re  6.2
Principle of Edm an degradation
[Legend: 1 The most common N-terminal block of N-Acetylation that occurs in eukaryotic 
proteins, further described by Walsh and Sasagawa(1984). Note: N-gycosylated residues 
are not blocked but fail to extract and thus present as a blank sequence cycle, 0- 
glycosylated residues can involve a modified cyclisation reaction that blocks further 
sequencing, thus yielding a reduced yield of sequencable material beyond this type of 
residue (pers. comm. Dr A. Moir.)]
The amino acid sequence obtained by Edm an degradation has to be 
reverse transla ted  into a nucleotide sequence. However as it is illustra ted  in 
Table 6.1, the genetic code is degenerate in th a t a num ber of codons specify
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one am ino acid. The design of nucleic acid probes from this information will 
thus necessitate the production of a highly degenerate prim er set, if the 
reverse transla ted  sequence is to share 100 % homology with th a t found 
w ithin the authentic gene. The design of this pool of degenerate 
oligonucleotides or guessmer’s followed the guidelines listed below and is 
sum m arised in  Table 6.1.
G rantham  et a l. (1980) dem onstrated th a t organisms have a codon 
preference for the same gene. This information combined with the 
approaches suggested below by Lathe (1985) resulted in an  increase in 
probe homology to the gene from 76% when a purely random choice of codon 
was used for a guessmer to 86% when the approaches described and codon 
usage of the species of in terest were taken into account. The three amino 
acids w ith 6 codon choices were avoided if possible. CpG sequences formed 
by adjacent codons were elim inated as this dinucleotide is significantly 
under-represented in m am m alian DNA and only occurs w ith about half of 
the expected frequency. If the most commonly used codon for a particular 
amino acid in  a given species produces the CpG dinucleotide then  the next 
most common choice is selected. If there is an unavoidable choice of 2,3 or 4 
bases then  a neu tral base, such as inosine is used as it  forms stable base 
pairs w ith all four conventional bases.
The above information relates to the design of degenerate pools of 
oligonucleotides. I t  was planned in this work th a t these pools would be 
initially used as PCR primers. Care was also taken so th a t the primers 
synthesised did not contain any complementary structures longer th an  2 
bases, especially a t the 3' end th a t can lead to the formation of a primer- 
dimer complexes. This is where the prim ers anneal to each other and so lead 
to the production of a short duplex product (Williams, 1989). Somner and 
Tautz (1989) also dem onstrated the importance of the las t 3 bases a t the 3’ 
end of prim ers th a t act as anchors to the DNA tem plate, therefore it is 
im portant th a t the neutral base, inosine was not included a t th is position in 
any of the prim ers synthesised.
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T ab le  6.1
Reverse translation methods for the production of degenerate prim er pools
Am ino A cid1 (*)
Lathe M ethod2 | In osine M ethod3
Optimal codon choice when following base is
A, C, T G I A, C ,T  G
(1) Methionine: Met. (M) ATG ATG
(1) Tryptophan: Trp. (W) TGG - TGG -
(2) Phenylalanine: Phe. (F) TTC TTT TTC TTT
(2) Tyrosine: Tyr. (Y) TAC TAT TAC TAT
(2) H istidine: His. (H) CAC4 CAT CAC CAT
(2) Glutamine: Gin. (Q) CAG - CAI -
(2) Aspartic acid: Asp. (D) GAC GAT GAT -
(2) Asparagine: Asn. (N) AAC AAT AAC AAT
(2) Lysine: Lys. (K) AAG - AAI -
(2) Cysteine: Cys. (C) TGC TGT TGC TGT
(2) Glutamic acid: Glu. (E) GAG - GAI -
(3) Isoleucine: lie. (I) ATC ATT ATI -
(4) Glycine: Gly. (G) GGC - GGI _
(4) Alanine: Ala. (A) GCC GCT GCI5 -
(4) Valine: Val. (V) GTG6 - GTI -
(4) Proline: Pro. (P) CCC7 CCT CCI -
(4) Threonine: Thr. (T) ACC ACA ACI -
(6) Leucine: Leu. (L) CTG CTI _
(6) Serine: Ser. (S) TCC TCT TCC TCI
(6) Arginine: Arg. (R) CGG - CGI -
[Legend: Amino acid1: Denoted by 3(1) letter code as illustrated by Cohn (1984). Reverse 
translation methods as suggested by Lathe (1985)2 and the inosine substitution method 
from Sambrook et al. (1989)3. 4CAT when followed by C. 5I: Represents neutral base 
inosine.. 6GTC when followed by T. 7CCA when followed by T Note: (*) numbers in brackets 
indicating the number of codons that code for that specific amino acid.]
This chapter describes the methods used to produce prim ary sequence 
information for the PAPP-A protein th a t was subsequently used to design 
and synthesise degenerate nucleic acid PCR prim ers for screening the 
placental cDNA library.
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6.2 M aterials and M ethods
The reagents, methods and techniques th a t were used to generate the 
results described in th is chapter are described fully in Chapter 2, section 
2 .8 .
6.3 R esu lts and D iscu ssion
The PAPP-A th a t had been enriched by a method based on the procedure 
described by Sinosich et al (1983) yielded m aterial th a t could be used as a 
tracer in a RIA , Figure 4.7 (Chapter 4). I t  was not suitable for obtaining the 
prim ary sequence for PAPP-A (Table 6.2) as this m aterial contained a t least 
6 polypeptide chains. F urther purification of PAPP-A was therefore 
required to produce PAPP-A in a form suitable for microsequencing 
(Chapter 5).
Table 6.2
Microsequencing of PAPP-A m aterial used for iodination
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
D Q E L N D K E F E E N F N V V
L N G A L V R I K M P R L Q D
V R P V K F G A G D W F L
M W F I R A A P H A
G Y S G
I T I
E A R G A T E E P S P P S R A L Y (1)
[Legend: Amino acids using 1 letter nomenclature, numbers indicate amino acid identified 
after number of Edman degradation cycles, the order listed indicating level of amino acid 
present with highest concentration at top of table. Note (1): indicates N-terminal protein 
region for PAPP-A from Kristensen et al. (1994) The enriched material sequenced was that 
used for iodination and was a PAPP-A enriched sample that was a gift of Ms K. Price. The 
material was microsequenced by the Leeds University central sequencing service, Appendix
31.
6.3.1 R esu lts O f CNBr Chem ical C leavage o f  PAPP-A
The solid phase CNBr digest and RP-HPLC method for separating 
peptides did not generate m aterial suitable for Edm an degradation. Control 
m aterial isolated from the RP-HPLC system was sequencable, indicating
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th a t peptides were recoverable from RP-HPLC system and separation and 
collection procedure did not block the N-terminus. The elution of the 
cyanogen bromide digest as monitored by absorbance a t 215 nm from the 
RP-HPLC did not yield m aterial th a t was sequenceable (Figure 6.3).
As shown in Chapter 2, section 2.8.1 it was not possible to elute PAPP-A 
protein from a membrane (nitrocellulose or PVDF) using any of the methods 
described to elute protein from a membrane. This was in  contrast to the 
control proteins which could be eluted using methods th a t other 
investigators have found successful for this purpose (Leykan and Strahler, 
(1992), Charbonneau, (1991) and Morris, (1992)). This difficulty in eluting 
PAPP-A may explain why the solid-phase CNBr digest approach did not 
yield any further information on the prim ary protein structure of PAPP-A.
The vapour phase in-gel digestion produced m aterial th a t could be 
sequenced bu t as can be seen in Appendix 3, the separation technique used 
did not adequately resolve the peptides produced to give any sequence 
information th a t could be used to design oligonucleotide primers.
6.3.2 L im ited P roteo lytic  D igestion  o f PAPP-A w ith  Lys-C
The results of a typical digestion with Lys-C are illustrated in  Figure 6.4 
with the individual method performed as outlined in Chapter 2, section 2.8.5 
yielded N-term inal information from the peptide Lys-Cl (Table 6.3). All the 
other bands th a t were sequenced represented peptide m ixtures and did not 
yield any further prim ary sequence information.
6.3.3 L im ited P roteo lytic  D igestion  o f  PAPP-A w ith  Glu-C
The results of a typical digestion with the endoproteinase Glu-C are 
illustrated in Figure 6.5 with the individual method performed as outlined 
in Chapter 2, section 2.8.5. The endoproteinase Glu-C can generate a 
sm eared bands with some substrate proteins (Fischer, 1983). PAPP-A as a 
substrate also generated a smeared band pattern , the significance or why 
some proteolytic enzymes generate this sm earing effect is unknown bu t was 
true of the PAPP-A/V-8 interaction.
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E lu a n t  (m is)
SO6020 40
Figure 6.3
RP-HPLC elution profile of solid-phase CNBr cleavage of PAPP-A
[Legend: (A): Represented marked peak as detected using a diode-array detector, A m ino  
acid analysis of the indicated peak ( ■  ), was a service provided by Dr A. Moir (Appendix 
3). (B): Elution profile of CNBr cleavage on the reverse phase HPLC system as described in 
Chapter 2, section 2.8.3. The dotted lines indicated peaks that eluted in a second solid- 
phase CNBr digest.]
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Lvs-C D ig estio n
a) Lys-C 1 produced an extended 
N -term inal region (Table 6.3)
b) Lys-C2
M ixture of at least 4 peptides 
(Appendix 3)
81
46
33
27
20
* Lys-C5
* L ys-C 4
*Lys-C 3
*Lys-C 2
* Lys-C 1
c) Lys-C3 
EAR(Por G)
?S tart of PAPP-A N -term inus 
but yield too low to sequence. 
(Appendix 3)
d) Lys-C4 
Peptide mixture 
(Appendix 3).
e) Lvs-C5
M ixture of at least 2 peptides. 
(Appendix 3).
F ig u re  6.4
Limited proteolytic digestion of PAPP-A with Lys-C. (P la te  in s e t  6.4: 
PVDF electroblotted sample as sent for sequencing).
[Legend: Arrows on left of blot wrere size of fragm ents in kDa calculated as described in 
Chapter 2, section 2.3.2.2.C. Bands tha t were sequenced are indicated by * and num ber that 
identifies the given sequence (Appendix 3) M aterial was sequenced by Mr J . Gilroy, 
Durham. A limited digest was performed with 1 gg of endoproteinase Lys-C (Appendix 1)]
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The in ternal peptide identified in this study (K-2, Figure 6.5) was not 
found in the published sequence but did share some homology with part of 
the V8 molecule. (Appendix 3). This could have been due to a num ber of 
factors:
• The monomeric band identified as PAPP-A was not pure. However this 
was unlikely because another protein th a t could have co-purified with 
PAPP-A would have to have the same Mr as the monomeric PAPP-A 
chain and also have existed as a disulphide bridged dimer and share the 
same physico-chemical characteristics of PAPP-A (Chapters 5 and 7).
• Sequencing of m aterial added to digestion (i.e. the proteolytic enzyme or 
a protein contam inant added in this enzyme preparation).
The degenerate prim er produced from this sequence (cPAPP-3, Chapter 
2, Table 2.6) did produce a specific PCR product w ith the prim ers produced 
from the N-term inal region of PAPP-A (Plate 6.1). This dem onstrated th a t 
the placenta contained mRNA th a t codes for PAPP-A and thus 
dem onstrated th a t PAPP-A is synthesised by the placenta.
T ab le  6.3
Comparison of PAPP-A N-Terminal Sequence information obtained during 
this thesis against the published sequence1
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
E A R G A T E E P S P  P S R A L Y (1)
E A R G A T E E P S I D I R A L I (2)
E A R G A T E E P (3)
K A R G A T E ? V (4)
E A R G A T E E P (5)
[Legend: Amino acids using 1 letter nomenclature, numbers indicate amino acid position 
for mature protein chain starting at N-terminus. Bold lettering indicates agreement with 
sequence for mature N-terminal region described by Kristensen et al, (1994)1. ?: indicated 
blank sequence indicative of cysteine or post-translationally modified N-linked amino acid. 
2: Lys-C digestion, own blot band K-l. Sequencing via 3: V-8 digestion, own blot, peptide 
band K-l. Sequencing via 4/5: PVDF blot, N-terminal sequence by Dr K. Lilley ]
Surprisingly the use of asymmetric PCR as described in  Chapter 2, 
section 2.8.8 confirmed th a t using the PCR prim ers N-PAPP-1/2 on their 
own generated a specific PCR product > 1200 bps. S im ilar results were
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obtained if the N-term inal primer, PAPP-4 was used. The use of the cPAPP- 
3 with the N-term inal prim er generated a specific product of approximately 
500 bps (Plate 6.1).
CO ^  lO CO CO
1375
947831
564
P la te  6.1
PCR using prim ers N-PAPP-1/2 and cPAPP-3 (an in ternal PAPP-A stretch, 
complementary primer)
[Legend: 7 ul of PCR product was run on a 2% agarose gel containing ethidium bromide in 
TAE (as described in Chapter 2 , section 2.3.2.1).Note: All other conditions were as 
described in Chapter 2, section 2.8.8 (1): 100 pmol cPAPP-3 and N-PAPP-1/2. (2): 100 pmol 
cPAPP-3 and 1 pmol N-PAPP-1/2 . (3): 100 pmol cPAPP-3 and 0.1 pmol N-PAPP-1/2. (4): 0 
pmol cPAPP-3 and 100 pmol N-PAPP-1/2. (5): 100 pmol cPAPP-3 and 0 pmol N-PAPP-1/2. 
(6): 0.1 pmol cPAPP-3 and 100 pmol N-PAPP-1/2. (7):. 1 pmol cPAPP-3 and 100 pmol N- 
PAPP-1/2. (8): Double stranded DNA size markers Appendix 1), numbers in Plate 
represented size in bp’s.]
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A search of the GENBANK/EMBL databases w ith the sequences 
described in Table 2.6 (Chapter 2) using the GCG package a t DARESBURY 
dem onstrated th a t the no two PCR prim er pairs shared homology with any 
of the published sequences. This did not exclude the possibility th a t these 
sequences were hybridising to something other than  PAPP-A. But an 
analysis of the published sequence dem onstrated th a t the 500 and >1200 bp 
PCR products could have been generated from the PAPP-A cDNA. 
Sequences present in the PAPP-4 prim er shared 100% homology with the N- 
term inus region and a 10 bp complementary sequence was located a t the 3’ 
prime end of this prim er th a t would give a >1200 bp product using the 
cDNA sequence as a tem plate. A sim ilar partial homology was observed for 
the degenerate cPAPP-3 prim er th a t would produce a 500 bp product with 
the N-term inus prim er using the described cDNA sequence as a tem plate.
The solid phase chemical method of cyanogen bromide cleavage did not 
yield sequenceable m aterial by Edman degradation. The vapour phase 
CNBr cleavage and limited proteolytic digestion using an adapted Cleveland 
method yielded sequence information, usually in the form of peptide 
m ixtures th a t were not well enough separated by the gradient SDS-PAGE 
method th a t was described in this thesis. F urther work using RP-HPLC or 
2D-PAGE (and electrobiotting) would have led to methods th a t would have 
resolved these peptide mixtures would have yielded single in ternal peptide 
sequence information. However the time taken to generate th is sequence 
information precluded a further examination of the cDNA. After the 
practical aspects of this work were completed a Danish group published 
work describing the isolation of PAPP-A cDNA (Kristensen et al (1994) and 
Oxvig et a l. (1993) th a t confirmed the N-terminus obtained for PAPP-A.
The presence of sequences other than  th a t described in the published 
cDNA (Kristensen et a l. 1994) is likely to be resolved when the entire gene 
sequence for PAPP-A has been obtained. I t  will also resolve why there are 
two distinct mRNA species of 9 Kb and 12 Kb in size which are much 
larger th an  th a t expected to produce a PAPP-A polypeptide chain w ith an 
estim ated size of 172 kDa (Oxvig et a l, 1994).
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CHAPTER
SEVEN
Chapter Seven
The M olecular C haracterisation  o f PAPP-A  
7.1 In troduction
During the time th a t this thesis was undertaken it became apparent th a t 
the there were a num ber of areas th a t concerned PAPP-A th a t were 
controversial in th a t contrasting results were described by different 
investigators. This chapter is involved with w hat was found in this study 
about the PAPP-A molecule with regards to:
• Glycosylation with an investigation of the glycan component in term s of 
extent and type of glycosylation (section 7.2).
• Studies on an a previously undescribed interaction th a t was observed in 
this thesis between PAPP-A and the endoproteinase Arg-C, which is 
discussed with the implications this interaction has on a suggested 
function for PAPP-A (section 7.3).
• The tertia ry  protein structure of PAPP-A was examined (section 7.4).
7.2. S tu d ies on The C arbohydrate C om ponent o f  PAPP-A
7.2.1 In tro d u c tio n
Glycoproteins are proteins which have been post-translationally 
modified, w ith the addition of carbohydrate residues (glycans) to the 
polypeptide chain. They may contain between 4 - 60% (w/w) of the glycan 
component (Lee et a l. 1990). The glycan can be linked to the polypeptide 
chain in  one of two major ways by:
•  N-glycosidic bonds through the amido nitrogen group of asparagine.
•  O-glycosidic bonds through the hydroxyl oxygen group of serine or 
threonine, bu t also 5-hydroxy-lysine or 4-hydroxy-proline.
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The glycan component can perform a variety of functions in 
Glycoproteins including:
• Protection of the polypeptide chain from proteolytic attack. This is 
probably due to a simple steric blocking of access of the enzyme to 
protein’s peptide core.
• Induction and m aintenance of a protein’s active form, e.g. de- 
glycosylation of the cysteine proteinase, th iostatin  results in it’s 
inactivation (Rusiniak et a l. 1991).
• Cellular signalling as it has become apparent th a t m any differentiation 
antigens on normal and neoplastic cells are the oligosaccharide 
determ inants of glycoproteins ra the r than  the peptide. (Feizi et ah 1987).
• M asking of cell surface antigens from immune surveillance. I t  has been 
reported th a t modification of the glycan component by addition of further 
carbohydrate residues can have a masking affect on antigens present on 
the cell surface (Childs et a l, 1983).
• Receptor interaction, with the observation by Alexander (1989) th a t the 
ligand for the sperm receptor on the ovum is an 0-linked oligosaccharide 
and it is the glycan component ra ther than  the polypeptide chain of the 
protein th a t is the recognition factor in  this interaction.
Changes in the glycosylation pa ttern  of serum  proteins occur during a 
variety of pathological conditions, e.g. alpha-2-macroglobulin has different 
patterns of glycosylation in patients w ith the autoim mune (rheumatoid 
a rth ritis and chronic inflammation) diseases than  th a t found in  healthy 
individuals (Silvestrinin et ah 1989). I t  has been reported th a t the pa ttern  
and extent of glycosylation play an im portant role in cell-cell signalling and 
changes in them  have been observed in neoplasia (Saso et ah 1992).
Methods th a t can be used to characterise the glycan constituent of 
glycoproteins have been extensively reviewed by Lee et a l. (1990), Faye and 
Salier (1989), M ontreuil et a l. (1986). Lectins can be used in a num ber of 
ways to study the glycan component of glycoproteins bu t the two m ain 
approaches have been described by Faye and Salier (1989):
• Crossed affino-immunoelectrophoresis (CAIE).
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• Probing of W estern blots with lectins.
Both methods allow a quick determ ination of glycan composition of a 
glycoprotein. CAIE allows an exam ination of the oligosaccharide chains 
linked to a protein if the tertiary  structure of the protein does not make 
them  inaccessible for interaction with the lectin, therefore a lack of 
interaction does not exclude the presence of a particular carbohydrate 
group. A disadvantage of the CAIE approach is th a t if a studied protein 
forms a complex with another protein then this method cannot differentiate 
between components of the complex, thus a positive resu lt w ith a particular 
lectin could be due to the carbohydrate group being present on the 
complexed protein.
The advantage of probing a blot with lectins is th a t glycoproteins are in a 
denatured form and thus the glycan is accessible for interaction with the 
lectin and any interaction is with the protein of in terest and not a complex 
(as described above). However it is not capable of detecting heterogeneity in 
individual oligosaccharide chains th a t may be present. The lectin probing of 
W estern blots combined with chemical or enzymatic deglycosylation was 
thus chosen to investigate the glycan component of PAPP-A. The affinity of 
lectins used in  this thesis for carbohydrate residues is sum m arised in  Table
7.1.
The glycan component of PAPP-A has been studied by various 
investigators (Table 1.3, Chapter 1). The glycan component of PAPP-A has 
been estim ated to be 13 - 19% (w/w) of the molecule. A num ber of
investigators have studied (Bischof, (1979a), Sinosich et a l. (1985,1990) 
Sutcliffe et a l. (1980) and Oxvig et a l. (1994) the overall am ount and type of 
carbohydrate residues present; although this is valuable information, it does 
not however determine the nature and type of oligosaccharide chains th a t 
were present on the PAPP-A molecule. The studies using CAIE (as 
undertaken by Sinosich et a l. 1985,1990) analysed the native PAPP-A 
molecule and in the light of the recent finding th a t PAPP-A is a complex 
with proMBP (Oxvig et al. 1993) it is unknown w hether the glycan assessed
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T ab le  7.1 Specificities of lectins for specific carbohydrate residues.
Carbohydrate S n ecific itv2
L ectin1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
BSL-1 + a + a - - - - - - - -
BSL-IB - + a -
BSL-II - - + tn -
Con-A - - - + + -
DSL - - - - 1 1 + o + o - - - - -
DBA + a - -
EBL - + - - - + + t  _ + - - - -
ECL - + s - - - +-H- - - - - -
Jacalin - - - - - +o-i - - - -
LCA3 - - + a + + a + + + « t _ -
LTL4 - - - - - - + a - - -
LEL - - +ol -
PHA-E4 - +l.n-l -j-l.n-1
PNA + + a - - - + + S - - - - -
PSA5 - - - - •f.l.n-1 _ _ _ - +l.n-l - - -
PWN - - -f-ol.n-1 - - - - - - -
RCA-I6 + t.s + t.s
STL - - +ol - - - - - - -
SJA + *
SBA7 ++t +
UEA-I - - - - - - + - - -
UEA-II + -
W A 8 +t« - - - - + - - -
WGA9 - - +ol.t.s - - - - - - -
WGA-S - - -fol.t - - - - - - -
VAA - - - - - - - + * - -
GNA - - - - - + - - - -
MAA10 - - - - + t + t - - - -
ABA -J-tn
LPA - +
CAA - +
WFA + 1
[Legend: Lectin1: Abbreviations for lectins and carbohydrate specifities adapted from those found
in Lis and Sharon(1986), Wu et al,(19881. Lee et al,(1990) and as used by Vector Laboratories 
(Appendix 1). Carbohydrate specificity2: (1) N-Acetyl-galactosamine. (2) Galactose. (3) N-Acetyl-P- 
D-glucosamine. (4) Glucose. (5) Mannose. (6) Mannose, branched structure. (7) Galactosyl (P-1,4)N- 
acetyl-glucosamine. (8) N-Acetyl-lactosamine. (9) Sialic acid terminal to galactose. (10) Galactosyl(P- 
l,3)N-Acetyl-Galactosamine. (11) Lactose. (12) L-Fucose. (13) Galactosyl residues. (14) N,N-di-Acetyl- 
Chitobiose. (15) Sialic acid. (+,++: Affinity for specific carbohydrate group, if more than one (+) then 
indicates relative affinity. Abbreviations: xa , Alpha linked residue. xtn , Non-reducing terminal
residue. xo1 , oligomers of residue, x0*1, O-linked residue, x11-1, N-linked residue. xs-, Only will bind 
residue if de-sialated. x1, only binds if both residues present, x1, binds if terminal residue. xs, residue 
needs to be sialated for lectin to bind. Notes: 3: More specific than Con-A, fucose also increases 
affinity. 4: Similar to UEA-I but has different affinities for carbohydrate residues. 5 : Increased affinity 
if terminal mannose. 6: Greater affinity for P-D than a-D galactose. 7: Binding blocked by substitutions 
in penultimate sugars. 8: Two isolectins, A4 binds terminal a-linked and B4 binds to single residue 
bound to serine/threonine. 9: Increased affinity for higher oligomers of N-Acetyl-glucosamine. 
10: Increased affinity for a-2,3 linked sialic acid to galactose. ]
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using this method was present on the PAPP-A monomer or on the 
proMBP/PAPP-A complex. The investigation carried out in this thesis used 
an isolated reduced monomeric chain of PAPP-A th a t was free of proMBP 
and the glycan component of the PAPP-A monomer is assessed in this 
section.
7.2.2 M aterials and M ethods
The m aterials and methods used in the section can be found in Chapter
2, section 2.4.
7.2.3 R esu lts and D iscu ssion
7.2.3.1 T he  A n tig e n ic ity  o f  PA PP-A
W estern blotting of PAPP-A reduced into a monomeric form, followed by 
immunodetection with a polyclonal antibody (DAKO) against PAPP-A 
yielded a specific band a t approximately 195 kDa (Chapter 3, P late 3.1A). A 
single band was however produced with this antibody only when a high 
concentration (0.6M) of salt was used to increase the specificity of the 
interaction with the immune serum. At this salt concentration the serum  
also had to be used a t a high concentration to produce a detectable band (a 
1:600 dilution for polyclonal anti-PAPP-A). Thus it was possible to make 
this antiserum  specific for PAPP-A, but this specificity was achieved a t a 
cost of using only a sub-group of paratopes present in th is antiserum , some 
of which were directed against the glycan component of PAPP-A (as 
determined by deglycosylation experiments which revealed th a t the 
recognised antigenic determ inants had a carbohydrate component, Chapter
3, Plate 3.4). To further characterise the antigen (PAPP-A)- antibody 
interaction, a chemical method for cleaving the carbohydrate groups was 
used as described in section 2.4.5 (Woodward et a l. 1985, see P late  7 .1)
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P la te  7.1
A chem ical assessm ent of the glycan epitopes detected by polyclonal anti- 
PAPP-A paratopes at high salt concentration (0.6 M NaCl).
[Legend: The W estern blots were prepared and treated as described in Chapter 2, section 
2.4. Development of the blot with antibody was as described in Chapter 2, section 2.4.3. but 
before development the blots were pre-incubated with: (1) TBS. (2) 2 mM sodium periodate. 
(3) 10 mM sodium periodate. The arrow indicated the 205 kDa molecular weight marker.]
It has been reported th a t not all carbohydrate groups are sensitive to this 
type of chemical treatm ent (Woodward et ah 1985), and as it can be seen 
from Plate 7.1; the carbohydrate components of the antigenic determ inants 
detected by the PAPP-A antiserum  were not sensitive to th is form of 
chemical treatm ent. Kabat (1976) has shown th a t the glycans which are to 
the chemical cleavage with periodate are a groove type of determ inant th a t 
have a repeat linear structure. Thus it is likely th a t such a structure is
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detected by th is sub-group of PAPP-A paratopes. I t  is also likely th a t this 
glycan is O-linked (Plate 7.4) as PAPP-A was still immunodetected after the 
removing the N-linked carbohydrate chains. The lectin analysis (Table 7.2) 
also supports the presence of a repeat un it present as a linear carbohydrate 
structure.
7.2.3.2 The C arbohydrate S tructure o f  The G lycan C om ponent o f
PAPP-A
The N-term inal sequence of the PAPP-A monomer determ ined in  this 
study has been confirmed by Kristensen et a l. (1994). However there is a 
difference in the carbohydrate structure reported in  th is study and th a t 
found by Oxvig et a l, (1994). These authors did not detect N-acetyl- 
galactosamine in the PAPP-A monomer (Table 1.3, Chapter 1), the PAPP-A 
monomer dem onstrated a weak interaction was observed with W A  (Table
7.2) thus indicating the presence of N-acetyl-galactosamine.
The interaction with the LEL lectin (Plate 7.2) which indicated the 
presence of oligomers of N-acetyl-glucosamine was further (Plate 7.2) 
investigated as a possible means of PAPP-A purification. Only one band was 
detected on blots probed w ith this lectin. Regardless of this, it was not 
possible to separate PAPP-A from its major contam inants (e.g. (X2M) using 
an LEL-column (Chapter 2, section 2.7.9).
The interaction of PAPP-A with Con-A has been described by Bischof 
(1979) who also used it as p a rt of a purification procedure. The PAPP-A 
present on the blot reacted strongly with the lectin, Con-A (Table 7.2). 
T reatm ents w ith its respective sugar (in the presence of detergents) failed to 
remove the Con-A bound to PAPP-A. Thus suggesting th a t the PAPP-A 
protein and not the carbohydrate groups may be binding th is lectin.
This explains the observations by Bischof et al, (1983) who
dem onstrated th a t PAPP-A appeared to be inhibit lymphocyte 
transform ation, this was probably due to a sequestering of the lectin used 
to stim ulate the lymphocytes.
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T ab le  7.2 Reduced monomeric chain PAPP-A’s reactivity w ith various 
lectins as determined from work in this thesis.
P e c t in :
2R e a c tiv ity
w ith
M onom eric
PA PP-A
L ec tin  h a s  sp e c if ic ity  fo r  th e  fo llow ing  
c a rb o h y d ra te  re s id u e s
LEL *** Oligomers of N-Acetyl-p-D-Glucosamine
STL * Similar specifities to th a t of LEL
W A **
Term inal alpha linked N-Acetyl-Galactosamine 
or a single residue of this bound to Ser/Thr. 
Galactosyl (a-1,3) N-acetylgalactosam ine.
DSL **
Branched Mannose structure, Oligomers of 
Galactosyl (P-1,4) N-acetylglucosamine and N- 
Acetyl-lactosamine.
ECL - Galactose, Galactosyl (p-1,4) N- 
acetylglucosam ine bu t will not bind if sialated
BSL-II - N-Acetyl-p-D-Glucosamine as a non-reducing 
term inal residue.
JACALIN 3?U nk. O-linked Galactosyl (a-1,3) N-acetyl­
galactosamine
Con-A
(?)
Presence of glucose/mannose residues.
[Legend: Lectins: Lectins that were used on the blots (see text), abbreviations were as 
found in Table 7.1. 2Reactivity with monomeric PAPP-A determined with Western blotting 
and immunodetection of PAPP-A with polyclonal anti-PAPP-A antibodies. 3?Unk: Unable to 
determine from material used for blotting if Jacalin reacts with PAPP-A as a strong 
interaction (****) with the > 205 kDa protein contaminant was seen (Chapter 6). 4: The 
interaction with Con-A was not able to be compared to the other lectins as this interaction 
was monitored using a Con-A-HRP conjugate (Appendix 1) Note: The relative intensity of 
staining of the blot was indicated by *, **, etc. with increased number indicating a stronger 
interaction, Indicated no observable interaction with lectin under the described 
conditions, see text of Chapter 2, section 2.4.]
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P la te  7.2
The reactivity of reduced monomeric PAPP-A with the LEL lectin 
[Legend: After incubation of the blots with biotinylated lectin as described in Chapter 2, 
section 2.4.4. They were pre-incubated with (1): TBS and (2): 0.5 M glucosam ine in TBS. 
End detection was with streptavidin-HRP conjugate as described in Chapter 2, section 
2.4.4. (3): Represented a W estern blot with subsequent immunodetection with polyclonal 
anti-PAPP-A antibodies. Note: The Arrow indicated the 205 kDa molecular weight size 
marker.]
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P la te  7.3
Enzymatic deglycosylation of control proteins, hum an serum  album in (A), 
fetuin and ovalbumin (B).
[Legend: (U): U ntreated  native protein, (O): Protein treated  w ith O-glycanase (N): Protein 
treated  with N-Glycanase (S): Protein treated  with neuram inidase. N ote: A and B were 
separated on a 10% SDS-PAGE gels. Arrows indicated positions of m olecular weight 
m arkers with size in kDa as indicated, SDS-PAGE conditions were as described in Chapter 
2 .].
The control protein, Hum an Serum Album in (HSA) contains a proportion 
of contam inating serum  globulins (as indicated by the m anufacturer). It was 
these that are deglycosylated and appear as the faint bands under the HSA 
band (Plate 7.3, A). The HSA band as indicated on this gel was not itself 
affected by enzymatic deglycosylation as HSA itself is not glycosylated.
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The control protein, ovalbumin has N-linked sugars as indicated by the 
enzymatic trea tm ent illustrated in Plate 7.3 (B). The control, fetuin has N 
and 0 -linked chains th a t were removed by the enzymatic treatm ent as 
indicated by reduction in size of the fetuin bands th a t were seen in Plate 7.3 
(B). Thus the control proteins reacted as expected to the enzymatic 
treatm ent th a t was capable of removing the N and O-linked glycans that 
are known to be present in these proteins.
(A) (U) (S) (S) (N) OD
(O) (O )
(S)
205
(B)
P la te  7.4
Enzymatic deglycosylation of an enriched PAPP-A fraction (A).
[Legend: All samples were treated  as described in section 7.2.2.3. Samples were separated 
on a 5% SDS-PAGE gel. N ote: (U): U ntreated native protein, (O): Protein trea ted  with 0- 
glycanase (N): Protein treated with N-glycanase (S): Protein treated  with neuram inidase. 
Note: W estern Blot and immunodetection of samples with Polyclonal (DAKO) anti-PAPP-A 
antibodies (B). Arrow indicated position of molecular weight m arker with size in kDa. SDS- 
PAGE and W estern blotting conditions were as described in Chapter 2, section 2.3.3.2. and 
2.3.].
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Experiments on the deglycosylation of PAPP-A using th is approach 
(Plate 7.4, A) dem onstrated removing of N-linked sugar w ith an estim ated 
reduction in size compared to original PAPP-A of approximately 8%. 
However fu rther treatm ent to remove the 0 -linked sugar groups did not 
result in  a reduction in size. Immunodetection of deglycosylated PAPP-A 
with the polyclonal antibody dem onstrated th a t a p a rt of the glycan 
component was still present as this had been shown to be necessary for the 
binding of this antibody. This could have been due to partia l removing of N- 
linked groups, bu t the denaturation in the presence of detergents and N- 
glycanase made this unlikely. I t  was more likely th a t 0 -linked groups were 
present on the monomeric PAPP-A isolated and th a t these groups were not 
removed following neuram inidase treatm ent. As the O-glycanase is sensitive 
to any substitutions present on the 0 -linked chains, this m ight indicate th a t 
they were likely to be present in a complex substituted O-linked form. An 
analysis of the types of glycan present from whole PAPP-A by probing with 
lectins and the periodate chemical treatm ent suggested the presence of 
linear repeat glycan groups.
This work was performed on the monomeric PAPP-A and therefore did 
not include the proMBP molecule th a t may have been present in  studies by 
other investigators, except those studies described by Oxvig et a l, (1994). 
The PAPP-A/proMBP content of carbohydrates found by these investigators 
(Sinosich et a l. (1990) and Sutcliffe et a l. (1980)) to be 19.2 - 19.4% (w/w) 
and agrees well w ith th a t of 17.4% (w/w) obtained by Oxvig et a l. (1994). 
However differences with the reported carbohydrate constituents of PAPP- 
A have been shown (Table 1.3, Chapter 1). The differences could have been 
due to the method of analysis or the purity  of the PAPP-A preparations. 
Possible reasons for these discrepancies are considered fu rther in  section 7.4 
of this Chapter.
As described in this section, PAPP-A is extensively glycosylated. This 
work suggests th a t PAPP-A contains N- and 0 - linked glycan groups. The 
presence of such an extensively post-translationally modified protein located 
a t the placental interface is another indicator th a t suggests an  im portant
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role for PAPP-A a t this interface. Because of the complex natu re  of the 
glycan component of PAPP-A, it is unlikely th a t recom binant PAPP-A 
expressed in bacteria will have the same biological activity as the native 
fully glycosylated PAPP-A th a t is produced during pregnancy. The function 
of the carbohydrate component could be further studied by comparing a 
recom binant PAPP-A protein (that is not post-translationally modified and 
hence lacks its carbohydrate groups) against PAPP-A th a t has been purified 
from the placenta.
7 .3  S tu d ies on An In teraction  B etw een  R educed M onom eric  
PAPP-A and The E ndoproteinase Arg-C.
7.3.1 In trod uction
W hilst a lim ited proteolytic digest of PAPP-A with endoproteinase Arg-C 
was performed (Chapter 2, section 2.8.5), an  interaction between these 
proteins was observed which resulted in the formation of an  SDS stable 1:1 
stoichiometric complex. F urther studies on this interaction were undertaken 
to assess any affect on the enzyme were carried out by m easuring the 
esterolytic activity of endoproteinase Arg-C (Levy et al. 1969).
7.3.2 M aterials and M ethods
A brief description of the method used to generate the results presented 
in this section can be found in Chapter 2, section 2.9.
7.3.3 R esu lts and D iscussion
When a lim ited proteolytic digest of PAPP-A with the endoproteinase 
Arg-C was performed using an in-gel slice technique (Cleveland method,
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Chapter 2, section 2.8.5), a surprising observation was made th a t the 
reduced monomeric chain PAPP-A formed a stoichiometric complex (Figure 
7.1) w ith th is enzyme (as determined from the size of th is complex when 
fractionated on a 5-20% modified SDS-PAGE gel).
I t  has been dem onstrated th a t the endoproteinase isolated from mouse 
subm axillary glands is composed of two forms, A and D (Levy et a l. 1967). 
Since their initial work, the kinetics have been further studied (Boesman et 
al, 1976) and the specificity of the enzyme has been analysed (Schenkein et 
aj, 1977). The characterisation of the forms A and D led to the identification 
of form D as epidermal growth factor binding protein (Taylor et a l, 1974). 
The D form’s activity was also noted to be affected by the presence of 
glycine. Schenkein et a l, (1980) have subsequently dem onstrated th a t the A 
form can be converted into the D form of this enzyme.
Reduced monomeric PAPP-A in the absence of glycine did not inhibit the 
endoproteinase Arg-C. The control BSA protein also did not have any 
m easurable effect on the esterolytic activity of the enzyme. (Figure 7.2). P re­
incubation of this enzyme with PAPP-A for 30 m inutes in the presence of 
glycine resulted in approximately 30% inhibition (The control protein BSA 
had no effect, Figure 7.3).
I t  was unknown w hether digestion of PAPP-A would have occurred if 
PAPP-A was incubated w ith this enzyme in the absence of glycine as the 
electrophoresis system used for the limited proteolytic cleavage (Figure 7.1) 
also contained glycine as p a rt of the electrophoresis running buffer.
I t  is accepted th a t the PAPP-A used for th is work was in a reduced 
monomeric form th a t was eluted from an SDS-PAGE gel and the results 
illustrated here may not be found in native PAPP-A. However when a 
PAPP-A:Arg-C complex was observed (Figure 7.1) and as was illustrated  in 
Table 7.3 th a t the formation of this complex required pre-incubation of 
PAPP-A with the enzyme suggesting th a t slow association between these 
proteins. This resulted in the inhibition of the enzyme because the control 
protein BSA, did not affect the activity of this enzyme and th is interaction 
seemed specific for PAPP-A in the presence of glycine.
7-15
C o m p le x  
c 205 
PA PP-A
C om plex  a
F ig u re  7.1
Incubation of PAPP-A containing gel slice with endoproteinase Arg-C
[Legend: Illustration of CBB stained electroblotted samples on a PVDF m em brane from a 
5-20% modified SDS-PAGE gel as described in Chapter 2, sections 2.3.2.2c, 2.3.2.2d and 
2.4.1. Note: (1) and (2) were performed as limited proteolytic digestion in-gel slices as 
described in Chapter 2, section 2.8.5. PAPP-A enriched samples from the purification 
schemes described in Chapter 5 were prepared as gel slices containing PAPP-A and 
incubated with the enzyme, Endoproteinase Arg-C: (1): 1 pg and (2): 4 pg. The am ount of 
PAPP-A present in the gel slices used in (1) and (2) was different (as assessed by 
densitometry). The arrow indicated the 205 kDa molecular weight m arker, ( A ), 
represented enzyme:PAPP-A complex and ( I  ) represented excess, unreacted PAPP-A.]
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<DCL 1 2 3 4 5 6
Endoprote inase A rg -C  Incubated With An Aliquot Of:
F igure 7.2
The calculated activity of the enzyme, endoproteinase Arg-C incubated with 
PAPP-A (non-specific control protein, BSA) in the absence of glycine.
[Legend: 5 pg of endoproteinase Arg-C was pre-incubated for 1/2 hour with: (1) Reaction 
buffer A, (2): 5 pg of PAPP-A. (3): 2.5 pg of PAPP-A. (4): 1.25 pg of PAPP-A (5): 15 pg of 
BSA and (6): 5 pg of BSA. Note: The amount of protease was determined from specific 
activity of endoproteinase (Appendix 1), Eluted PAPP-A and BSA were calculated by 
densitometry as described in Chapter 4, section 4.3.4. Results were expressed as a mean 
activity of (1) +/- range for three determinations. The calculated % activity remaining in 
pre-treated enzyme aliquots (2 - 6) was calculated by comparing activity present in these 
aliquots to what was found in the mean aliquot (1).]
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Endoprote inase A rg -C  Incubated With An Aliquot Of:
Figure 7.3
The calculated activity of the enzyme, endoproteinase Arg-C incubated with 
PAPP-A (non-specific control protein, BSA) in  the presence of glycine.
[Legend: 5 pg of endoproteinase Arg-C was pre-incubated for 1/2 hour with: (1) Reaction 
buffer A containing 0.19 M glycine (Appendix 2) (2): 5 pg of PAPP-A in reaction buffer A 
containing 0.19 M glycine. (3): 15 pg of BSA in reaction buffer A containing 0.19 M glycine. 
Note: The amount of protein and the calculated TAME activity were estimated as described 
in Figure legend 7.2]
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T ab le  7.3
The esterolytic activity of endoproteinase Arg-C after pre-incubation for 
various tim es with PAPP-A (or BSA) incubated in  buffer A containing 
0.19 M glycine.
Endoproteinase Arg-C 
pre-incubated with:
Time of Pre-incubation (Minutes)
0 5 15 30
PA PP-A 102+/- 2 91 +/- 2 79+/- 1 70+/- 3
BSA 102 +/- 2 100 +/- 1 99 +/- 1 101 +/- 4
[Legend: 5 |ig of endoproteinase Arg-C were incubated with buffer A containing 0.19 M 
glycine, 5 pg of PAPP-A or 15 pg of BSA. Results were expressed as % calculated TAME 
activity compared to the mean +/- range of esterolytic activity measured in the 
endoproteinase Arg-C incubated in buffer A containing 0.19 M glycine, 3 determinations 
were made for each time point. The esterolytic activity was determined after a 30 minute 
incubation with substrate as described in Chapter 2, section 2.3.8]
This inhibitory effect was only observed when a sequencing grade of 
endoproteinase Arg-C (Appendix 1) was used. However th is inhibition was 
consistently observed with different batches of the enzyme. On a very 
speculative basis an  explanation for this process could be th a t PAPP-A is 
interacting a t the level of conversion of forms A to D th a t is known to occur 
(Schenkein et a l. 1980). The exact na tu re  of this interaction will have to 
await fu rther characterisation of the PAPP-A/Arg-C interaction. A specific 
inhibition of this enzyme was observed with the monomeric PAPP-A. Care 
should however be exercised in translating  an in-vitro occurring reaction to 
w hat is observed in-vivo.
7.4 The T ertiary S tructure Of PAPP-A
Information obtained during this study yielded data concerning the sub­
unit structure of PAPP-A. Assuming a molecular weight of 205 kDa for 
myosin (Appendix 1), the reduced monomeric chain of PAPP-A has an 
estim ated molecular weight of 195 +/- 5 kDa in the SDS-PAGE systems
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th a t were employed in  this thesis. This monomer was also disulphide 
bridged to form a dimer as it was detected in non-reducing conditions by the 
same gel system (Plate 5.2, Chapter 5).
Assuming th a t the monomer was 195 kDa, then  a pure dimer not 
containing any pro-MBP should have a molecular weight of approximately 
400 kDa. The proMBP has an estim ated size of 29 kDa (Popken-Harris et 
al, 1994) and Oxvig et ah (1993) has suggested an equimolar 2:2  complex of 
PAPP-A/proMBP therefore the proposed dimer should have a theoretical 
weight of a t least 440 kDa. Therefore by looking a t the PAPP-A separated 
by gel filtration, an  assessm ent of the size and structure of this dimer can be 
made.The m aterial th a t was eluted a t 0.3 and 0 .6  M NaCl from the heparin 
affinity m atrix yielded PAPP-A th a t eluted in different fractions from the 
gel filtration column. The 0.3 M heparin eluted fraction had  a molecular 
weight of approximately 480 kDa whereas the 0 .6  M heparin  eluted fraction 
had a molecular weight of approximately 400 kDa as determ ined by gel 
filtration chromatography (Figure 7.4). This suggests th a t the heparin 
affinity column is possibly separating different forms of PAPP-A. This is 
interesting in the light of the described proMBP/PAPP-A complex. A sim ilar 
observation th a t PAPP-A purified from different sources is eluted from the 
heparin affinity m atrix in different ways was made by others (Davey et ah 
(1983) and Davey and Teisner (1982). PAPP-A isolated from the placenta 
was eluted from the heparin affinity m atrix a t 0 .6  M NaCl (it was also 
shown to have a very different p i to PAPP-A isolated from m aternal serum, 
Chapter 1) bu t did not elute a t 0.3 or 0.4 M NaCl. W hereas PAPP-A from 
m aternal serum  could be eluted from this m atrix a t 0.3, 0.4 and 0 .6  M NaCl. 
Re-chromatography of the fraction eluted a t 0.4 M resulted in  a proportion 
of the protein which was eluted a t 0 .6M NaCl, thus suggesting th a t this 
affinity m atrix allows separation of PAPP-A into fractions w ith different 
affinities for heparin. This could be due to molecular heterogeneity of PAPP- 
A. The differences in the ability of PAPP-A to inhibit HGE which have been 
observed between the m aterial purified by Oxvig et a l. (1994) and Sinosich
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(1990) could also be due to a difference in the tertiary  structure of the 
PAPP-A prepared by these two groups.
E lu a n t  (m is)
F ig u re  7.4
Elution profile of 0.3 and 0.6 M (Figure overlay) heparin eluted fractions on 
a SuperDex-200 gel filtration column (P la te  in se t  o v e rla y  7.4: A 5% SDS- 
PAGE gel of the fraction containing the peak PAPP-A of m aterial eluted at 
0.6 M from the heparin affinity matrix).
[Legend: PAPP-A was determined by SDS-PAGE as previously described, the indicated 
fractions were separated on a 5% SDS-PAGE gel, Plates 5.1 and 5.2). Note: SDS-PAGE of 
0.6 M eluted heparin fraction and material separated on the gel filtration column 
(1): Fractions 4/5. The arrow represented the 205 kDa size marker and the PAPP-A
marked was detected by immunodetection with anti- PAPP-A antibodies as previously 
described.]
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The proposed PAPP-A/proMBP complex raises in teresting questions 
about the observed relationship between these two proteins as the affinity 
of PAPP-A for L-arginine th a t is described in this thesis (Figure 2.16, 
Chapter 2 ) dem onstrates th a t PAPP-A will bind to L-Arginine. proMBP is 
rich in arginine (Gleich et a l. 1979) and therefore may associate with PAPP- 
A. Once in close association proMBP has been shown to have a tendency to 
form SDS-stable oligomers. Recently Oxvig et al. (1995) have also 
dem onstrated th a t proMBP also forms complexes w ith other plasma 
constituents. An understanding as to the specificity and affect of these 
interactions on the individual components will have to aw ait fu rther studies 
to characterise this interaction.
A unique feature of the placenta is th a t it continues to undergo 
differentiation throughout the gestation period (Boime et ah 1986). This 
necessitates the regulated expression of specific genes a t different stages, 
e.g. only 3 of 7 P-hCG genes are expressed in the placenta. The presence of 
these proteins in extraplacental sites suggest th a t they may be involved in 
other physiological processes such as cell growth. The multigene natu re  of 
proteins produced by the placenta has been dem onstrated for other
placental proteins, e.g. S P l (Chan and Qui, 1988). Bonno et al, (1994a,
1994b) dem onstrated by in-situ hybridisation th a t proMBP and PAPP-A 
were synthesised by X-cells of the placental septa. In  addition PAPP-A was 
also synthesised in  syncytiotrophoblast cells of the placenta. The PAPP-A 
mRNA is present as two distinct species of 8 and 12  kbp (Kristensen et al. 
1994). A though  a single N-terminus has been found by microsequencing of 
purified PAPP-A this does not exclude the possibility th a t N-term inally 
blocked chain(s) were also present in this m aterial. Analysis of the 
proteolytic cleavage products dem onstrated the presence of amino acid 
stretches th a t were not present w ithin the published cDNA sequence for 
PAPP-A (Kristensen et al. 1994). Thus the tertiary  structure and forms of 
PAPP-A present still rem ain to be resolved. Suggestions from the work in 
this thesis are th a t different PAPP-A complexes may exist in the  m aternal 
serum but th is requires further investigation.
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CHAPTER
EIGHT
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8.1 Sum m ary and G eneral D iscu ssion
The aim a t the s ta rt of this work was to isolate and characterise the 
PAPP-A cDNA with the view to study the structure and expression of the 
PAPP-A gene. A commercially prepared library of placental cDNA's in an 
expression vector lambda phage g t l l  was selected for this purpose. A 
polyclonal antibody against PAPP-A (DAKO) was used for screening. 
Characterisation of this antibody by W estern blotting detected a single band 
which had size and tertiary  structure as described for PAPP-A by other 
investigators (Chapter 1 , section 1.4.2.1). However one clear band of PAPP- 
A monomer was only achieved when:
• The antibody was incubated in a high (0 .6  M NaCl) sa lt concentration.
• The antibody was also used a t a relatively high concentration, a 1:600
dilution.
Approximately 1.2  million plaques were screened and no putative 
positive clone was found. W estern blotting with this antibody revealed th a t 
the sub-population of paratopes in the anti-PAPP-A antiserum  which was 
used a t this high salt concentration required a glycan component as p a rt of 
the antigenic determinant(s). Polypeptides expressed in E. coli are not post- 
translationally modified e.g. glycosylated (Chapter 3). Thus an  alternative 
approach to isolate the PAPP-A cDNA was undertaken, th is utilised 
oligonucleotide probes. Such probes necessitated the knowledge of some 
prim ary amino acid structure for PAPP-A. No prim ary amino acid 
information was available for PAPP-A when this work was being 
undertaken. The PAPP-A available and suitable for use as a Tracer in a 
PAPP-A RIA was not pure PAPP-A and was composed of a t least 6  different 
proteins (Table 6 .2  , Chapter 6). Therefore purification of PAPP-A was 
undertaken to produce PAPP-A in a form th a t would yield the prim ary 
sequence information th a t was necessary for the production of PAPP-A 
specific oligonucleotide probes.
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I t  was hoped th a t a purification scheme based on the described affinity of 
PAPP-A for heparin  would yield m aterial sufficiently enriched to facilitate 
its microsequencing. Heparin affinity matrices (Affi-gel and Pharm acia, 
post-1984) did not enrich PAPP-A as expected. The heparin  affinity m atrix 
produced post-1984 had  lost its ability to bind PAPP-A a t a salt 
concentration of 0 .6  M NaCl. O ther investigators had  previously shown 
th a t it  was this high affinity binding site th a t was necessary to enrich 
PAPP-A and separate it from other plasm a protein contam inants (Davey et 
al, 1983). The loss of this high affinity site necessitated the development of 
purification schemes to enrich PAPP-A.
Subsequent control experiments with a heparin affinity m atrix produced 
pre-1984 confirmed th a t the heparin m atrix was capable of enriching PAPP- 
A, it was determined th a t the provider of the m atrix (Pharmacia) had 
changed its supplier of the affinity m atrix. Information from this supplier 
revealed th a t the chemistry used to link the heparin to the affinity m atrix 
and the type of heparin preparation had been changed. The original 
m anufacturer of the heparin m atrix pre-1984 was found (Reactiv’s IBF) and 
it was found th a t this affinity m atrix was capable of enriching PAPP-A as 
previously described (Davey et al, 1983).
The use of the heparin affinity m atrix (Reactiv's IBF) to purify PAPP-A 
dem onstrated a heterogeneity of PAPP-A separated as distinguished by 
w hat bound and eluted a t 0.3 M and 0 .6  M NaCl from this column and was 
subsequently separated by gel filtration (Figure 7.4, Chapter 7). This 
difference th a t was seen in the tertiary  structure of PAPP-A could explain 
the contradictory results regarding its activity on H um an granulocyte 
elastase th a t have been found by different groups for PAPP-A purified by 
different groups (Sinosich and Zaker, (1991), Bischof and Meisser, (1988) 
and Oxvig et a l, (1994).
Microsequencing of the PAPP-A purified during this thesis revealed a 
protein with a single N-term inal sequence (Table 6.3, C hapter 6) thus 
indicating th a t the m aterial isolated as a monomeric chain was 
homogeneous. Analysis of this sequence against the D aresbury D atabase
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dem onstrated th a t the N-term inal region obtained did not share any 
homology w ith any published sequences a t th a t time. The verification of any 
clones identified would have also required further prim ary sequence 
information. Therefore further lim ited partial proteolytic digests were 
performed (Chapter 6). These digests consistently yielded N-term inal amino 
acid sequence or a mixture of sequences th a t were not well enough 
separated to be useful in determining any in ternal prim ary sequence 
information for PAPP-A. One digest did however reveal a putative in ternal 
stretch for PAPP-A. Degenerate prim ers were designed and synthesised 
from this information (Table 2.7, Chapter 2). These degenerate prim ers 
yielded two PCR products (Approximately 500 and > 1 2 0 0  bps), when the 
placental cDNA library was used as the DNA tem plate thus confirming th a t 
PAPP-A was expressed a t a mRNA level in the placenta during pregnancy 
(Chapter 6 , P late 6 .1).
An analysis of the carbohydrate structure of PAPP-A from work 
described in this thesis dem onstrated the presence of 0  and N-linked 
carbohydrate residues. The N-linked residues were approximately 8 % (w/w) 
of the monomeric PAPP-A. The O-linked chains were extensively modified 
and consisted of repeat oligomers of N-acetyl-glucosamine. I t  was this 
structure th a t was also responsible for binding to the antibody paratope 
subset th a t was shown to bind a t a high (0 .6  M NaCl) sa lt concentration 
(Chapter 7). PAPP-A is thus extensively glycosylated and was shown to 
contain O-linked groups th a t were post-translationally modified because 
these glycan groups could not be removed using standard  enzymatic 
techniques (Chapter 7).
An interaction with endoproteinase Arg-C (or epidermal growth factor 
binding protein) was observed using reduced monomeric PAPP-A. These two 
proteins formed a complex th a t was stable in SDS. A slow association of 
PAPP-A to endoproteinase Arg-C was dem onstrated th a t resulted in 
inhibition of the esterolytic activity of this enzyme (Chapter 7).
I t  was hoped th a t during this study to characterise the cDNA for PAPP- 
A, however because of the factors described above and the tim e th a t was
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requ ired to produce partial amino acid sequence information for th is protein 
this was not achieved. The N-term inal sequence of the PAPP-A monomer 
produced in  th is thesis has subsequently been confirmed by Oxvig et a l,
(1993).
8.2 H ypothesis Of A P ossib le  F unction  For PAPP-A
Many clinical and biochemical observations have been made about 
PAPP-A by various investigators since its discovery in the early ‘70s, some 
of them  are listed in  Figure 8.1. Exploiting the observations made by these 
investigators and w hat was seen for PAPP-A from work described in this 
thesis, I would like to speculate on a possible function for PAPP-A protein. I 
would like to propose th a t PAPP-A is involved in the regulation of growth 
hormones. These are necessary for the growth of some tissues; such as the 
developing foetus, bu t would cause inappropriate growth in adult tissues I 
propose th a t PAPP-A acts as a barrier to control the inappropriate secretion 
of growth hormones.
Taylor et ah (1974) suggested th a t EGF-BP converts epidermal growth 
factor (EGF) from an inactive to active form in a sim ilar m anner to th a t 
observed for Kallikrein. EGF has a carboxy term inal arginine and the 
esterase, EGF-BP removes this and converts it to its active form. The 
observed interaction described in this thesis (Chapter 7) between PAPP-A 
and EGF-BP may act to lim it the activity of some form of the pro­
enzyme/hormone.
If PAPP-A was performing this function then it would be expected to be 
found almost entirely in the m aternal ra th e r than  foetal compartm ents, as 
is seen for PAPP-A. O ther areas th a t exhibit growth pa tterns inappropriate 
to the adult tissues are those th a t are involved in development of gametes. 
PAPP-A has also been found in seminal plasm a and follicular fluid (Figure 
8 .1)
M aternal serum  PAPP-A levels are increased in  Twin pregnancies and 
reduced in conditions th a t result in growth retardation, such as ectopic 
pregnancy. Reduced levels of M aternal serum  PAPP-A are also observed in
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Cornelia-de-Lange and Down’s syndrome and could also be explained by this 
control hypothesis as they are both conditions which have elements of a 
growth disorder. One interesting observation reported is th a t the protease 
nexin -2 has been seen to form stable stoichiometric inhibitory complexes 
w ith EGF-BP th a t are stable after treatm ent with SDS (Van Nostrand et al. 
1990). This has been postulated to have an affect on cause of the 
neurodegenerative lesions th a t are seen in Downs syndrome. I t was also 
noted th a t PAPP-A was very difficult to separate from the serpin, alpha-2 - 
macroglobulin. A num ber of Kallikrein-like enzyme inhibitors have been 
dem onstrated in the mouse, but relatively few have been described in the 
hum an, perhaps PAPP-A is p a rt of this family.
A single amino acid replacement of arginine to valine in APP-KD, a 
member of this family results in the formation of a potent inhibitor of HGE 
(Sinha et ah 1991), and may explain PAPP-A’s inhibition of HGE.
C linical O bservations
PAPP-A leve ls  w ere raised  in:
• Tw in pregnancies (Lin et a l. 1974a).
PAPP-A leve ls  found to reduced  in:
• Downs (Wald et a l. 1992).
• Cornelia-de-Lange syndrome (W estergaard e ta l, 1983c).
• Ectopic pregnancy (Tornehave et a l. 1987).
O bserved L ocalisation  o f  PAPP-A
• U nilateral secretion into the m aternal compartm ent during pregnancy.
• Present w ithin granulosa cells, production was static in atretic follicles, 
levels were depressed in ovarian cysts where no egg was present but 
increased where two oocytes were growing compared to single follicular 
event.
• PAPP-A found in  seminal plasm a but absent from the Testes and 
proximal portions of the vas deferens. (Sinosich, 1985)
O bserved B iochem ical Features:
• Interaction and inhibition of esterolytic properties of endoproteinase Arg- 
C, which was also shown to be epidermal growth factor binding protein. 
(Work described in  this thesis).
Figure 8.1
Observations made for PAPP-A
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The PAPP-A th a t was isolated and used in this study was in a reduced 
monomeric form (while it is present as a disulphide bridged dimer in the 
blood). I t  was also denatured, with the extent of refolding by the processes 
used to elute the protein being unknown. Therefore the described 
observations seen between PAPP-A and the endoproteinase Arg-C were with 
m aterial th a t was dissimilar to th a t found under physiological conditions, 
more work will have to be done to confirm or refute these findings. I t  was 
however seen to bind to endoproteinase Arg-C in a very specific way, with 
control proteins and PAPP-A in the absence of glycine seen not to inhibit 
this enzyme, thus a specific physical interaction has been observed (Figure 
7 .1 , Chapter 7) th a t was noted to have an inhibitory affect on the esterolytic 
properties of th is enzyme (Figure 7.3, Chapter 7), in  particular the D form 
th a t has subsequently been shown to be EGF-BP.
8.3 C onclusions and P ossib le  F uture W ork for PAPP-A
PAPP-A has thus been confirmed to be a disulphide linked dimer. Studies 
on the purification of PAPP-A have revealed heterogeneity in  size for the 
PAPP-A isolated. In  light of the proposed PAPP-AproMBP structure (Oxvig 
et a l. (1993)) it is unknown whether all the PAPP-A is linked to pro-MBP. 
PAPP-A has shown to be linked to bind to L-Arginine, pro-MBP has been 
shown to bind other basic proteins in the serum  (Oxvig et a l. (1995)) thus it 
is unknown w hether all the PAPP-A or th a t isolated using the purification 
schemes described in Chapter 5 contains pro-MBP bound to PAPP-A. At the 
time this work was being undertaken, serum  components were seen to affect 
the m easurem ent of PAPP-A (Chapter 4) but it was unknown w hat these 
components were. I t  would be interesting to determine the presence or 
absence of proMBP as bound to PAPP-A by W estern blotting using a specific 
antibody for proMBP for PAPP-A isolated using the purification schemes 
described in this thesis. The PAPP-A monoclonal antibody produced by 
Mowles et a l. (1986) was shown in this thesis to bind to the PAPP-A dimer 
(Chapter 3) bu t not to the monomeric form, it would be in teresting to re ­
examine this binding in light of the proposed proMBP interaction to
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evaluate w hether the monoclonal antibody was binding to PAPP-A or the 
proposed PAPP-A/proMBP complex. As seen in Chapter 4, an  ELISA was 
produced for PAPP-A th a t m easured a component present in  the plasm a of 
men, it would be interesting to examine w hether this component being 
m easured was in fact proMBP. The PAPP-A tertiary  structure has been 
seen to have an  affect on PAPP-A m easurem ents and has been observed by 
many investigators (Chapter 1 , section 1.4.5). During the development of 
methods to m easure PAPP-A different levels and effects were seen on the 
individual assay systems th a t also seemed to be linked to the tertiary  
structure of the PAPP-A molecule. An investigation into the affect proMBP 
has on imm unoassay systems should be made as this may explain why 
different groups are obtaining contradictory results when trying to use 
PAPP-A as a biochemical m arker for clinical conditions (Chapter 1 , section 
1.4.7).
The work described in this thesis has produced a series of new questions 
for PAPP-A bu t further confirms th a t PAPP-A is likely to be an  im portant 
protein th a t is located a t the border between m aternal and foetal systems.
The further study of such a protein a t the genetic level should answer 
some of the questions th a t have been raised about PAPP-A in th is thesis.
The isolation of PAPP-A cDNA and expression of PAPP-A in heterologous 
systems will enable the generation of large amounts of pure PAPP-A, free of 
proMBP. However it has been dem onstrated th a t PAPP-A is extensively 
glycosylated so this type of expression will have to occur in m am m alian cell 
systems th a t are capable of mimicking the glycosylation found on the native 
protein. Protein expressed in this way could be used further to examine the 
interactions th a t have been described for endoproteinase Arg-C and HGE.
The use of probes with in-situ PCR in the clinical conditions of Down’s 
and Cornelia-de-Lange syndrome should help clarify w hether the levels of 
PAPP-A th a t are reduced in the blood a t a protein level are also reduced a t a 
mRNA level in  syncytiotrophoblast cells. These approaches a t a DNA level 
will help to confirm and possibly offer an insight into the control and allow a 
definition of the function of this intriguing protein.
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APPENDIX
ONE
A l -  1
A ppendix I
1.1 M aterials 
A ntibodies
Rabbit Anti - Human Albumin (DAKO: A001)
Rabbit Anti - Human Alpha2-Macroglobulin (DAKO: A033).
Rabbit Anti - Human Placenta(DAKO: A146. Lot 061A).
Rabbit Anti - Total Human serum (DAKO: A209)
Rabbit Anti - Human SP3 (Pregnancy zone protein, DAKO: A132).
Rabbit Anti - Human Pregnancy-associated plasma protein-A (DAKO: A230).
Donkey Anti- Rabbit immunoglobulins (IDS: A-PPT1).
B acteria l stra ins
Escherichia coli, strain: Y1090(Clontech; Cat. No. HLl008b).
Genotype: F' ,A(lacU169), proA+, A(lon), araD139, strA, supF, [trpC22: TnlO(tetr)]> 
(pMC9). hsdR(rk", m ^ ) .
Buffer/Buffer A dditives
Thimerosal(Sigma: T-5125)
Sodium azide(Koch Light: 61-15036).
Aprotinin(Koch Light).
Leupeptin(Sigma: L2884)
TPCK(Sigma: T-4367). - 20°C.
TLCK(Sigma: T-7254). - 20°C.
Phenylmethylsulfonyl Fluoride(Sigma: P7626).
0.5 M EDTA(Disodium salt) (Sigma: E7889)
C hrom atography Supports
L-Arginine-Agarose(Sigma: A-8405)
DEAE-Trisacryl®M(IBF reactivs).
CM-Cibachron-Blue 3GA (Sigma: C-8658).
Agarose-Bound Lycopersicon esculentum Lectin(Vector: AL-1173)
LKB Heparin-Ultrogel A4R(LKB: 2214-610).
Heparin-Ultrogel® A4R(Sepracor)
Heparin Affi-gel®(Bio-Rad: 153-6173).
HiLoad 26/60 Superdex™ 200 'prep, grade' (Pharmacia: 17-1071-01)
Pre Column LiChrosorb RP-18(5 pm)(BDH: 15692 2T).
A l - 2
LiChrosorb RP-18(7 pm) 4mm x 250 mm(BDH: 15934 2R).
Sulphated Dextran Beads(Sigma: D-5650).
D etergen ts
Nonidet P40 ’Lab. Reagent’(BDH: 56009)
Sodium deoxycholate 'Biochemical Gr.'(BDH: 43035)
Sodium Dodecyl Sulphate 'Specially purified Biochemical' (BDH: 44244). 
Tween-20 (Sigma: P-1379).
Triton X-100(Sigma: T-6878).
MEGA-10 (ICN: 150657).
E lectrophoresis(A crylam ide Supports/C ross-L inkers.)
Acrylamide 'Electran' (BDH: 44299).
Acrylamide 'Electran' Grade I (BDH: 44313).
Acrylamide/bis-acrylamide Mol biol. grade 19:1 (Sigma: A2917). 
Piperazine di-Acrylamide(PDA)Bio-Rad (Cat. No. 161-0202). 
N,N-methylenebisacrylamide 'Electran'(BDH: Cat. No. 44300). 
N,N-Diallytartardiamide 'Electran'(BDH: 44224 2W).
Ammonium persulphate (Mol. Biol. Grade)(Sigma: A9164)
TEMED. Mol. Biol. Gr.(Sigma: T7024)
E lectrop horesis (Agarose)
Litex HSA agarose(Park scientific)
Agarose 'Mol. Biol. Gr.(Sigma: A-7431).
Agarose(Type I: Low EEO)(Sigma: A-6013).
Agarose(Type II: Medium EEO, Sigma: A-6877).
Agarose(Type VIII: Special High EEO, Sigma: A-4905).
E lectrop horesis (Buffer Com ponents)
Boric Acid 'Analar'(BDH: 272052).
CAPS(Sigma: C-2632).
Diethyl Barbituric acid.
N-Ethylmaleimide(Sigma: E3876).
Glycine 'Electrophoresis grade'(Sigma: G-8898)
Calcium Lactate.
Taurine ( Sigma: T-0625)
TRIZMA® Base'Mol. Biol. Gr.'(Sigma: T7149).
A l - 3
Tris-Borate-EDTA(5X concentrate)Mol. Biol. Gr.(Sigma: T-6400)
USB Urea 'Ultrapure'(Cambridge Bioscience: 23040A)
E lectrop h oresis (M arkers)
Low Mr markers (BDH: Cat. No. 44247 2L).
Medium Mr markers (BDH: Cat. No. 44264 2L).
High Mr markers (BDH: Cat. No. 44358 2U). 
ct2-Macroglobulin for SDS-PAGE (Sigma: M-3398)
Myosin 'Electrophoresis grade' (Sigma: M-3889).
Lambda DNA EcoRI & Hindlll digest (NBL: 030604).
Enzym es
Chitinase(Sigma: C-6137). 
a-Chymotrypsin (Type I-S: Sigma C 7762).
Endoproteinase Arg-C(Sigma: P-8402).
Endoproteinase Arg-C 'Sequencing grade' (P-6056).
Endoproteinase Glu-C 'Sequencing grade'(Sigma: P-6181).
Endoproteinase Lys-C 'Sequencing grade' (Sigma: P-3428).
N-Glycosidase F(Boehringer Mannheim UK: 903337).
Neuraminidase from Clostridium perfringens (Sigma: N-2876). 
0-Glycanase@(Genzyme: O-ASE-25).
Endo-a-N-acetylgalactosaminidase (from cultures of Diplococcus pneumoniae, Sigma:). 
Pepsin(Sigma: P-6887).
Taq DNA polymerase(Advanced Biotechnologies: AB-0192).
T^ jj DNA polymerase(Advanced Biotechnologies: AB-0193).
Vent™ DNA polymerase(New England Biolabs).
G eneral C hem icals
Ammonium sulphate 'Mol. Biol. Gr.'(Sigma: A-4418).
Ficoll type 400(Sigma: F-4375).
Glycerol M. Biol. Gr.(Sigma: G5516).
Human IgG (Sigma: 1-2511)
Mineral oil M. Biol. Gr.(Sigma: M5904).
Poly-Vinyl Sulphuric acid-Potassium salt(Sigma: P-6000).
G rowth m edia/com ponents
Caesein Hydrolysate (NZ-Amine, ICN: 22692).
Tryptone 'Bacto' (DIFCO).
Yeast Extract Bacto® (DIFCO).
A l - 4
Bacto® - Agar (DIFCO).
Ampicillin Sodium Salt (NBL: 070609)
Kits/Kit com ponents
Silver Stain kit (Bio-Rad: 161-0443).
Protein assay kit II(Bio-Rad: 500-0002).
Bicinchoninic acid solution(Sigma: B-9643).
CLIK® Clontech Lambda(^) g t l l .  Human cDNA library(placenta, 34 wks) with 1 x 10® 
clones(Average insert size range of 0.8 - 3.6 kb. (supplied through Cambridge Bioscience: 
Cat. No: HL-1008b).
Isopropyl-P-D-thiogalactoside (NBL: 070206).
Geneclean II kit (Stratech scientific).
Gene Amp™ PCR amplification kit (Perkin-Elmer Cetus: N801-0043).
ExtrAvidin™ Biotin staining kit (Sigma: Extra-3(Rabbit)).
ExtrAvidin™ Biotin staining kit (Sigma: Extra-2(Mouse)).
Vectastain® Elite ABC Kit (Rabbit, Vector Laboratories: PK-6101).
Biotinylated lectin kit III(Vector: BK-3000)
Con-A, Peroxidase labelled(Sigma: L-4010)
Protein-A-Peroxidase conjugate(Sigma P-8651).
M em branes
Dialysis Visking Tubing(Size 8 32/32, BDH: 1270-05).
Nitrocellulose:
- 0.20 pm Biometra.
- 0.45 pm Schleicher and Schuell(Via Anderman).
- 0.20 pm NC plus(Sartorius: SM 12807).
- 0.45 pm 82 mm Circles (Whatman: Cat. No.7184008) WCN Type.
- 0.45 pm 132 mm Circles (Schleicher and Schuell, via Anderman)
PVDF:
- 0.2 pm Fluorotrans (PALL: Cat. No. PVM020C200S).
- 0.45 pm Immobilon-P (Millipore: Cat. No. IPVH 151 50).
M iscellaneous
Parafilm® PM-992(BDH: 2350416X02).
Molecular Sieves Type 3A(BDH: 54002).
Amerlex-M (Amersham).
A l - 5
O ligonucleotide S yn th esis R eagents
Phenoxyacetyl dA p-cyanoethyl phosphoramidite(Pharmacia: 27-1223-01). 
Phenoxyacetyl dG P-cyanoethyl phosphoramidite(Pharmacia: 27-1724-01). 
Isobutyrl dC P-cyanoethyl phosphoramidite(Pharmacia: 27-1725-01). 
dT P-cyanoethyl phosphoramidite(Pharmacia: 27-1236-01). 
DMT-Biotin-C6-PA(CRB: DR-16-100A).
P rotein  M odifying R eagents
Chloramine-T 'GPR' (BDH: 27670).
Cyanogen Bromide (Sigma: C-6388)
DL-Dithiothreitol(Sigma: D-0632)
2-Mercaptoethanol(Sigma: M-6250).
Glutathione (Reduced, Sigma: G-4251)
Iodoacetamide(Sigma: 1-6125).
Thioglycolic acid(T-0632)
Trifluoroacetic acid 'Sequencing grade' (Sigma: T-1647)
R adiochem icals
125j0dine (Amersham: IMS.30)
125Iodine (ICN: 63034)
Solvents
Acetonitrile Far UV HiPerSolv™ HPLC(BDH: 15251)
Ammonia solution HiPerSolv™(BDH: 15331)
Di-Ethyl Ether(M&B).
N,N-DimethylFormamide(Sigma: D-4254).
DMSO 'ACS' reagent(Sigma: D-8779).
Ethanol 'GPR'(BDH).
Hexafluoroisopropanol(Sigma H8508)
Methanol 'HPLC Gr. 205'(M&B: MF1087)
Methanol 'GPR'(BDH).
Propan-2-ol 'Analar'(BDH)
Stains
Brilliant Blue G(Sigma: B-0770)
Brilliant Blue R-250 65 % Dye content(Sigma: B-6630).
Bromophenol Blue 'ACS' free acid(Sigma: B-6896).
Ethidium Bromide (Sigma: E-8751)
Xylene cyanol FF(Sigma: X-0377)
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Substrates/Substrate C om ponents
Human serum albumin 'Fraction V ': 96 - 99% (Sigma: A-1653). 
4-Chloro-l-Napthol(Sigma: C-8890).
Hydrogen Peroxide 30%(Sigma: H-1009)
Chitin(Sigma: C-3387).
TAME(Sigma: T-4626)
TMB(Sigma: T 2885).
A ppendix 1.2 E quipm ent 
C entrifuges:
Beckman J2-21(Rotors: JA-20 and JA-10).
MSE Mistral 2L.
ALC® micro-centrifugette 4124(Supplied by CAMLAB)
E lectrop horesis E quipm ent
LKB 2197 Power supply.
LKB 2117 Multiphor.
LKB 2201 Multitemp bath.
EC570 Power supply(Via Biometra).
Gallenkamp Vertical electrophoresis system  
Minigel system(Biometra: Cat. No. G41)
Fastblot®(Biometra: Cat. No. B33)
FPLC system
Pharmacia LCC-500 Controller.
Pharmacia P-500 pumps.
Pharmacia IJV-M monitor.
Pharmacia Frac-200 fraction collector.
Pharmacia FPLC manager(Ver 1.1) Software.
HPLC E quipm ent
Pharmacia HPLC 2152 Controller.
Pharmacia HPLC 2150 pump.
Pharmacia Low pressure Ultrograd 11300 mixer driver. 
Pharmacia Frac-100 fraction collector.
Pye Unicam LC-UV Detector
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M iscellaneous:
TA40 CRT Instant camera(GRI)
Gallenkamp SuperCold 85 (-70 °C Freezer).
W hatman No. 1 Filter paper (Whatman).
Whatman 3MM Filter paper (Whatman).
Glass immunoelectrophoresis plates (Sizes: 26 x 76. 84 x 94 mm) 
Centricon -100 (Amicon: 4211).
Centriprep - 30 (Clear base)-100(Blue base):(Amicon: 4307).
NAP-5 column (Pharmacia).
Magic™ Minicolumns(Promega).
Pye Unicam 292 pH meter.
PREM™ PCR (LEP Scientific)
LKB M ultiwell gamma counter (with software RIACALC).
Grant water Baths.
Gallenkamp Orbital Incubator 
UV-Tr ansilluminator (GRI).
UV-Safety faceshield (GRI).
FinnPipettes(variable 0.5 - 10, 40 - 200, 200 - 1000 pi and 1 - 5 ml). 
Titertek 8 channel variable pipettes (Flow).
Microtitre plates: Falcon 3915 (Becton Dickinson)
Titertek M ultiskan plus (Ver 2.0) microtitre plate reader (Flow). 
Nalgene® Centrifuge tubes.
NICK™ spin columns (Pharmacia)
Bio-RAD Model 620 Video densitometer(Plus ID analyst software). 
4RT-Rocking table (GRI).
Gyrotory® Shaking water Bath (NBS).
Innova 2000 Platform shaker (NBS).
Pum ps
LKB varioperpex® II pump.
LKB ReCyChrom® pump.
LKB MicroPerpex®S Peristaltic pump
W ater Supply
Autostill IIplus.
Fi-Stream Cyclon™(Glass distilled water).
Barnstead NanopureII(Glass distilled/de-ionized/filtered water).
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A ppendix 1.3 L ist o f Suppliers
Applied Biosystems(ABI): Warrington, Cheshire, England.
Advanced Biotechnologies Ltd: W est Hampstead, London.
Amersham International Pic: Amersham, Buckinghamshire, England. 
Amicon Ltd: Stonehouse, Gloucester, England.
Anachem: Luton, Bedfordshire, England.
Anderman: Kingston-upon-Thames, Surrey, England.
BDH Ltd: Poole, Dorset, England.
Becton Dickinson & Co: Cowley, Oxford, England.
Biometra Ltd: Maidstone, Kent, England.
Bio-Rad Laboratories Ltd: Hemel Hempstead, Hertfordshire, England. 
Boehringer M annheim UK Ltd: Lewes, East Sussex, England.
The Binding Site Ltd: Edgbaston, Birmingham, England.
British Oxygen Co: Leeds, W est Yorkshire, England.
Cambridge Bioscience, Cambridge, England.
Cambridge Research Biochemicals(CRB): Northwich, Cheshire, England. 
Camlab Ltd: Cambridge, England.
DAKO Ltd: High Wycombe, Buckinghamshire, England.
Denley Instrum ents Ltd: Billinghurst, Sussex, England.
DIFCO Laboratories UK Ltd: Molesby, Surrey, England.
Fisons Scientific Ltd: Peterborough, England.
Flow Laboratories Ltd: Irvine, Ayrshire, Scotland.
Fluka: Glossop, Derbyshire, England.
Gallenkamp:(Fisons Pic. Sci. Equip, div. Loughborough, England).
Genzyme, W est Mailing, Kent, England.
Genetic Research Instrum ents Ltd(GRI): Dunmow, Essex, England.
ICN Biomedicals Ltd: High Wycombe, Buckinghamshire, England.
IDS: Washington, Tyne & Wear, England.
IBF reactivs: Villeneuve-la-Garenne, Paris,France.
Jones Chromatography Ltd: Hengoed, Mid-Glamorgan, Wales.
Koch-Light Ltd: Haverhill, Suffolk, England.
LEP Scientific Ltd: Milton Keynes, England.
May & Baker Ltd: Dagenham, Essex, England.
Millipore UK Ltd: Watford, Hertfordshire, England.
NEN® DuPont UK Ltd: Stevenage, Hertfordshire, England.
New Brunswick Scientific(NBS): North Mymms, Hatfield, England. 
Northumbria Biologicals Ltd(NBL): Cramlington, Northumberland, England. 
Pall Biosupport Division: Portsmouth, England.
Park Scientific Ltd: Northampton, England.
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Perkin-Elmer Cetus: Chalfont St Giles, England.
Pharmacia LKB Biotechnology: Milton Keynes, Buckinghamshire, England. 
Promega UK Ltd: Southampton, England.
Rathburn Chemicals Ltd: Walkerburn, Peeblesshire, Scotland.
Sarstedt: Leicester, England.
Sartorius Filtration Ltd: Epsom, Surrey, England.
Scigen Ltd: Sittingbourne, Kent, England.
Serva:(UK supplier Uniscience, London, England).
Sigma-Aldrich Chemical Co: Poole, Dorset, England.
Stratech Sciences Ltd: Luton, Bedfordshire, England.
Vector Laboratories: Bretton, Peterborough, England.
Whatman International Ltd: Maidstone, England.
A1 -10
APPENDIX
TWO
A2 - 1
APPENDIX II.
P reparation  and Storage o f R eagents/B uffers.
S ection  2.3.2.1: Horizontal Agarose Slab Gel Electrophoresis of DNA
• E lectrop horesis buffer: 2 0 X (Stock) Tris-Acetate-EDTA. Stored a t RT. 
800 mM Tris-base (96.9 g), 400 mM Na acetate (32.8 g), 20 mM EDTA (7.45 
g), was adjusted to pH to 7.4 w ith glacial acetic acid and made up to 1 litre 
with distilled water.
• Sam ple buffer: 6X (Stock). Stored a t 4 °C.
Composed of 1.5 ml Glycerol, 1 ml Bromophenol blue (1% (w/v) in 
distilled water), 1 ml Xylene cyanol (1 % w/v in distilled water) and 0.5 ml 
distilled water.
•  E th id ium  Brom ide: (Appendix 1) Stored in  foil wrap a t 4 °C.
Stock solution a t 1 mg/ml (w/v) in distilled water. (CARE ! Suspected 
carcinogen !).
S ection  2 .3 .2 .2 : SDS-PAGE
• Sam ple Buffer: Stored a t 4°C
1 ml 10  % (w/v) SDS, 4.8 g Urea, 0.15 ml 1 M Tris-HCl (pH 6 .8 ), 0 .1  ml 2 - 
mercaptoethanol and 0 .2  m is Bromophenol Blue stock (3 % w/v dissolved in
ethanol and stored a t 4°C), made up to 10  ml with distilled water.
• A crylam ide/B is-acrylam ide Stock: Stored a t 4°C in  the dark.
Monomer solution (30 % T, 2.7% Cbis)> 58.4 g acrylamide and 1 .6  g Bis-
acrylamide (Appendix 1) were made up to a final volume of 2 0 0  mis in 
distilled water.
• 20 % (w/v) am m onium  persulphate: Made up in  distilled water, 
aliquoted and stored frozen a t - 20°C.
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• W ater-saturated n-Butanol: Combine N-Butanol (Appendix 1) with
and equal volume of distilled w ater , the top phase was used to overlay 
gels.
S ection  2.3.2.2c; SDS linear gradient gel electrophoresis
• P ep tid e  Gel Buffer: 5X stock.
3 M Tris-HCl (adjusted to pH 8.45), containing 0.3 % (w/v) SDS.
• A node Buffer: 10X stock.
2M Tris-Base (adjusted to pH 8.9)
• C athode Buffer: 10X stock.
1 M Tris-Base containing 1M Tricine and 1% (w/v) SDS.
S ection  2 .3 .3 : Measurement of chitinase activity
• P reparation  o f  ch itin  substrate.
Crude ch itin (Appendix 1) was purified by dissolving 2 0  g of chitin in  2 0 0  
ml of concentrated HC1 in an ice-bath. The residue was filtered through 
glass wool. The dissolved chitin was then  precipitated by adding 2 0 0  ml of 
absolute ethanol. The purified chitin was washed with distilled w ater until a 
neutral pH was obtained, this was then  air dried and resuspended in  PBS. 
I t  was stored a t 4°C.
S ection  2.3.4 : M easurem ent of N-acetyl-glucosamine
• P reparation  o f DMAB reagent
10  g. of p-Dimethylaminobenzaldehyde was dissolved in 90 mis of glacial 
acetic acid and then  made to 100  mis w ith 10  mis of concentrated 
hydrochloric acid. The 10 fold concentrated stock was stored a t RT and ju st 
prior to use an aliquot was diluted 1:10  w ith glacial acetic acid.
S ection  2.3.5: The general protease assay
• BSA substrate  solution: A 1 %(w/v) was made in PBS, centrifuged a t 10  
K x g for 5 m inutes and the supernatan t was carefully removed and used 
as the protein substrate.
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• TCA R eag en t: 5% (w/v) solution of Trichloroacetic acid made in distilled 
water. Stored a t RT.
S ection  2.3.6: M easurem ent of Tosyl-arginine methyl ester (TAME)
• TAME substrate: 0 .1  M solution of TAME was made in  0 .1M Tris-HCl 
buffer (pH 8).
• R eagent A: Prepared immediately prior to use. Equal volumes of 3.5M 
NaOH solution and a 2M Hydroxylam ine hydrochloride solution.
• TCA reagent: A 3% (w/v) Trichloroacetic acid solution made in 0.19M 
HC1.
• F erric C hloride Reagent: 0 .1 1  M Ferric Chloride made in 0.04M HC1.
S ection  2.4.1 : Sem i-Dry Electro transfer (W estern Blotting)
•  S tock 10X E lectro-transfer Buffer. Stored a t 4 °C.
480 mM Tris-base, 390 mM Glycine and 0.3 % (w/v) SDS. Made IX just 
before use and containing 10  % (v/v) methanol.
•  S tock  10X E lecro-Transfer buffer II: Stored a t 4°C.
100  mM CAPS, 22.13 g of CAPS in  900 ml of water. T itrated w ith 2 M 
NaOH to pH 11 and distilled w ater added to make the volume up to 1 L.
S ection  2.4.2: Detection of Protein on PVDF Blots
• C BB-Staining solution: 0.1% CBB R-250 in 1% acetic acid/40% MeOH. 
lg  of CBB was dissolved in  400 ml methanol, Stirred for 1 hour then  10
ml of glacial acetic acid was added and made up to 1 L w ith distilled water. 
I t  was stirred for another 30 m inutes then  filtered. Stored a t RT.
S ection  2.4.3: Probing W estern Blots
• IX TBS (Tris buffered saline): 0.05 M Tris-HCl, 0.15 M NaCl a t pH 7.5.
• IX TBS-T (Tris-Tween 20 Solution), as above but w ith 0.2% (v/v) Tween- 
20 .
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S ection  2.4.4: Lectin Probing
• TB-GT: Tris buffer as above but containing 0.05% (w/v) Gelatin 
(Appendix 1) and 0.05% (v/v) Tween-20.
• In c u b a tio n  b u ffe r: Biotinylated Con-A solution.
10  jig of biotinylated Con-A/ml of a 2 % (w/v) PVP-360 solution containing 
ImM  Ca2+ and Mn2+.
S ection  2.4.5: Periodate Chemical Treatm ent of Nitrocellulose Blots
• B u ffe r A: A 50mM Solution of Sodium Acetate, pH 4.5.
• PBS-T: As described in section 2.6.3 (Appendix 2 ).
S ection  2.4.6: Enzyme D igest T reatm ent of Proteins Electroblotted onto 
Nitrocellulose
P ro te a s e  In h ib ito rs  (S tocks s to re d  a s  a l iq u o ts  a t  - 2 0 °C).
Aprotinin: 1 mg/ml (in dH£0 ). 500X final concentration.
Leupeptin: 1 mg/ml (in dH2 0 ). 500X final concentration.
PMSF: 2 0 0  mM (in EtOH). 2 0 0 X final concentration.
TPCK: 3 mM (in EtOH). 250X final concentration.
TLCK: 3 mM (in dH£0). 250X final concentration.
EDTA: 500 mM (in dH2 0 ). 500X final concentration.
S ection  2.4.7:
• S am ple  B uffer: As described in section 2 .3.2 .2  (Appendix 2 ).
S ection  2.5: Screening A Placental cDNA Library
• T ry p to n e  B ro th  (TB) M edium :
- 10  g Tryptone(DIFCO)
- 5 g NaCl
Distilled w ater to 1 litre, Autoclaved and then  add to a final 
concentration, 10 mM Magnesium sulphate from 0.5 M Autoclaved stock
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and 0 .2 % maltose from a 2 0  % filter sterilised stock. TB medium was stored 
a t 4°C.
• P la te  A gar:
- 4 g NZ amine.
- 2  g Bacto yeast extract.
- 2 g Sodium Chloride.
- 0.8 g M agnesium Sulphate
- 6 g Bacto-Agar.
Distilled w ater to 400 ml, Autoclaved prior to pouring plates.
• L am b d a  P h a g e  D ilu en t: 10  mM Tris-HCl, pH 7.5, containing 10  mM 
MgCL and 0 .1  mM EDTA. Autoclaved and stored a t 4°C.
• T op A garose:
- 1  g NZ amine.
- 0.5 g Bacto yeast extract.
- 0.5 g Sodium Chloride.
- 0 .2  g M agnesium Sulphate
- 0.7 g Agarose (Type 1 , low EEO, Appendix 1)
Distilled w ater to 100  ml, Autoclaved and stored a t 4°C.
• IPT G  im p re g n a te d  f ilte rs : Sterile nitrocellulose filters soaked for 1 
hour in  a lOmM IPTG solution made in  sterile distilled water.
• A m p ic illin  S to ck  S o lu tion : Ampicillin (Appendix 1) was made to 10  
mg/ml in distilled water, filter sterilised (0 .2 2 pm) and stored in aliquots 
at-70°C.
• TBS-TB: Tris Buffered Saline made as in section 2.4.3 (Appendix 2 ) 
containing 0.05% (v/v) Tween-20  and 2 0 % (v/v) Bovine serum  albumin.
• TBS-T: Tris Buffered Saline containing 0.05% (v/v) Tween-20.
• S to ck  X-Gal: 100  mg X-Gal (NBL) in 1 ml dimethylformamide.
• S to ck  IPTG : 1 M solution of IPTG.
• TN b u ffe r: 25 mM Tris/HCl, pH 7.5 containing 0.5 M NaCl.
• TNT b u ffe r: 0 .1% (v/v) Triton X-100 in TN buffer.
(X-CN-H2 O2  so lu tio n : 6  mis of Reagent A added to 30 mis of Reagent B
immediately prior to use. Reagent A: 3 mg/ml solution of a-CN made in
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methanol. Reagent B: 150 pi of 1 M Imidazole and 15pl of a 30% solution of 
H2O2 made in  30 mis of TN buffer (Made ju st prior to use).
S ection  2.6.1 : Rocket Immunoelectrophoresis
• E lectrop horesis buffer: (4X Stock) Tris-Barbital Buffer. Stored a t RT. 
-44.3 g of Tris
- 22.4 g of Diethyl Barbituric acid
- 0.533 g of Calcium Lactate
Distilled w ater to a final volume of 1 litre with buffer stock having a 
final pH of 8 .6 .
S ection  2 .6 .2 : Radial Immunodiffusion (RID)
• P reparation  o f  agarose for RID
1 g of agarose is dissolved in 100  ml of Tris-barbital running buffer and
aliquoted into glass tubes (sealed with parafilm  and stored a t 4 °C.). The 
volume of agarose required for a 1.5 mm thick was calculated. An aliquot 
was liquefied in a boiling w ater ba th  and this stock agarose was diluted to a 
final concentration of agarose of 0.75 % (v/v) made to contain a final 
concentration of 2 % (v/v) PEG 6000 solution (using a 40 % (w/v) PEG 6000 
solution dissolved in  Tris-barbital running buffer and stored a t RT) w ith the 
difference in  volume being made up with running buffer. This was left to
equilibrate in a w ater ba th  a t 55 °C and then the appropriate antibody was 
added (see plate captions).
• P rocedure for "Coating" g lass p lates
Gently wipe a "hot" solution (approx. 70 °C) of 1 % (w/v) low EEO 
(Sigma) across the electrophoresis glass plate and allow to dry by 
convection. Repeat this procedure 2 - 3 times. The plate was then  said to be 
coated.
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• P rocedure for P ressing/W ashing and D rying o f  E lectrop horesis  
plates:
1 : The wells of the plate were filled with distilled water.
2 : Carefully cover the gel w ith a damp W hatm an filter.
3: Cover the plate w ith a wad of dry tissue.
4: Place a flat surface on top of the tissue and leave a 1 kg weight to press 
down on plate (leave for about 5 minutes).
5: Carefully remove wad of tissues and repeat from step 3. until tissues
no longer appeared to be damp.
6 : Carefully remove filter covering plate (from step 2) and place the plate 
in a 0.15 M NaCl solution for about 15 minutes.
7: Repeat step 6 .
8 : Repeat steps 2 - 5 .
9: Carefully remove filter paper and place plate in distilled for about 15 
minutes.
1 0 :Repeat step 9. 
ll:R ep ea t steps 2 - 5.
1 2 :Carefully remove filter paper and dry plate gently by leaving it on the 
lid of a w ater ba th  a t 95 °C until the wet opaque agarose appears clear.
• S ta in in g/D esta in in g  o f e lectrop h oresis p lates
The plate was immersed plate in stain  (see below) for 10  - 45 minutes, 
then  placed in  destain and left until the desired contrast between 
immunoprecipitin and background on the plate had  been reached.
• Im m unoelectrophoresis Stain(CBB-R250)/Destain.
- 0.5 % CBB(w/v).
- 45 % EtOH(v/v).
- 10 % Glacial Acetic Acid(v/v).
Made to 100% with distilled water.
D estain consisted of the same ratio of chemicals, except no CBB-R250 was 
included.
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S ection  2 .6 .3 : Sandwich ELISA for PAPP-A
• ELISA B lock in g  Buffer: PBS-Block (plus BSA): PBS containing 5 
%(w/v) BSA. Prepared on day of use.
•  ELISA A ssay Diluent: PBS-TB (plus BSA):PBS-T containing 0 .2  % 
(w/v) BSA. Prepared on day of use.
• ELISA W ash Buffer: PBS-Tw een (PBS-T): PBS containing 0.05 %(v/v) 
Tween-20. Prepared on day of use.
•  Substrate developm ent Buffer: C itric acid -P hosphate Buffer (pH  
5.6): A 0 .1M solution of Citric acid monohydrate and a 0 .2M solution of 
N a2 HPC>4 , 12  H 2 O were mixed until the pH was 5.6 a t RT.
• ELISA Substrate Stock (as originally described by Goka and Farthing, 
1987). Essentially 10  mg/ml TMB (Appendix 1) was dissolved in  DMSO, 
containing 8 mM Imidazole. I t  was stored in a foil wrapped container a t 
RT.
• ELISA colour reagent: Ju s t prior to use the ELISA substrate  stock was 
made to a final concentration of 0.1  mg/ml and 0.005 % H2O2 (from a 30% 
(v/v) H2O2 stock) in  substrate development buffer (see above) and used 
immediately.
• ELISA stop reagent: 1 M sulphuric acid in  distilled water. Stored a t RT. 
S ection  2.6.4:
• RIA assay  diluent: 50 mM Phosphate Buffer, pH 7 .4  containing 0 .1% 
(w/v) BSA and 50 mM NaCl.
• Colum n B lock ing Solution: 30 % BSA (v/v) made in RIA Assay Diluent 
(see above).
S ection  2 .8 .1 : Assessment of Protein Elution Methods from Blotting
Membranes
• Sam ple Buffer: As described in  section 2 .3.2 .2  (Appendix 2 ).
S ection  2.8.4: Vapour Phase CNBr Cleavage of PAPP-A in  Gel Slices
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• S am p le  B uffer: As described in section 2 .3.2 .2  (Appendix 2 ).
S ection  2.8.7: De-protection of PAC amidites
• Place cassette (flange up) in sterile 1.5. ml eppendorf tube.
• Pulse spin in  microfuge.
• Remove cassette and place in sterile 2 ml flat bottom tube.
• Add 1 ml of 30% Ammonia solution and pulse spin in microfuge.
• Ensure cap is sealed tightly w ith parafilm, place inside universal tube.
• H eat Un iversal a t 70°C for 1 hour.
• Let tube equilibrate to 4°C before opening.
• Remove cassette and place flange uppermost in  sterile 1.5 ml eppendorf.
• Pulse spin in  microfuge and discard cassette.
• Pool ammonia and precipitate oligonucleotides.
S ection  2.8.7: Precipitation of oligonucleotides
• Aliquot the 1 ml of ammonia containing oligonucleotides into 3, 330 ul in 
sterile 1.5 ml eppendorf tubes.
• Add 33 ul of 3M sodium acetate and 915 ul of absolute ethanol to each 
tube.
• Allow tubes to stand overnight a t -2 0 °C.
• Spin a t 13 k rpm for 15 m inutes in a microfuge a t 4°C.
• Discard supernatan t and resuspend pellet in 0.5 ml of 80% ethanol.
• Pool all 3 tubes into 1 sterile 1.5 ml eppendorf and spin a t 4 °C as above.
• Discard ethanol, cover with perforated parafilm  and freeze dry.
• Resuspend oligonucleotide pellet in 600 ul of sterile distilled water.
S ection  2.9: The interaction between reduced monomeric PAPP-A and 
the endoproteinase Arg-C.
• B u ffe r A: 0 .1M Tris-HCl, pH 8 .
TAME s u b s tra te :  Solution as in section 2.3.6 (Appendix 2 ).
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R esu lts  o f to ta l  A m ino a c id  a n a ly s is  o n  th e  se le c te d  p e a k  f ro m  a 
CNBr d ig es t (F ig u re  6.3). S e rv ice  p ro v id e d  b y  D r A. M oir.
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AIII.2 P rotein  M icroseq u en cin g
A III.2 .1  R e su lts  o f  v a p o u r  p h a se  CN Br c leav ag e  o f PA PP-A  as 
d e sc r ib e d  in  C h a p te r  6 , s e c tio n  6.3.1. S e q u e n c in g  w as p e rfo rm e d  by 
M r J . G ilroy , D u rh a m  U n iv e rs ity .
Band sizes in kDa of CNBr digest of PAPP-A
Fragm ent Size
CNBr 1 70
CNBr 2 48
CNBr 3 42
CNBr 4 32
CNBr 5 21
CNBr 6 18
CNBr 7 13
Only CNBr4 gave a reasonable am ount of m aterial th a t could be sequenced, 
a sum m ary of the information obtained from this peak is given below.
AAci d AAcid R.T i n e C. Time Pmol Pmol Pmol Pmol AAcid
ID ( m i n ) ( m i n ) ( r a u ) ( - b k g d ) ( 4 1 eg  > Rat i o ID
\j i ■ S 4 . 5 7 4 . 5 7 S . 49 S .  09 S .SS 9 . 7 4 SER
T> 2 A i .S c 7 - 5 1 2 7 . 4 5 7 3 . 7 3 7 9 . 7 3 4 5 . 5 7 ALA(4 3 A 7 4 — 7 ~ • ~ ^  “7 IZS .5 3 128 .5 3 7 “ “7- ALA
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REPETITIVE YIELD ANALYSIS:
r. i Z , w , 4
A v e r a g e  AA R e p e t i t i v e  Y i e l d :
Combined AA R e p e t i t i v e  Y i e l d :
R e p . Y i e l d  V a r i a n c e  
5 2 . 5 3  S 1 . 0 3 3  : SEP.
1 2 0 . 5 7  % 0 . 5 7 3  :ALA
11 1 .81  %
?> *7 'Tir
T h e o r e t i c a l  I n i t i a l  Y i e l d :  E 2 .S 5  pmol ( 5 2 . 9 3  V, )
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AIII.2.2 I n i t ia l  N -te rm in u s  fo r  PA PP-A  o b ta in e d  fro m  m a te r ia l
p u r if ie d  u s in g  sch em e  1 as i l lu s tr a te d  by  a ★ in  F ig u re  5.2 
(C h a p te r  5). S e q u e n c in g  w as p e rfo rm e d  by  D r K. L illey .
CYCLE No. RESIDUE AMOUNT(pmoIes)
1 Lys 2.3
2 Ala 11 .4
3 Arg 6.7
4 Gly 10.0
5 Ala i—I
6 Thr 10.6
7 Glu 5.7
8 ?
9 Val 3.5
AIII.2.3 C o n se n su s  se q u e n c e  fo r  N -te rm in u s  o f PA PP-A. 
S e q u e n c in g  w as p e rfo rm e d  by  M r J . G ilroy.
CYCLE No. RESIDUE AMOUNT(pmoles)
1 Glu 2 .9
2 Ala 5 . 7
3 Arg 1.2
4 Gly 3 . 6Leu 1.6
5 Ala 2 .6
6 Thr 2 . 6
7 Glu 2 .6
8 Glu 4 . 6
9 Pro 2 .8
A3 - 4
AIII.2.4 PAPP-A N -term inal seq u en ce  obtained  from  Lys-C d igestion
of fragm ent (a) as seen  in  F igure 6.4 (Chapter 6). S eq u en cin g
was perform ed by Mr J. Gilroy.
SAMPLE : rr.FFr./LYS-C-l /ME
I I n i t i a t e d  5 Nov i SSZ 5 : -3am ]
CYCLE SUMMARY :
R e a c t i o n  c y c l e  : FSLOT 
C o n v e r s i o n  c y c l e  : FSLOT 
G r a d i e n t  : FSLOT
AMINO ACID 
Filtered Data
D at a  c o l l e c t  t i n e  
D ata  i n t e r v a l  
I n j e c t  volume
[ S Nov 1SSZ 10:01 an ]
0 . 0  t o  I S . 3 min 
i . 5  s e c  
E5 o f  1S0 uL
0 . 0 1 0 0  FU
J  j  i i
10.0
AMINO ACID S Z 
Filtered Data
C £ Nov 1SSZ 1 0 : 33am 1 0 . 0 1 0 0  FU
JS.Q
A3 - 5
AMINO ACID ft 
f ii tE r ;d  Oaia
rA + II -!'l A ?, A -
i. 5 Nov 1552 ! 1 :05an J 0 . 0 1 0 0  FU
(<
:.u 1 0 . 0
7" i — • M.
AMINO ACID ft 4 
Filtered Data
C S Nov 1552 1 1 :37am ] 0 . 0 1 0 0  FU
A3 - 6
AMINO ACID ft 
fiiwred Gat-a
Jl - } 4  j\ "
L i  \J L.-‘LL L_J ■-
C 5 Nov 1 -  5Z i - iO - on  j
t_T ..I
0.310S FU
i.l s.u lu. 0
AMINO ACID ft 
Filtered Data C d Nov l o r .1 ! 2 i  40 c n 3 0 . 0 1 3 0  FI
J L L i l M  i\ a - fi t  IL t  h% +i\
5.0 iu.G 15.0
A3 - 7
AMINO ACIO It 7  C 5 N o v  1 S=Z 1 : 1 2 o n  3 0 . 3 1 8 0  FU
fiitersd Cata
I L L j M J b ... i 'u ^ i______
13.0
R e t e n t i o n  T i n e :  M i n u t e ;
AMINO A d O  £  8
fiiiartd Oata
5 Nov 1 5 5 1  1 : 4«ipn 8 . 0 1 0 0  FU
+ -r
/' H _._Aiy t) 1- " n +!; - a
e
J L _ jl_ J a ±A.
3. 2' 3.0 10.0 13.0
A3 - 8
AMINO ACID 2  5 t S Nov 1=52 2 : l £ p n  I 0 . 0 1 0 G  FU
filter'd Oata
15.0
AMINO ACI D * 1 0  C S N o v  1 5 = 2  2 : 4 S p m  ]
filtered 3a ia
0 . 0 1  GO FU
10 A C ID  S  1 ' 
t i  Oata
iL t-
[ 5 Mcv 139-  - - : iwcn J
U  - A
'3.5123 F U
u U<
S. 3
R e t e n t i o n  T i n e :  M i n u t e s
1 S . Q
/* - 1 i  u — =»+ • in n  ' r  - U 'J  •
AMINO ACID  
Filtered Oata
c  N o v  1 S S Z  : S e e n  j S . 3 1 Q S  FU
A3 -10
SAMPLE : FAPFn/LYS-C-i /MS
[ i n i i i a t s d  5 Nov 8:A3am ]
Sampl e Amount: 100 pmci
Aftcid ftftcid R .Ti me  C.Ti me  
H ID (m i n )  (m i n )
1
f
(P ) 5
R.
EA
a6
ft
T
E
EP
S
I
D
©ft
L
I
5 . 0 0
7 . 5 7
S . 0 3  
5 . G3
A. 70
1 5 . 0 3
3 .E2
1 5 .0 0
S . 00
1 3 . 5 7  
1 5 . 3 5  
12. &S 12. a?c c r
5 . 0 0
*7
50 o.o
i 4 
12
2-a ■03 
00
— (
30
C O
3740
AS
pmol F no i Pmol P:n o l ftftcid
( r a u ) ( - b k g d ) ( + I a g ) Rat  i o ID
- = . o / 32 . 75 inU)i> £ ( . 4 — GLU
33 . 55 32 . 2 5 33.  10 47 .50 ALA
. 1 3 Q
32
. 2 0  
. 4  7
11 . 24
3 3 . 2  i
? 1 
70
. 5 4 GLY
GLY
31 . 12 23 .53 3 3 . 3 2 T p . 5 3 ALA
2 0 . 35 14 . 4 8 1 3 . 3 2 37 7 - THR
. 0 2 2 2 . 43 3 0 . 3 3 4 1 . 1 2 GLU
42 . 1 3 27 .5 5 “ V _ 00 35 . 5 5 GLU
33 .32 1 0 . 7 3 1 J . 4 o 1 i «o ** PRO
10 CO 4 . 7 7 S . 55 15 . S3 SER
1 5 . 37 1 0 . 0 1 14.21 1 2 . 47 ILE
.CO 4 . 34 4 .5 7 c .45 ASP
1 5 . 05 a . 5 3 12 .55 11 . I 3 ILE
10 . 2 1 3 . 1 2 4.  17 13 HIS
IS . 5 4 3 . 5 0 3 . 5 4 7 . 0 5 ALA
25 . 55 o . 1 3 c . 33 * . SO LEU
13 .31 c . 0 5 7 .51 5 . 55 ILE
13 .48 0 . 8 5 1 .38 0 55 PRO
. 37 3 . 2 7 8.51 5 .81 PRO
1 5 .35 1 . 3 3 3 .51 GLY
REPETITIVE YIELD ANALYSIS:
E: 1 , 7 , £
A: 2 ,  5 . 15
5 :  3 ,  A, 23
r : 5 , 1 5 , 1 5
I: 1 1 . 1 3 , 17
Ave r a ge  ftft R e p e t i t i v e  Y i e l d :
Combined AA R e p e t i t i v e  Y i e l d
T h e o r e t  i c a l I n i t i a l  Y i e l d :
R e p . Y i e l d  V a r i a n c e  
= 5 . 50  % 0 . 5 5 A
5 A. 37 % 
5 7 . 3 5  2 
8 4 . 4 2  :: 
5 3 . 5 5  2
SS.3Z 7.
0 .53- 
0 . 7 5 3  
0 . 5 3 3  
0 . 5 2 5
0 . 7 4 2
: SL'J 
: ALA 
: GLY : PRO 
: ILE
AO.11 p n o l  ( 4 0 . 1 1  2 )
A3 -11
AIII.2.5 S eq u en cin g  obta in ed  from  Lys-C d ig estio n  o f  fragm ent (b)
as seen  in  in F igure 6.4 (Chapter 6). S eq u en cin g  w as
perform ed by Mr J. Gilroy.
SAMPLE : FAPFA/LYS-C-2/MS
C i n i t i a t e s  11 Nov 1552 8:S3am 3
Sampl e  Amount: 1Q3  pmol
AAci d AAcid R.T ime C.Ti me Pmol Pmol Pmol Pmol AAcid
2  10 ( m i n ) ( m i n ) < r a y ) ( - b k g d ) ( + i a g ) Rat  io ID
1 5 N 3 . 3 2 3 .E 2 I 1 . 5 3 1 1 . 2 5 13 .04 £ 0 . 8 2 ASN
2 Q  < P 12.Q3 1 2 . 3 2 1 1 -.35 5 . 7 5 7 . 9 3 11 = = PRO
3  & < - T 5 . 0 b ' 5 . 0 2 1 4 .4 2 1 I . 7 5 15 .32 j : t THR
~ 7) <4- V 1 2 .8 3 1 2 .8 7 1 I . 55 7 . 7 0 5.01 4 3 . 5 5 VALc  <  p 1 2 .8 3 1 2 . 0 2 2 0 . 8 5  . 12 .  84 IE .55 2 4 . 1 5 PRO
5 . . S E . 32 Z • Cj u 3 4 .  IS I S . 85 2 2 . 2 5 •a. 57 GLY
7 ip+  E 5 . 7 3 z  - / c 1 7 .2 0 5 . 3 3 1 1 . 33 2 3 . 0 4 GLU
3 0 4.7Q 4 . 7 0 1 5 .7 0 9 . 2 5 1 2 . 2 0 11 .31 GLN. 5 q w  V 12 .3 5 1 2 . 8 7 1 2 . 2 2 6 . 4 7 7 .7 5 3 7 .  3S VAL
IQ D ” •* . Jc 25 . 3 4 10 .  32 15 .25 1 5 . 3 7 ASP
II T) T 5 . 0 8 5 . 0 3 1 L • S i 4 . 0 8 b . 0 .1* 1 2 .2 5 THR
12 C  T S .  08 5 . 0 2 1 4 .2 2 5 . 2 3 4 .S 3 5 . 4 5 THR
13 f  H 5 . 1 5 8 . 1 7 5 . 23 Z . 4 2 3 . 40 5 . 5  = HIS
14. 6 n H S . I 2 8 . 1 7 1 0 .0 5 5 . S S 7 . 7 2 1 5 . 8 8 HIS
15 f* H S.  10 8 . 1 / 1 1 . 36 7 . 0 2 7 . 3 ! 1 5 . 0 4 HIS
IE L I E . 27 ' 1 E . 25 14.  S3 4 . 4 S 7 . 3 4 2 0 . 0 2 LEU
17 A 7 . 7 0 7 .E 3 3 2 . 3 5 S .  35 5.71 5 . 3 5 ALA
13 E 5 .  S2 E . 78 1 7 .  4S 2 . 7 4 3 . 0 4 E . 35 GLU
12 3 .  E2 3 . 8 2 5 . 5 5 0 . 4 2 0 . 3 8 ! . 75 ASN
2-3 ^ " C v ? ? c.  ^1 ~ 6 1 2 . 8 7 1 1 . 4 3 . 2 4 1 5 . 1 8 VAL
REPETITIVE YIELD ANALYSIS:
Re p . Yi e l d Var i a n c e
N I , 15 S 3 . 2 8 % 1 . 0 0 0 : ASM
P 2  f 5 1 3 0 .4 2 •r I . 000 :FP.O
T 3 , 1 1 , 1 2 8 5 . 5 3 £ 3 . 8 3 S : THR
V 5,  2 0 S4.SQ % 0 . 9 8 b : VAL
E 7 , 13 8 5 . 4 8 % 1 . 0 0 9 : GLU
H 13 , 14 ,  15 1 7 0 . 2 5 /. 0 . 8 5 3 : HIS
A v e r a g e AA R e p e t i t i v e  Y i e l d : I 12 .5 4 %
Combined AA R e p e t i t i v e  Y i e l d : 5 1 . 1 3 x 0 . 4 S 2
T h e o r e t i c a l  I n i t i a l  Y i e l d :  15 .31 pmol ( 1 5 . 3 1  V. )
A3 -12
AIII.2.6 S eq u en cin g  obta in ed  from  Lys-C d igestion  o f fragm ent (d)
as seen  in  F igure 6.4 (Chapter 6). S eq u en cin g  w as
perform ed by Mr J. G ilroy.
SAMPLE : PAPPA/LYS- C-4/ MS
C i n i t i a t e d  12 Nov i s s : 1 0 : 3 2 am
SampI e Amount :  103 pmol
A A c i d A A c i d  R . T i m e C. Ti me Pmol Pmol Pmol Pmol A A c i d
ID <mi n) ( m i n ) ( r a u ) ( - b k g d ) ( + I a g ) R a t i o ID
1 S 4 . 4 7 A . 42 5 . 2 7 3 . 7 4 3 . 5 5 2 7 . 5 5 SER
2 Q A . 73 a . S7 3 .  S a 1 . 9 2 ~ o S . 5A GLN
3 I I E . 70 1 5 . 5 3 j  . 3 w 1 . 2 3 1 .1 0 3 . 0 5 ILE
A G 5 . 3 3 c . 23 1 2 . 3 0 5 . 4 8 5 . 3 7 Z  n GLY
c R 1 1 . 0 3 10 . S 3 2 . S 3 1 . A3 1 . 7 5 1 2 . i 5 ARG
s T 5 . 0 3 5 . 0 3 3 . 5 0 1 . 0 9 3 . 7 8 THR
REPETITIVE YIELD ANALYSIS:.
C o m b i n ed  AA R e p e t i t i v e Y i e l d : 8 E . 0 8 £ 0 . 1 55
T h e o r e t i c a i  I n i t i a l  Y i e l d : 3 . 5 A  pmci 3 . 5 A  % )
SAMRLE PAFPA/LYS - C - 4 / M 6
Sa m p l e  Amount : 100  pmci
Dai s / I i m e  o f  Run : 12 No ve mbe r  1S92 1 0 : 0 9 am
C y c l e s  Run : 1 ST D, S AA
R a u  D a t a  T a b u l a - t l o n  . . . ( i n  p o o l s )
R 5c H 0 C E 0 5 H T l :< n r ? S 'J Y 0
lyci* ELa. BRG RSH BSP CVS SL'J SLH ELY HIS ILE LE'J LVS BET PHE P85 SC THR 12? IY8 URL
i 5.3 2.2 -.0 3.* 0.0 6.! 2.1 i 2.3 1.1 2.2 1.4 0.0 0.0 0.9 2.5 S.S 3.0 1.4 1.5 * 7
2 n.Q 0.0 1.! 1.5 0.0 2.5 3.3 4.1 0.2 3.3 0.9 0.1 0.0 0.0 0.9 1.7 0.5 Q.3 0.0 3.0
j S.7 0.3 1.4 2.5 0.0 0.0 3.2 S.S O.S 1.3 0.0 0.0 0.5 0.0 Q.O 1.1 1.3 0.1 0.9 0.0
i 2.0 0.0 1.4 2.1 0.3 0.0 1.3 12.3 1.1 •  } 3.3 0.0 0.5 0.3 0.0 1.1 1.0 0.4 0.0 0.0
5 0.0 2.5 1.2 3.1 0.0 3.1 2.0 S.S O.S 2.9 0.0 0.0 0.4 u.O 0.0 1.2 2.2 3.0 0.0 0.0
5 0.0 2.1 1.5 3.9 0.0 0.0 3.1 S. I 0.3 2.= 0.0 0.0 O.S o:o 0.0 1.1 3.S* 0.1 0.0 0.3
A3 -13
AIII.2.7 S eq u en cin g  obtained  from  Lys-C d igestion  o f fragm ent (e)
as seen  in F igure 6.4 (Chapter 6). S eq u en cin g  was
perform ed by Mr J. Gilroy.
SAMPLE : PAFFA/LYS-C-E/IMS
C i n i t i a t e d  10 Nov 159
Sample Amount: 100 p no i
AAcid AAcid R.Ti me C.Ti me
ID < m i  n ) < min >
1 S ,rfi^ 4 . 5 9 4 . 7 3
0 E. 12 E. 12T A S.  13 S .  17
4 S 5 . 7 3 E . S3
p p ^ ,  P w c 4 - D -  P 3 .  S2 3 . 5 3
Oo ■V'T G ---:rp M .r p i 3 .  17 1 3 . 1 3
REPETITIVE YIELD ANALYSIS:
Pmol Fmol Fmol Pmol AAcid
( r a u ) ( -bkgd ) ( +1 ag ) Rat i o ID
S.  EE S .  s z S . 7E 2 1 . 5 4 SER
25 . 5 7 1 5 . 0 4 2 0 . I 3 1 S . SE GLN
1 3 . 5 3 S.  25" 5 . 5 7 13 .5 5 ALA
2 3 . 4 5 1 2 . 4 7 12 .4 7 17 .5 ! GLY
1 1 . 5 5 5 .  EE" 5 .31 5 . 0 6 ASP
0 . 3 5 0 . 10 2 . 0 0 MET
Combined AA R e p e t i t i v e  Y i e l d :  5 3 . EE '!. 0 .  4S0
T h e o r e t i c a l  I n i t i a l  Y i e l d :  4 5 . 1 3  pmol ( 4 5 . 1 3  % )
SAMPLE : PAPPA/LYS-C-5/MB
Sample Amount : 100 pmol
Cate / T i m e  o f  Pun : 10 November 1992 8 :36am
C y c l e s  Run : 1 STD, G AA
Lag Corrected Tabulation ... (in preols}
3 3 H 3 C £ q u I I •< n r p 3 T U Y 0
313 335 3SH as? CrS Slti ELM GLY HIS ILE n o LYS n r PHE PHQ SEP THR 18? fyr USL
0.0 0 .5 0.1 -1 .0 '0.-! 0.1 5 4 1.0 - 1 .) 5.3 -0.1 -0 .0 TL>.2 1.2 6 .9 0 .7 0 .3 2 .9 -3 .2
-3 .2 •0 .1 0.1 0.7 -1 .0 2.3 20.2 0 .7 -0 .5 -1 .1 0 .3 5.1 -3 .3 -0.1 -0 .2 3 .0 -1 .0 -0.1 -1 .9 3 .9
6 .7 1.0 *0.9 -0 .3 -1 .3 -0 .0 0.1 -1 .3 -3 .5 1 .7 -0 .5 0 .3 -3 .0 -3.2 -1 .5 1 .5 9 .3 “*J. - 9.0 3 .3
0 .3 -3 .1 0.1 -0 .9 -1 .0 - i s -1 .9 12.5 0 .2 9 .5 -0 .3 -0.1 -0 .0 -0 .2 2.5 0 .0 1 .5 -0 .9 -2.1 -3 .0
O.S -3 .3 -0 .0 6 .3 -1 .0 5 .3 -3 .6 -3 .3 0.1 2 .0 -0 .1 -0.1 -0 .0 0.0 6 .5 -0 .5 0 .3 0.1 6 .3 -3 .2
-3 .5 0.5 0.1 0 .3 -1 .0 0 .3 1.1 0 .5 0 .0 -1 .9 0 .9 -0.1 0.1 0 .2 0.3 0 .9 -3.1 0 .3 1.3 - 0 .0
A3 -14
aijll.z.8 ir'AJr'F-A JN-terminal seq u en ce obta in ed  from  Glu-C d igestion
o f fragm ent (a) as seen  in F igure 6.5 (Chapter 6). S eq u en cin g
w as perform ed by Mr J. Gilroy.
Simple : frpf^
Sample Amount: ! 32 pmcl
ftft c i d  AAcid R.Time C.Ti ms  
it ID ( n i  n ) (Min)
Eft
Gft
molau r n o i  (-eked) Pmol >  1 a g )
c .*? 'Z z  i t ; *J . : " 3 . To _ ■z z z  z_ _ __ - - — 1 o  ^c — — — z  Z■ .2 2’ Z w* • c - 1 C . Z Z i —C r . ! z -i . 5 - ! . S3 z  .o -f Z  j_ v : z  Z  Z . E.3! 1 z  .- z  ~ " . 53 o. Eo : C 23 I z  .c ~5 C. ! = 7 ~'~ 3.72 - : : i 5 .
z 5 . 53 r . OS J. 32 - 230 ■ z ~ =  “ * •. V - a . 55 3 5- ; 0 .- Z 2 i — . — ■ : , i V L  . d 0 .
Fmol AAci c  
R a t i o  ID
GLUftlft
THR
GLY
ALA
THR
GLU
GLU
PRO
REPETITIVE YIELD ANALYSIS:
Average  Aft R e p e t i t i v e  Y i e l d :  
Combined Aft R e p e t i t i v e  Y i e l d :
R e c . Y i e l d  V a r i a n c e
T h e o r e t i c a l  I n i t i a l  Y i e l d :
AIII.2.9 S e q u e n c in g  o f io d in a tio n  g ra d e  PA PP-A  (T able  6 .2 , C h a p te r  
6). Sequencing performed by Leeds university central 
sequencing service.
i J3 '+qT- •'
1 G c L  I'LiSP" V l.s 1 CS3. M
s £ M  / I c . S ^ S ’r ' W  A t j m R .  i c ^ c a
■j. U < &/
A '  7 ^ 5 - 1 3 7  /
P F I -5 3^ 3L.
f H ~  i ^ c c c c . V  3 ^ / t Z - L l ' b O
A K* 1 L  » i i s m • R  ^ ‘ c-rq c 7
T &  ■~  I w c c c V : ' 3 7 3 2 5 F A  r C - f ’a G 1 T - 7 m c
t £ ^ 3 * 2 3 / <  E T cSv-? / t  ~r-l££.
7 - f £  T  i v t t o j  ,
‘c £ K  3 7 - 3 ^ 7 "  n r v w G  s ^ r ? / fit 'ZZSCC,
■1 £ — 25^000 M iZT/S'f- 4  '• 'T C C C C p 7 . ' 1 1 ^ c\z / V (° -  S s c c c H - 1 c - r c s :
3 F ^  Z z « * c
<r W L  S 3 L S Y A /  - ~ ' 'S 2 o c o i
V <* L £ g ? / S ‘ ^  2 c ,7 4 .3 ^ ^ - G Z i . Z r n / / - P r J-r '>
L \ /  - r S c c o 1 -!  (N o te , 10,000 e q u iv a le n t  to  1 p m o l)
A3 -15
AIII.2.10 S eq u e n ce  o b ta in e d  fo r  d e sig n  o f cPA PP-3 p r im e r  fro m  
f ra g m e n t (b) fro m  Glu-C d ig e s tio n  as se e n  in  F ig u re  6.5 
(C h a p te r  6 ). S e q u e n c in g  w as p e rfo rm e d  by  M r J . G ilroy .
SAMPLE : rnFPft/K-2/ME 
£ i n i t i a t e d 37 Ju i  1333 2 : 0 0 cm ]
Sample Amount: 1 0 0  pmo l
AAcid AAcid R.Time C. Time Pmol Pmol Pmol Pmol AAcidID ( m i n ) < m m ) ( r au > ( -bkgd) ( +1 ag ) ■ R a t i o ID
1 H 7 .  EE < . 0 <j 11 . 4 3 S . 71 ! 1 . 3 1 3 5 . 5 7 HIS-i F I E . S3 | C CT -  P7 3 . 3 2 j . 9 / 3 . 5 2 PHE3 N 3 . 3 3 3 . 5 3 1 2 . 2 5 10 .71 12 . 5 3 5 2 . 7 3 ASN
A . 7 .3 3 i * o o 1 4 .  3E 9 . 52 11 .15 i 7 . 2 2 ALAc D 3.  S3 " c t 7 . 0 3 3 . 0 3 3 . 5 3 1 3 . 2 4 ASPs G E.E0 E . 4.3 > i • *2 -■ 7 . 1 2 5 . 1 4 1 2 . S = - GLY
G 3 . 4 3 5 . 4 " ! . 5 7 6 . 3 0 C ; r ( 1tn GLYL 13 . 63 IS.EG ‘ ** ^ 2 .9 1 3 . 5 3 4 .SS LEUc S i . S Z 4.  EE 3.  44 0 . 4 3  ' 1 . 33 SER
REPETITIVE YIELD ANALYSIS:
6 : a , 7
A ve r age  AA R e p e t i t i v e  Y i e l d :  
Combined AA R e p e t i t i v e  Y i e l d :
R e p . Y i e l d  V a r i a n c e  
SS .5 !  X 1 . Q0 ;
0 . - 3 0
: GLY
T h e o r e t i c a l  I n i t i a l  Y i e l d : -.'6= pmci \ )
cr.hr i_E
Sample Amount 
Date /T ime o f  Eu: 
Cyc l e s  Run
: PAFPA/K-3/MS 
1 0 0  pmol
24. A ug us t  1SSZ 8:S'4.am 
1 STD, 9 AA
Lag Corrected Tabulation ... (in pools)
R ! R 5 £ r c- 5 H I i .1 ri 3 S 7 U Y >J
Cycle ffl.5 fixG BSH hi? CVS elu Sin SLY HIS IL£ LIU LV BIT PHE rSO 315 THjf Ix r TVS UfiL
1 -0 .7 1 .2 0.2  0.8 -1 .0 -1 .0 0.0 11.5 u. 4 24.0 -0 .4 -ii - 3.1 10 .4 -0 .3 15.2 10.3 4.2 -0 .3 0 .5
£ 1.1 -3 .4 -G.S 37.5 -1 .0 0 .3 -0 .2 -3 .5 0.1 0 .0 0 .5 12 ■3 . -0.0 0.0 10.9 0 .0 2 .3 0 .0 0.5 -1 .6
£ 32.1 0 .7 0.0  8.2 -1 .0 0 .5 w 0.0 0.0 0 .0 -0 .5 y -0 .3 -0.1 3.4 0 .0 0 . 8 ' 0.0 -0 .5 i.O
13.7 0.1 0 .4  0.3 - I . " 2.1 -0 .2 0.0 -0 .4 17 .3 -4 7 -0 .2 0 .2 0 .0 -0 .3 0 .3 -0 .1 -0 .2 1 .5
s 0.5 1,3 0.5  -3.1 -1 .0 0 .0 1 .V 5.5 -3 .3 -0 .4 0 .3 ij 3 7.0 -0 .4 0 .5 -0 .5 -0 .1 -3 .4 -0 .3 0 .9
5 3.0 -0 .3 G.l .-0 .8 -1 .3 5 .0 2.2 1.3 -0 .5 -0 .3 12.3 JJ : 0.3 -0 .3 -0 .2 -0 .3 -0 .5 -0 .3 1.2 0.1
7 0.2 *U. i -0.G -0 .5 -1 .0 2.3 1 .2 1.4 *0.5 n ■u . t ? •: 1 0 -0 .2 1.5 0 .4 -0 .4 1 .5 -3 .0 0.4 i . i
8 -0 .3 9 .9 -5 .1  G .l -l.Q 0 .4 0 .0 0.3 0.5 G .l 1 .5 t P 0.0 3.3 -0.1 0 .7 -0 .2 0.1 0.1 Q.S
5 0.2 7.1 -0.1 0.7 -1 .0 -0 .3 -0 .5 -0 .3 0 .2 0 .0 -1 .1 -0 4 *0.2 -0 .3 -0.1 u.O 0 .4 0 .4 -0 .5 -0 .8
A3 -16
-       «-■— w  \  v /  M U  U  W A A  A A A  X - X  ^  t i X  V-/ V* •  t J
(C h a p te r  6 ) fro m  Glu-C d ig e s tio n  . S e q u e n c in g  w as 
p e rfo rm e d  by  M r J .  G ilroy.
SAMPLE F'AFPA/K-3/MS
C i n i t i a t e d  2U i
Sample  Amount: 1-30 pmci
AAci d AAcid R.Ti me C.Time  
it ID (min )  (m m )
I 5i 0 
A
L 1
M i
K i >R I 1
c :  i s
S3AT O' -
1 2
f I
Pmol  
( r a w )
Pmol Pmol Pmol AAc i d
( -bkgd) ( + l a g ) R a t i o ID
2 0 . 2 5 2 3 . 5 5 7 3 .  i 5 ILE
Z5.S1 3 7 .  US 7 7 .  s 2 ASP
2 2  . 2 2 T 7 , | i 7 0 . 5  5 ALA
1 3 . 0 ! 1 T . 5 5 15.SU LEU
6 . 2 5 7 . 0 0 2 5 . 2 5 •MET
1 0 . 27 12 .5 3 1 _ . Sw LEU
3.31 2 - — 5 . S 0 GLU
T i 2 9 .5 9 tt j ^ ARG
S.  52 ARG
REPETITIVE YIELD ANALYSIS:
L: 
P.:
Ave r age  AA R e p e t i t i v e  Y i e l d : 
Combined AA R e p e t i t i v e  Y i e l d .*
R e p . Y i e l d  Var i anc e  
SS.Su. " 1 . 0 tr2
12°.73 X :.030
:  ^5 • 2 9 %
C
T h e o r e t i c a l  I n i t i a l  Y i e l d :  i S . o _  p - o i
AIII.2.12 S e q u e n c e  o b ta in e d  fro m  G roup-X  c o n ta m in a n ts  f ro m  
i l lu s t r a te d  b lo t in  F ig u re  5.4 (C h a p te r  5). S e q u e n c in g  w as 
p e rfo rm e d  b y  D r A. M oir.
>cnM
-jc\>
G
o O — i
J T ' J - J
-  _?
J D
“7 > t d
• o
Ol "VO 7^ °1
r
A3 -17
A III.3 O lig o n u c leo tid es  S y n th e s is e d
AIII.3.1 N -PA PP -1 p r im e r  d e s ig n e d  fro m  in it ia l  PA PP-A  N -te rm in u s  
(see A III.2 .2 ).
S€‘:uer,c= name : N—FAPPi 
S e q u e n c e  l e n g t h  : 21  
D a t e  l a s t  s d i t e c  : 2 6 / 0 2 / 9 1  
A u t n o r  n am e :
D escrip tion  :
y :
10 20
e  —A 3  A G L ./ h G A h GxGCXACXGA A— 3 '  G C G
D a t e : 2 6 / 0 2 / 1 9 9 1S e c  u . e n c s : N—FAFF' 1S y n t h e s  i s : N -F A F P 1S c a l e : 0 . 2  m i c r o m o l ee q u e n c E  L e n o t h : 21Co 1 Limn : “ IF i n  a  I D e t  r  i  t v  1a t  i  o n : Y e sCo u p  1 i n g  E f f i c i e n c y  T h r e s h o l d : 9 0  X
F e s B a s e R e t e n t i o n D u r a t i o n  iP e a k  h t A c c  A r e a L a s t  e f fm i n e m i  n s %FS *'.m i  n /.
21 A 0 .  4 0 0 .  5 9 4 7 Q 5 2 .  § 6 -2 0 A 0 .  3 3 0 .  6 9 7 6 6 S:6 . 9 5 —19 G 0 . 3 / 0 . 5  / 7 1 £ 7 6 .  1 2 —I S X 0 .  3 9 0 .  6 6 7 8 3 8 6 .  8 1 —1 7 C 0 .  41 0 .  7 0 7 1 5 9 0 .  5 0 —I S A 0 .  4 0 0 . 6 7 8 0  a 9 3 .  2 0 1 0 1 .  215 X 0 .  4 0 0 .  6 5 S 0 7 8 7 .  2 2 —1 4 c 0 .  4 2 0 .  7 4 7  6 6 9 6 .  3 1 1 0 2 .  11 3 G 0 .  3 9 0 .  5 9 7 0 2 7 7 .  6 2 1 0 0 .  31 2 X 0 . 4 1 O. 6 9 ZZs 9  1 .  3 7 —11 G • 0 .  41 0 .  6 3 , -33 7 9 .  6 8 1 0 1 .  31 0 G 0 . 4 1 0 .  6 6 7 4 2 7 S . 8 6 9 9 . 09 AG 0 .  4 2 0 .  6 8 7 3 1 8 6 .  9 0 —S G 0 .  4 2 0 .  6 5 6 7 4 7 9 . 2 3 1 0 0 . 27 AC 0 .  4 4 0 .  7 2 7 6 0 9 2 .  6 0 —6 X 0 .  4 4 0 .  7 0 /  6 0 8 7 . 9 4 —5 C 0 .  4 5 0 .  7 2 7 7 S 9 3 . 2 4 9 9 .  64 G 0 .  4 4 0 . 6 6 6 1 3 7 5 .  4 4 9 8 .  8- r•-* AG 0 .  4 5 0 .  6 3 6 1 5 7 9 .  0 9 —
.4. A 0 . 4 5 0 .  7 1 6  7 S 8 3 .  8 8 9 9 . 3
Fas B a s e R e t e n t  i o n D li r  a t  i  o  n P e a  k h t A c c  A r e a L a s t  e f fm i n e m i  n s - X F S  . 7.m i n •// •
1 A 0 .  4 5 0 .  7 5 7 6 3 8 9 .  6 3 1 0 6 .  8
Total synthesis yield from start = 100.0 V.
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AIII.3.2 N-PAPP-2 prim er d esign ed  from  in itia l PAPP-A N -term inus
(see AIII.2.2).
E s c u s n c  = n a m e  : N—F AF F2  
S e q u e n c e  l e n q t h  : 21 
D a t a  l a s t  e c i t e c  : 2 6 / 0 2 / 9 1  
A u t h o r  name  :
D e s c r i p t i o n  :
E a s e  X :
E a s e  Y
10 20
—AAa u L XHi-A6  6 .* lzC XACxlrA G~  G C G
D a t e : 2 6 / 0)2 / 1 9 9 1S e c u e . n c e : N -P A P P 2S y n t n s s i s : N—FAF'F 2-S c a l e : Os. 2  m i c r o m o l es e c u e n c e  L e n o t h : 2 1C o l u m n : 2F i n a l D e t r i t v  l a t i o n : Y e sCo up  l i n o  E f  f  i  c  i e n c y  Th r s s h o 1 d : 9 0  %
:‘CS B a s e R e t e n t  i o n D u  r  a t  i  o  n F s  a  k h t A c c  A r e a L a s t  ei n i n s m i n e ::f s '/.m i  n '*
2 1 G 0 . 3 3 0 . 5 6 3 6 7 4 1 .  6 8 -2 0 A 0 .  3 7 0 . 6  9 9 1 6 1 0 0 . 7 9 —IF G 0 . 3 6 0 .  6 3 3  /  / 0  6  . '•.) O —1 3 X 0 . 3 7  . 0 . 6 6 9 2 2 9 6 .  0 5 —1 7 c 0 .  3 ? 0 . 7 1 9 2 4 1 0 2 . 1 2 —I t A 0 . 3 9 0l • 6 6 9 0 6 9 5 .  2 6 9 8 .  61 5 X 0 .  3 9 0 .  6 3 9 2 5 9 9 .  0 5 —1 4 c O. 4 0 0 .  7 3 1 0 5 3 1 I S . 3 7 1 0 5 .  01 3 R 0 . 3 8 0 .  6 7 8  16 8 6 . 9 6 9 9 .  8
1 2 X • 0 . 3 9 0 .  7 0 8 8 9 1 0 4 . 8 4 —_L1 G 0 .  4 0 0 .  6 4 7 1 4 8 1  . 3 0 9 6 .  7
1 0 G 0 . 3 9 0 .  6 7 7 7 3 S 3 .  9 2 1 0 3 .  2? AG 0 .  4 0 0 . 6 6 7 9 3 8 6 . 2 3 —S G 0 . 4 0 0 .  6 4 7 3 m 7 3 .  8 2 9 6 .  97 AC 0 .  4 2 0 .  7 4 8 2 6 9 4 .  S 3 —
6 X 0 .  4 2 0 .  7 4 S O .6 9 0 .  7  1 —U c 0 .  4 3 0 .  7 7 7 7 6 9 4 .  9 6 9 7 .  64 G 0 .  4 2 0 .  7 3 6 4 2 6  9 . 2 6 9 6 .  8AG 0 . 4 3 0 .  7 9 7 2 6 7 9 .  1 0 —■-3, /• A 0 .  4 3 0 . 3 9 /  6 6 8 5 .  0 0 9 9 .  2
:'uS B a s e R e t e n t  i o n D u r a t  i o n  P e a k  h t A c c  A r e a L a s t  em i n s m i n s  * ^ 2 F S V.m i  n V.
i A 0 .  4 4 0 . 9 2 •7 7 3 8 4 .  3 3 9 9 .  2
Total synthesis yield from start = S7.0
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AIII.3.3 cPAPP-3 in tern al prim er design ed  from  seq u en ce  ob ta in ed
from  Glu-c d igestion  (see AIII.2.11).
Sscusncs length : 21
Date la s t  e d ited  : 1/01/3- cPA.PP'3
Author name :
D e s c r i p t i o n  :
E s s e  X : 
Ease V :
10 • 20 .■______J_J.. l_ J _ . 0  I 1 Cl VJ ” i u x  t L r ;  i 11—  ■—!»—>6 i !_r -j' ^
Date : Secuence S vn thee is  Scale Secu.ence Lenoth Lc1umnFinal D e tr ity la tic n  Coup lino E f f ic i  enc v T'n re she 1 d
1 / 0 1 / 1 9 3 4  P A P F - 3  F AF'F - 30.2  micrciTiOle 21  1Yesvo y.
pQS Base Reten t ion Durat icn Peak ht .CC Ir-tf" drinins m i n s >:fs *i;Ti i n
r 1 G 0. 42 0. 63 513 6 1 . 00Mon i to r f a iled to autozero for base 21 ( read ino=384'20 T 0 . 44 0 . 73 717 9P. 0919 GA 0. 4 1 0 . 6 6 / 79 94. 05IS A 0. 42 0 , 64 301 92. 3317 A 0. 42 0. 64 gno 93. 9~16 AG 0 . 41 0 . 62 796 9 1 4  215 T 0. 43 0. 69 759 96 . S-.J1 — T C:>.  a,5 0. 7 1 764 99. 6613 AG 0. 42 0.67 734 90 - 6 112 C 0. 44 0, 63 753 96.0111 G 0 .26 0 . 13 141 4. 24Mon i to r f a ile d to autozero for base 1i_^ ( read ino = l 1410 X ' 0 . 42 0 . 62 / 3 3 Gy . 61Mon i tor fa iled to autozero t O' f’■ b a s s 10 < r e ad i n o — 1 1 t9 C 0. 45 0 . 68 741 92. 64Mon i to r fa ile d to autozero for base 9 ( readino=1143 T 0 .46 0.72 748 91.797 GA 0. 44 0. 69 702 36.156 C 0. 45 0.67 713 39. 05erw C 0. 46 0 . 63 699 8 / . 654 VA 0. 45 0 . 63 699 87. 02c 0. 46 0 . 68 633 33.04'■h.4. c 0. 46 0.69 662 36. 39
Poe Base 1Retention !Durat i on Peak ht Acc Aream i n s m ins V.FS /liTi i n
1 X 0. 46 0. 63 671 . S3. 16
Last e f -
101 . 2
100 . 1 101. 1
98. 9
) 9 8 .  6
9  8 .  8. 
9 8 .  4
100 . 2 9 3 .  1
Last e f f
Total synthesis yield from start = -
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AIII.3.4 PAPP-4 prim er designed  from  con sen su s PAPP-A
N -term inus (see AIII.2.3).
S e q u e n c e  name : RAFP - 4  
S e q u e n c e  iencth : 25
Date last scited : 1 /0 1 /54
Author name :
Description :
Ease X :
Ease V :
1 0 2 0
-• -'-HH GLaAGAG G X G ___L ( (- X '<—■ X G A A G A A C — 'It L G G G
Date : 1 /0 1 / 1 984Gecuer.es : FAFF-4Syr. thesis : FAFF-AScale : O'. G mic romolebecusncs Length : .2Lc 1umn ! ^Fina1 Detri tv 1 ation : YesCoup lino Efficiency Threshold : 9 0
Fee Ease Re ten t i on Du ra t i on c'esk ht Acc Area Last efmine mine V.F3 V.m i n
25 C 0 . 40 0 . 45 691 55. 12 -24 AG 0 .35 0 .47 1 142 69. 90 —'T* "T A 0.36 0.47 1192 74. 76 —-2. G 0 .36 0 .43 105 = 64. 33 —
2 1 AG 0. 40 0 . 58 / o / 74. 2 S —2 0 A 0.40 0.60 790 79. .= 1 1 0 2 . 119 G 0.40 0.61 719 69. 26 102. 5IS X 0.41 0.54 / P o 75. 53 —17 c 0 - 42 0.61 793 78. 97 —16 A 0.42 0.57 773 73. S3 98. 115 X 0 . 4v 0 .5 b 761 73. 95 —14 c 0.44 0.59 / / 3 76. 71 99 . 013 G 0 . 43 0.55 660 6 2 . 57 46 . 31 2 X 0.4o 0.59 6  S9 70. 10 —
1 1 G 0.43 0.5/ 649 53. 59 92. 5-1 0 G 0.44 0 . 5o 5 T G 58. 97 1 1 0 . 09 AG 0.45 0.59 571 >—■ G. —S G 0.45 0.57 583 58. 56 99-T77 AC 0.45 0.63 624 64. 27 —6 X 0.45 0.58 621 60. 52 —
F'os Ease Reten t ion Duration Peak ht A c c  Area «) Last efmine mins V.FS Mm in 7.
5 C 0.46 0.61 614 . 64. 39 93. 14 G 0. 45 0. 5 / 525 52. 78 97. 4— AG 0.47 0.52 4 7 7 45. 40 —2 A U .46 O .5v 559 57. 16 98. 2  ■
1 G 0.46 0.53 495 48. 23 97. 0
Total synthesis yield from start = S7.0 ::
A3 -21
